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Talin is a 250 kDa cytoplasmic protein that activates integrins and provides a link to cytoskeletal 
actin, thus producing the necessary force to stabilise adhesions.  Talin is classically defined as an 
integrin-activator, but here we show that talin also couples adhesion assemblies to cortical 
microtubules via the Cortical Microtubule Stabilising Complex (CMSC) and plays a role in the 
mechano-regulation of the cell cycle.   
Cross talk between cortical microtubules and focal adhesions (FA) plays a critical role in cell polarity 
and migration.  Microtubules regulate the turnover of adhesions and, equally, FAs help capture 
and stabilise microtubules in their vicinity. The molecular basis for this mechanism was unknown 
and remained a key question within the field.   
Here, I describe biochemical and biophysical evidence that the interaction between KANK and talin 
is the crucial link between the macromolecular assemblies FAs and CMSC.  Fluorescence 
polarisation (FP) and Nuclear Magnetic Resonance (NMR) data show that the conserved KN domain 
in KANK1 binds to the talin rod domain R7 via a LD talin-binding motif.  Through the design of point 
mutants in both the KANK1 KN domain and talin R7 domain this interaction could be perturbed. 
Our data show that the KANK1 KN domain binds to talin through a helix addition mechanism.  
Immunofluorescence work in HeLa cells corroborates our findings on the importance of this 
interaction, and that a single talin point mutation (G1404L) is enough to abrogate the association 
of FAs with the CMSC and, in turn, disrupts microtubule dynamics at the cell edge. The discovery 
of KANK1 as a binding partner of talin provides the missing link for how microtubules are targeted 
to FAs. 
The talin:KANK interaction gave a new insight on LD talin-binding motifs and allowed us to develop 
a novel pipeline for identifying talin-binding partners.  After designing a LD talin-binding search 
motif, we identified cyclin dependent kinase1 (CDK1) as a talin-binding protein.  CDK1 is the master 
regulator of the cell cycle, helping to drive cells from G2 phase into mitosis.  Using similar 
biochemical and biophysical techniques I characterise the interaction between talin and CDK1.  FP 
and NMR show that CDK1 binds to the talin R8 domain via helices 32 and 33 and based on structural 
modelling, we propose that this interaction also occurs through helix addition.   
Biochemical data combined with phosphoproteomics shows that the CDK1-cyclinA complex 
phosphorylates talin1 and talin2 isoforms at two unique sites (Ser1589 in talin1 and Ser1489 in 
talin2). Interestingly, in talin2 this novel phosphorylation site is in the talin actin-binding site 
(ABS2). We postulate that this could be a mechanism to regulate the coupling/uncoupling of actin 
to talin.  Talin phosphorylation could perturb actin binding, thus reducing tension across the 
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adhesions and leading to their disassembly.  This interaction gives an insight into how adhesions 
and the cell cycle are entwined and poses many questions regarding how adhesion formation and 
disassembly regulates or occurs within the cell cycle.  
My thesis describes the discovery of two novel talin-binding partners KANK and CDK1 which reveals 
talin is a crucial player in both coupling FAs to microtubules and gives new evidence into how 
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2.1 Cell Migration  
Multicellular organisms are organised through tightly co-ordinated cell-cell and cell-matrix 
interactions. Cells are continually sensing their extracellular environment, identifying different 
biochemical and biophysical properties and translating this information into a broad range of 
biological outputs including: cell migration, cell proliferation and cell differentiation.  
Cell migration is vital for all eukaryotic life and is essential for embryonic development, tissue 
formation, immune responses and wound healing (Case and Waterman, 2015).   When 
misregulated cell migration can cause huge damage to organisms including: tumour formation and 
metastasis, chronic inflammatory diseases and vascular disease (Carmona-Fontaine, Matthews and 
Mayor, 2008).  For a cell to dictate direction of movement and co-ordinate with surrounding cells 
it needs to have a defined leading edge (front) and a rear end (back).  This is achieved through cell 
polarity, which gives the cell an asymmetric organisation of cellular components, vital for cell co-
ordination, shape, structure and function (Case and Waterman, 2015).   
Additionally, all migrating cells need to apply force to generate traction against their immediate 
surroundings.  The actin cytoskeleton is one of the major sources of internally generated force that 
enables the cell to regulate shape and drive migration (Pollard and Cooper, 2009).  For actin to be 
able to transmit force to the outside of the cell, the force must first be transmitted through the 
cellular membrane.  This can occur through specific cell surface receptors known as cell adhesion 
molecules (CAMs).  CAMs can bind to the extracellular matrix (ECM) or to other cells and generate 
the traction needed to help the cell move.  Fully understanding which proteins are involved in the 
regulation of this process would aid in the development of novel therapeutic cancer treatments, 
transplant methods and the manufacturing of artificial tissues. 
2.2 Cell adhesion Molecules  
CAMs are divided into five main groups: integrins, selectins, cadherins, mucins and 
immunoglobulin superfamily as seen in FIGURE 2.1 (Lodish 2016).  Selectins, cadherins, mucins and 
immunoglobulins can form cell-cell interactions, whereas integrins provide a link between cells and 




FIGURE 2.1: TYPES OF CELL ADHESION MOLECULES (CAMS) 
Diagram representing the five classes of CAMs in cell-cell and cell-matrix adhesions; cadherins, integrins, Ig-
superfamily, selectins and Mucins.  The CAMs are separated into homophilic interactions and heterophilic 
interactions.  Figure based from: (Lodish et al., 2000)  
2.2.1 Selectins  
Selectins, are a family of three structurally and functionally related adhesion molecules: L-selectins, 
P-selectins and E-selectins.  P-selectins are primarily found on platelets and leukocytes, E-selectins 
are expressed on endothelial cells and L-selectins are present on leukocytes, monocytes, 
neutrophils and eosinophils (Bou-Gharios and de Crombrugghe, 2008).   All selectins have a 
common domain structure consisting of an important N-terminal Ca2+ dependent lectin domain 
(see FIGURE 2.1), which is integral for selectins function (Ley, 2001).  The selectin family are 
adhesion molecules that facilitate the binding of cell-cell interactions; they specialise in capturing 
leukocytes from the blood stream and attach them to the vessel wall.  This contact between the 
leukocyte and the vessel wall allows the process known as leukocyte rolling to take place.  This 
process occurs in a cascade –like fashion whereby the leukocyte cell is captured and rolls along the 
cell membrane before it slows down enough to extravasate from the blood vessel into the tissue 




Cadherins are a large family of adhesion receptors that are defined by the inclusion of the 
extracellular cadherin (EC) domains and the requirement of Ca2+ for their activity (Morishita and 
Yagi, 2007).  The number of EC domains can vary dependent on the isoform, they form Ca2+ 
dependent linkages with other cadherin EC domains forming a cell-cell interaction (Helfrich et al., 
2008).  The cadherin receptors can be categorised into four groups: classical cadherins, 
protocadherins, unconventional cadherins and desmosomal cadherin’s.   
Classical cadherin’s include E-cadherin, P-cadherin and N-cadherin that all have a similar structure 
with five EC domains, a transmembrane region and intracellular C-terminal domain.  The 
cytoplasmic tail can interact with β-catenin which forms a link to the actin cytoskeleton.  This 
interaction with actin allows tension and contractility to be transferred to the adjoining cell which 
can drive cell re-arrangement at both a local and a tissue level (Lecuit and Yap, 2015).    
2.3 Integrins 
Integrins are expressed in all metazoan species and are formed of two subunits: α and β.  Integrins 
were first discovered in 1986 and were named on the basis they could integrate the intracellular 
and extracellular environments of a cell (Tamkun et al., 1986).  Humans have 18 α and 8 β integrin 
subunits that can form 24 αβ heterodimeric pairs of integrin shown in FIGURE 2.2 (Campbell and 
Humphries, 2011).  Integrins are expressed in nearly all cell types and different cell types express 
different combinations of integrins; each integrin has distinct patterns in cell-types and tissue 




FIGURE 2.2: INTEGRIN SUBUNIT PAIRINGS 
A schematic of all integrin α and β subunits illustrating the pairings they can make in humans and categorised 
into the ECM component they can interact with.  Figure based from (Lal, 2009).   
 
2.3.1 Integrin Structure  
α integrins comprise around 1000 amino acid residues whereas β integrins are composed of around 
750 amino acids (Hynes, 2002).  Both subunits contain an ectodomain, a single transmembrane 
region and an intracellular domain as shown in FIGURE 2.3.   
α integrin ectodomains are composed of four, or five, domains depending on the α integrin subtype, 
whereas β integrin ectodomain is spilt into several domains which have flexible linker regions 
joining them.  Both α and β integrins have a single transmembrane region (TM), these regions are 
highly conserved and link to a short cytoplasmic tail of around 25-50 amino acids.  The cytoplasmic 
tails appear to be flexible until bound to a ligand (Campbell and Humphries, 2011).  Integrin tails 
are important for the communication between the cell and the ECM; they form ‘hub’ interactions 
with a number of cellular proteins which is especially important for inside-out activation of the 
integrins (Wegener and Campbell, 2008), see section 2.3.3.   
The cytoplasmic tails of β integrins have two Asp-Pro-x-Tyr (NPxY) motifs- where x is any amino 
acid, which are important for the binding of many proteins including talin and kindlin.   As shown 
in FIGURE 2.3B, the two NPxY motifs are defined as proximal and distal regions and these 
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sequences are found in all β integrins (Wegener and Campbell, 2008). α integrins also have a 
common sequence found in all isoforms, the GFFKR motif (shown in FIGURE 2.3B), which has been 
found important for binding both sharpin and the mammary-derived growth inhibitor (MDGI) (Li 
et al., 2014).  Sharpin and MDGI are both inhibitors of integrin activation and are needed to keep 
the integrin in an inactive state (Rantala et al., 2011).   
 
 
FIGURE 2.3: STRUCTURE OF INTEGRINS 
(A), There is variation in integrin ecto domain structure and this represents a schematic of the domains 
present in integrin α4β1. (B) The cytoplasmic tail region of integrins, the NPxY motifs on β integrin tails are 
highlighted in blue and the binding regions for several integrin activators and their specific integrin subtype 
are indicted, this image is adapted from: (Bouvard et al., 2013).  
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2.3.2 The extracellular matrix  
The ECM is a non-cellular component that is found in all tissues and organs and provides a 
scaffolding network for surrounding cells (Frantz, Stewart and Weaver, 2010).  The ECM is a made 
up of three main components: proteoglycans including, keratin sulphate and heparan sulphate; 
insoluble collagen fibres (which provide strength) and soluble multi-adhesive ECM proteins such as 
fibronectin and lamin (Frantz, Stewart and Weaver, 2010).    
Although the ECM is primarily made up of the same components, all tissues have a unique ECM 
composition and topology which is determined during embryonic development through various 
cellular components such as fibroblast cells (which secrete all major precursors for the ECM). The 
difference in ECM composition is a major element in what gives different tissues and organs their 
mechanical and biochemical properties.  The composition is tightly regulated to maintain stability 
of tissue and organ physiology.  In diseases such as cancer the ECM becomes disordered and 
unregulated, often stiffer and more fibrous which leads to the promotion of cell migration and 
cancer metastasis.  Abnormalities in the ECM can also lead to tumour-associated angiogenesis 
which in turn gives tumour cells their own microenvironment and facilitates further spreading (Lu, 
Weaver and Werb, 2012). 
2.3.3 Integrin activation  
Integrins receptors link the actin cytoskeleton to the ECM which allows the cell to generate traction 
an important feature for cell shape, adhesion and migration (Calderwood et al., 1999).  One 
important and reversible mechanism for regulating integrin adhesions comes through the 
regulation of integrins activation state.  Integrins fluctuate between states of high affinity (‘active’ 
confirmation) whereby it can interact with the ECM (see FIGURE 2.4 and a state of low affinity 
(‘closed’ conformation) where it is unable to make interaction with the ECM (Calderwood, 2004).  
The state of affinity can be controlled by intracellular signals (in a process known as ‘inside-out’ 
activation) binding to the integrin cytoplasmic tails, these interactions induce conformational 
changes in the integrin extracellular domains that can result in integrins having a higher affinity for 




FIGURE 2.4: ACTIVATION STATE OF INTEGRINS 
Schematic diagram illustrating the integrin affinity states.  Integrins fluctuate between states of low affinity 
where they are in a ‘closed’ conformation (left) and a high affinity ‘active’ confirmation (right).   Talin binding 
the β integrin tail induces conformational changes in the integrin extracellular domains that can result in 
integrins having a higher affinity for the ECM.   
 
The cell has to ensure that the integrin is in an ‘active’ confirmation only when required otherwise, 
adhesions to the ECM could occur in unwanted places leading to problems such as blood clots and 
cell metastasis (Ganguly et al., 2013).  Integrins use a network of dynamic interactions known as 
the integrin adhesion complex (IAC) to mediate their activation state.  The complexity of the IACs 
has been highlighted in analysis of the ‘integrin adhesome’ where mass spectrometry of multiple 
integrin adhesion complexes revealed a network of >240 proteins are involved in integrin 
regulation (Horton et al., 2016; Ronen Zaidel-Bar, 2007). 
Further analysis of the integrin adhesome indicated that there is a consensus adhesome of around 
60 proteins that all centre around four different centred around four ‘axes’ comprising ILK-PINCH-
kindlin, FAK-paxillin, talin-vinculin and α-actinin-zyxin-VASP (Horton et al., 2016). 
In all of the different ‘axes’ of the IAC it appears that the adapter protein talin is linked in some 
way.  Talin is a cytoplasmic adapter protein that is vital to integrin activation; talin can bind to the 
highly conserved proximal NPxY motif in the β integrin tail via the talin FERM F3 domain 
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(Calderwood et al., 2002).   This interaction between talin and integrin disrupts a salt bridge 
interaction between the integrin α β tails, which holds the two tails in close proximity keeping the 
integrin in a low affinity state (Calderwood, 2004).   Talin F3 still with the β integrin bound forms 
elecrostic interactions with lipid groups in the membrane (as shown in FIGURE 2.5) which leads to 
conformational change in the positioning of the talin-integrin complex and results in the separation 
of the α β integrin tails and activates the integrin.   
 
 
FIGURE 2.5: TALIN-INDUCED INTEGRIN ACTIVATION 
 
Structural representation of the talin F3 domain binding to the membrane distal region of the β integrin tail.  
Talin F3 subsequently, engages with the membrane proximal region of the β integrin which leads to the 
disruption of the putative integrin salt bridge highlighted by green box.   Talin can then make electrostatic 
contacts with the lipid head groups in the membrane, this results in the change of positioning of the β integrin 
tail and forces apart the α β integrin tails and activates the integrin.  Figure adapted from (Goksoy et al., 
2008) 
 
2.4 Different adhesive structures  
IACs form distinct adhesive structures which include: focal adhesion complexes, nascent adhesions, 
focal adhesions, fibrillar adhesions and podosomes.  These adhesive structures can be categorised 
by their distinctive structures and play different roles in cell migration, shape and adhesion as 





FIGURE 2.6: LOCATION OF CELL-MATRIX ADHESIONS ACROSS A CELL 
Diagram highlighting where the different cell-ECM adhesion types are located across a migrating cell.  The 
diagram also highlights the levels of tension the adhesions are under and the adhesion turnover rate.  Figure 
from (Wehrle-Haller, 2012). 
2.4.1 Nascent adhesions  
Nascent adhesions are found to assemble under filopodia and lamellipodia protrusions (Ridley et 
al., 2003); they are the smallest type of integrin adhesion and typically assemble in milliseconds.  
Nascent adhesions provide crucial links between the integrin and actin cytoskeleton through the 
interaction of integrin:talin:actin.  The addition of actin allows nascent adhesions to transition to 
focal adhesions (FAs) a more stable adhesion.    
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2.4.2 Focal complexes and focal adhesions  
FAs and focal complexes arise from nascent adhesions and are larger measuring around 1 µM in 
size (Anderson, Owens and Naylor, 2014).  In FAs talin is a crucial player in coupling integrins to the 
actin cytoskeleton,  as the force increases across the adhesion (through binding of actin) talin 
domains can unfold revealing vinculin binding sites.  These unfolded domains allow vinculin to bind 
which re-enforces talin in a stretched confirmation and prevents the talin domains from re-folding 
(Yao et al., 2014).  Additionally, vinculin binding to talin is thought to activate vinculin as it out-
competes the interaction between the vinculin head and tail (associated with auto-inhibited 
vinculin).  This addition of vinculin binding talin promotes a formation of stronger actin linkage and 
assembles and more stable adhesion.  
2.4.3 Fibrillar adhesions  
Fibrillar adhesions are located away from the leading edge and near to the nucleus and vary in size, 
ranging from 1 µM to 10 µM in diameter (Anderson, Owens and Naylor, 2014).  Fibrillar adhesions 
develop from mature FAs and are characterised through the inclusion of the protein tensin which 
cross links actin cables to fibronectin fibrils located in the ECM (Huveneers and Danen, 2009).  
Fibrillar adhesions can be distinguished from FAs as they are not attached to stress fibres which 
prevents them from dis-assembling when force across the adhesion is relaxed (Zamir et al., 2000).     
2.4.4 Podosomes 
Podosomes are found at the lamellopodia (see FIGURE 2.6) and differ structurally from the other 
adhesive structures.  Structurally, the most distinguishing feature of podosomes is their two part 
organisational design; they have a dense F-actin core that is surrounded by a ring structure of 
adhesion proteins such as talin, vinculin and integrins (Linder and Kopp, 2005).  The actin-rich core 
is not found in any of the other cell-matrix adhesion types and consequently actin regulation 
proteins exert a major influence on the podosome-type contacts.  Podosomes are typically found 
in macrophages, dendritic cells and osteoclasts.  However, they are also found in a number of other 
cell type including endothelial cells and smooth muscle as they play a large role in matrix 




2.5 Talin  
A key protein found in all of the cell-matrix adhesion types is the adapter protein talin.  Talin is a 
large 270 kDa adapter protein that was first discovered in 1983 as a component of FAs and ruffling 
membranes (Burridge and Connell, 1983).  Talin is comprised of an N-terminal FERM domain (head) 
attached to a C-terminal rod domain by an unstructured linker (as shown in FIGURE 2.7).  The rod 
domain encompasses 13 alpha helical bundles, each comprised of either four or five helices (Goult, 
Zacharchenko, et al., 2013). 
 
FIGURE 2.7: TALIN DOMAIN STRUCTURE AND CONSERVATION 
(A) Structural model of talin showing highlighting the different domains, vinculin sites are detailed in red 
across the protein.  (B) Schematic representation of the talin domain structures coloured by sequence 
identity between the two isoforms. The domain boundaries are given for mouse talin1 (UniProt: P26039) and 
talin2 (UniProt: B2RY15).  Figure adapted from (Gough and Goult, 2018).   
 
Talin is one of the key elements in integrin activation  and provides the link between integrins and 
actin cytoskeleton (Shattil, Kim and Ginsberg, 2010).  The interaction between integrin-talin-actin 
forms the basis of a nascent adhesion allowing the recruitment of numerous other FA and signalling 
molecules, to form a more stable adhesion (Calderwood, Campbell and Critchley, 2013).  
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Furthermore, talin is a mechanosensing protein, with its 13 alpha helical rod domains capable of 
undergoing force-dependent conformational transitions that can modulate binding interactions 
with mechanosensitive ligands (del Rio et al., 2009; Goult, Zacharchenko, et al., 2013; Yao et al., 
2014, 2016; Yan et al., 2015).  Until the work presented here in this thesis and the subsequent 
publications (Bouchet et al., 2016; Sun et al., 2016) it was not known that talin also has a pivotal 
role in linking adhesions to cortical microtubule stabilising complexes, through its interaction with 
the KANK family of proteins (see chapter 4).     
2.5.1 Talin Isoforms  
There are two isoforms of talin; talin1 and talin2 which share an identical domain structure and 
have a 74% amino acid sequence identity (shown in FIGURE 2.7B).  In vertebrates, the isoforms are 
encoded by two different genes, TLN1 and TLN2, both of which have highly conserved intron and 
exon boundaries (Monkley, Pritchard and Critchley, 2001; Senetar, Moncman and McCann, 2007).  
The genes are located on different chromosomes; TLN1 is located on Ch9 and TLN2 is located on 
Ch15, furthermore, TLN2 (190 Kb) is a larger gene than TLN1 (30 Kb) due to larger introns.   
2.5.1.1 Talin2 
TLN2 has  been shown to have multiple splice variants which lead to multiple talin2 isoforms as 
shown in FIGURE 2.8 (Debrand et al., 2009).  These talin2 isoforms still currently have no known 
function but the expression of the different splice variants is interesting.  The shorter isoforms 
(lacking the N-terminal FERM domain) are found to be expressed in the brain, kidneys and testes 
which raises the prospect that they are not involved in integrin binding and may serve other 
functions (Debrand et al., 2009).  Furthermore, it was found that if a talin1 fragment (the same as 
the short C-terminal testes specific talin2 isoform) was expressed in cells depleted of talin1 then 
this was sufficient to rescue cell cycle progression suggesting a potential role in cellular signalling  




FIGURE 2.8: TALIN2 SPLICE VARIENTS 
Schematic diagram displaying the main talin2 isofoms that arise due to alternative splicing. Vinculin binding 
sites are highlighted in blue and red crosses indicate the vinculin binding regions that have been deleted due 
to exon skipping.  At the top of the diagram the longer talin2 isoforms are shown and at the bottom the 
shorter talin2 isoforms, that are lacking the FERM domain.  Figure taken from: (Debrand et al., 2009). 
 
TLN2 is the ancestral gene, and through early duplication in the chordate lineage it led to the 
emergence of talin 1 (Senetar and McCann, 2005).   Interestingly, over evolution the talin domain 
structure has not changed, even since the talin2 duplication in the chordates lineage that lead to 
the emergence of talin1; the sequence length has remained the same (talin1 2541aa and talin2 
2540aa).  This is quite an unusual finding compared to other large multi-domain proteins  such as; 
filamin, titin and spectrin of which all have varied in length over evolution (Higgins et al., 1994; 
Baines, 2010; Light et al., 2012).  This unvarying domain structure gives compelling evidence that 
every domain within talin has an important functional role.   
Independent functions of the two isoforms within cells have not yet been fully understood but it 
has been found that tissue expression and cellular localisation varies significantly between both 
isoforms.  Talin2 expression is more variable than talin1 and unlike talin1, it has not been found to 
be expressed in all cell types for example, there is no expressed talin2 in endothelial cells (Kopp et 
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al., 2010; Monkley et al., 2011).  There is however, high expression of talin2 in heart muscle, 
kidneys and the cerebral cortex of the brain (Manso et al., 2013). 
2.5.1.2 Talin1 
Talin1 on the other hand, is expressed in nearly all tissues and is believed to be ‘the more essential 
talin isoform’.  TLN1-knockout mice embryos are not viable and mice die due to arrested 
gastrulation, indicating that talin1 is essential for early development (Monkley et al., 2000).  In 
contrast a TLN2-knockout is not lethal at embryonic stages and instead, mice were viable and fertile 
expressing only mild dystrophic phenotypes with small variations in mouse pups reaching 
adulthood (Debrand et al., 2012).  Evidence does show that talin2 can rescue the cell’s phenotype, 
following the loss of talin1 after embryonic development. In fact, in embryonic fibroblasts cells 
(MEFs) of TLN1-knockout mice, TLN2 expression is rapidly up-regulated, to compensate for the loss 
of talin1 and resulting phenotype (Zhang et al., 2008).  Similarly, a knockout of both talin isoforms 
entirely destroys cell-ECM adhesions, highlighting the essential role that talin plays in integrin 
adhesions (Manso et al., 2017).   
In fibroblasts both isoforms localise to FAs with talin1 being directly recruited to the cells leading 
edge via RIAM, the RAP1 effector (Rap1-interacting adapter molecule) (Lee et al., 2009; Lagarrigue 
et al., 2015).  The mechanism that recruits talin2 to the leading edge is not yet understood.  Talin2 
is known to bind RIAM although this is thought to cause aggregates to form throughout the cell 
which have been found to overtime co-localise to fibrillar adhesions.   Fibrillar adhesions are found 
in the centre of the cell (see FIGURE 2.6) and localisation of talin2 to fibrillar adhesions could 
suggest that it is involved in fibronectin assembly or possibly invadopodia formation (Singh, 
Carraher and Schwarzbauer, 2010; Qi et al., 2016).  Recently it was found that talin2 was essential 
for generating the traction force needed to allow invadopodia-mediated matrix degradation which 
is required for invadopodia formation (Qi et al., 2016).    
2.5.2 The talin head 
Both talin isoforms have a N-terminal head domain (as shown FIGURE 2.9); this is formed from an 
atypical FERM (4.1 protein, ezrin, radixin, moesin) domain containing four sub-domains: F0-F3.  The 
talin FERM domain is classed as atypical as it comprises of  four subdomains rather than three (F1-
F3) and also because of the linear structure it takes compared to the more commonly found clover 
leaf shape of other FERM domain proteins (Elliott et al., 2010).    
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The FERM domain is essential for talin to bind and activate integrin; the talin F3 domain binds to 
the β-integrin tail via interaction with the membrane proximal NPxY motif (Calderwood et al., 1999).  
This interaction with talin breaks the electrostatic interaction holding the two integrin tails (α and 
β) together, converting integrin to an active confirmation (Vinogradova et al., 2002).   
Isolated Talin F3 can bind to β-integrin tails however, it is fairly ineffective at activating integrins 
due to the need of the other talin sub-domains to form an effective ‘integrin activation lock’ and  
hold the integrin in the active, high-affinity conformation (Bouaouina, Lad and Calderwood, 2008).  
The other sub-domains help to promote this ‘integrin activation lock’ through the formation of 
interactions with phosphoinositides such as PtdIns(4,5)P2 (PIP2) at the cell membrane.  The F2 sub-
domain has a basic patch on the membrane interacting surface which promotes interaction with 
the membrane helping stabilise the talin-integrin interaction (Anthis et al., 2009; Saltel et al., 2009; 
Franceschi et al., 2017).  Additionally, the F1 sub-domain contains a large unstructured loop 
insertion, which can interact with  PIP2  which is essential for integrin activation (Goult et al., 2010).  
The F3 domain itself has also been shown to form electrostatic contacts with the membrane when 
bound to the β-integrin tail (Vinogradova et al., 2002) and together the electrostatic interactions 
from the talin sub-domains and the membrane provide the force on the integrin needed to  help 
stabilise the integrin-activated state.  
In addition to integrin binding the talin head can also bind PIP kinase gamma (de Pereda et al., 
2005) through interaction with the F3 sub-domain.  PIP kinase gamma is required to produce PIP2 
at the membrane which is needed to promote integrin activation (Legate et al., 2011). The F3 sub-
domain can also bind a host of other ligands including: RIAM (Yang et al., 2014), FAK (Lawson et al., 
2012), T-Cell Lymphoma Invasion And Metastasis 1 (TIAM) (Wang et al., 2012) and G-protein 
subunit Galpha13 (Gα13) (Schiemer et al., 2016).   
Both talin isoforms have three actin binding sites (ABS1,ABS2 and ABS3) (Hemmings et al., 1996).  
ABS1 is the only actin binding site found in the talin head in sub-domains F2 and F3 (Lee et al., 





FIGURE 2.9: TALIN1 FERM DOMAIN INTERACTING WITH THE MEMBRANE 
Schematic model of the complex between the talin FERM and β3-integrin tail docked against the membrane 
surface.  The talin FERM domain is in an elongated confirmation and the + indicate areas of electrostatic 
interactions between talin and the membrane.   Figure from  (Elliott, et al., 2010). 
  
2.5.3 The talin rod 
The talin head is connected to the talin rod via an 82 amino acid unstructured linker (Bate et al., 
2012).  The talin rod is comprised of 62 alpha helices which are folded into 13 alpha helical bundles 
of either four or five helices (see FIGURE 2.7)  (Goult, Zacharchenko, et al., 2013).  Four-helix 
bundles are commonly found in nature; in contrast five-helix bundles are quite unusual.  The extra 
helix that packs onto the side of a four-helix bundle (creating a five-helix bundle) has a great impact 
on the talin structure and functional ability in the cell.  Five-helical bundles determine that the N 
and C-terminus of the bundle are at opposite ends which allows the bundles to pack side by side 
in a linear rod-like arrangement as shown in FIGURE 2.7; this rod like arrangement allows talin to 
transmit force.  Furthermore, five-helix bundles provide more mechanical stability than four-helix 
bundles due to extensive contacts throughout the length of the helices and more hydrogen 
bonding (B. T. Goult et al., 2010).   
The talin rod contains a C-terminal dimerisation domain (DD) which enables talin to form an 
antiparallel dimer with another talin molecule (Gingras et al., 2008).  Talin dimers in literature have 
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been found to be homodimers.  Dimeric talin is able to form an autoinhibited confirmation in the 
cytosol whereby, the two talins wrap around each other to form a ‘double-doughnut’ shape with 
the talin FERM domain buried inside (Goult, Xu, et al., 2013).  Activation of talin from this inactive 
state does not appear to happen via one interactor instead a variety of activators have been 
discovered including: RIAM and Gα-switch (Lee et al., 2009; Schiemer et al., 2016).  
2.5.3.1 The R7R8 fold  
In the centre of the talin rod there is an unusual 9-helix bundle comprised of domains R7 and R8.  
These domains are in an unusual confirmation that is not seen anywhere else in talin;  R8 is a four-
helix bundle that is inserted into the R7 five-helix bundle as shown in  
FIGURE 2.10 (Gingras et al., 2010).  This confirmation of one bundle inserted into another was 
probably created by chance however, due to importance in function it has remained in this 
confirmation throughout evolution.   
The R7R8 fold is conserved in both talin isoforms; the R8 domain is inserted between the α3 and 
α4 helices on R7 (see FIGURE 2.10) and the two domains are joined via flexible linkers between 
helices 30-31 and 34-35 (see FIGURE 2.10).  The flexible linkers are joined together through 
hydrogen bonding and allow the R7R8 domain to be in different confirmations of ‘open’ and ‘closed’ 
dependent on what ligand is bound.   
As described a four-helix bundle is less mechanically stable than a five-helix bundle and so it would 
be predicted that the R8 domain should unfold at low force however, due to the insertion into R7 
the bundle is protected from unfolding (Yao et al., 2016).   This ‘protection’ of R8 is integral for 
many talin functions; the folded R8 helix binds many ligands including; actin, RIAM, DLC1 and as 






FIGURE 2.10: TALIN R7R8 DOMAIN STRUCTURE 
(A) Schematic of the helices in talin R7 and R8 indicating in brackets the helix number in full length talin and 




2.6 Talin rod interactions within adhesions 
2.6.1 Actin  
As previously mentioned both talin isoforms have three actin binding sites; ABS1, ABS2 and ABS3.   
The talin rod contains ABS2 and ABS3 as shown in FIGURE 2.11A and both are important for 
adhesion assembly and creating the force for mechanosensing capabilities of talin.    
ABS2 is positioned across talin domains R4 and R8 (Hemmings et al., 1996; Atherton et al., 2015; 
Kumar et al., 2016) and the main actin contacts are with talin domains R4 and R8 domains 
(Atherton et al., 2015).  R4 and R8 domains have abnormally high pI values (compared with the 
other talin rod domains), causing the talin surface to be positively charged at a physiological pH as 
shown in FIGURE 2.11B and C.  This positively charged surface can form electrostatic interactions 
with negatively charged actin; ABS3 and ABS1 also demonstrate similar properties.   
ABS3 is located at the talin C-terminus across domains R13-DD (McCann and Craig, 1997; Gingras 
et al., 2006).   ABS3 is essential for adhesion assembly, and the current working model indicates 
that ABS3 is the initial site that binds to actin which in turn creates enough force on the talin rod 
to unfold the mechanosensitive R3 domain, and allowing vinculin to bind.  This interaction between 
talin ABS3 and actin promotes maturation of focal adhesion assemblies (Yao et al., 2014).   
Following the un-folding of talin R3 (through force generated by actin binding to ABS3), the ABS2 
site on talin is activated and can bind actin.  This interaction has been found to be essential for FA 




FIGURE 2.11: ACTIN BINDING SITES ACROSS TALIN 
(A) Schematic of talin, red domains indicate areas of talin involved in actin binding and green helices 
represent vinculin binding sites. (B) Talin1 and talin2 R7R8 domain structures (talin1 R7R8 PDB ID:2X0C and 
talin2 R7R8 modelled using Phyre2). (C) Talin1 and talin2 R4 domain structures modelled using Phyre2. 
Structures in both B and C were modelled in PyMOL with electrostatic surfaces indicating the surface charge 
on the protein.  Blue indicates positively charged and red indicated negatively charged.  
 
2.6.2 Vinculin  
Vinculin is a cytoplasmic actin binding protein that was first discovered in 1979 (Geiger, 1979; Peng 
et al., 2011).  Vinculin is enriched at focal adhesions and is found to be a key talin interactor binding 
to 11 of the 62 talin helices in the rod domain (Gingras et al., 2005).  Vinculin binding sites (VBS) 
on talin are not found on the helical bundle surfaces (like other talin interactors) but instead are 
buried inside the helical core and can only be accessed when talin is under mechanical force as 
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shown in FIGURE 2.12F (Yao et al., 2014, 2016).  Vinculin has also been shown to activate talin 
(Carisey et al., 2013) and the exposed VBS on talin can activate vinculin (Bois et al., 2006).   
 
FIGURE 2.12: LAYERS OF AUTOINHIBITION IN TALIN 
Schematic diagram representing the layers of talin autoinhibition. (A) Represents talin in closed cytoplasmic 
conformation with the FERM domain buried inside. (B) Open talin confirmation commonly found at adhesion 
sites under no force. (C) A representation of the layers found in talin. (D) Talin rod domain R3 (white) with 
buried vinculin binding sites shown in red. (E) R3 domain stretched as a result of being under force exposing 
the buried vinculin binding site, (F) shows the now exposed VBS with vinculin bound.  Figure adapted from 
(Goult, Zacharchenko, et al., 2013; Gough and Goult, 2018) 
2.6.3 Integrin 
As discussed previously talin has an integrin binding site on the F3 sub-domain in the talin head 
which is known as integrin binding site 1 (IBS1).  IBS1 is crucial for activating integrin through 
‘inside-out’ integrin activation and increasing ECM binding (Shattil, Kim and Ginsberg, 2010).    
Talin also contains a second integrin binding site known as IBS2 (shown FIGURE 2.14), which is 
located in the rod between helical bundles R11 and R12.  The structural mechanism of how talin 
IBS2 binds integrin is currently unknown and it appears that integrin binds across the two talin rod 
domains (R11 and R12) without the helical bundles being folded or unfolding instead it is thought 
to be in some sort of intermediate confirmation (Rodius et al., 2008; Gingras et al., 2009; Ellis et 
al., 2011).  The physiological role of talin binding IBS2 in mammals is unknown however, it is 
thought that in it may be linked to nascent adhesion formation as mutations in the region lead to 
reduction in nascent adhesion clusters (Changede et al., 2015).  Interestingly in flies it has been 
shown that the role of IBS2 in integrin activation is more clear than IBS1 (Shattil et al., 2010; Ellis 
et al., 2011).   
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2.6.4 Talin-moesin  
The talin rod also binds directly (via its C-terminus domain) to the FERM domain of moesin (Beaty 
et al., 2014).  Moesin is a member of the ERM family and contains a FERM domain.  Moesin is 
localised to filopodia and helps to attach actin filaments to the plasma membrane making it an 
important protein for cell signalling and movement (Pearson et al., 2000).  This interaction between 
talin and moesin is required for recruiting the sodium hydrogen exchanger (NHE-1) to adhesion 
sites at invadopodia (Beaty et al., 2014), which can lead to localised alteration of intracellular pH 
at the adhesion sites.  Even a small change in pH can have a dramatic effect on surrounding residues 
for example, a histidine residue has an imidazole group in its side chain, at pH 5 the imidazole group 
is positively charged and hydrophilic whereas at pH 7.4 the group is neutral and hydrophobic 
(Rötzschke et al., 2002).  Protonation can be considered a post-translational modification 
(Schönichen et al., 2013) and many important protein:protein interactions have been shown to be 
regulated by pH in this manner.  One of which is the interaction between talin ABS3 and actin 
(Srivastava et al., 2008); talin1 knock-down decreases the cytosolic pH at invadopodia and blocks 
cofilin-dependent actin polymerisation which leads to instability of invadopodia and matrix 
degradation (Beaty et al., 2014).   
2.6.5 Talin-alpha synemin could provide a link to intermediate filaments 
Talin has been found to link to the actin cytoskeleton and in chapter 3 it is described how talin also 
forms a link to the microtubule cytoskeleton.  Furthermore, an interaction between the talin rod 
domain and alpha-synemin (an intermediate filament (IF) protein that is expressed in skeletal 
muscle) (Sun et al., 2008) reveals that talin may also provide linkage to IF.  This suggests that talin 
could potentially co-ordinate interactions between all cytoskeletal (actin, microtubule and IF) 
networks.    
2.6.6 Talin binds LD-motifs 
An emerging, mechanism for ligands to bind to the talin rod is via Leucine-aspartic acid (LD) binding 
motifs, which are short alpha helical interaction motifs.  These LD-motifs were first identified in 
paxillin (Brown, Curtis and Turner, 1998) and since have been identified as crucial players in 
connecting cell adhesion with cell mobility and survival (Alam et al., 2014).  LD sequences are 
named because of their core amino acid sequence LDxLLxxL (where x is any amino acid) which is 
made up of a hydrophobic cluster with an embedded positive charged amino acid.   LD-motifs are 
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recognised by LD-motif binding domains (LDBDs) (Zacharchenko et al., 2016) and in some cases the 
same LD-motif can be recognised by different LDBDs (Alam et al., 2014).     
Talin R8 has been identified as a LDBD and can bind to multiple LD ligands including; RIAM and 
DLC1 (Goult, Zacharchenko, et al., 2013; Zacharchenko et al., 2016).  RIAM is a Rap1 effector 
protein and has been found to have a central role in integrin activation through its ability to bind 
to both talin and Rap1 (Lee et al., 2009; Goult, Zacharchenko, et al., 2013; Chang et al., 2014).  DLC1 
is a tumour suppressor gene which is frequently inactivated during cancer and it encodes a Rho-
GAP focal adhesion protein needed for GTPase activation; negative regulation of RhoGTPases are 
required but not entirely sufficient for tumour suppression (Li et al., 2011).  These LD-motifs bind 
to the talin R8 domain by helix addition, the ligand forms a helix and packs against the side of the 





FIGURE 2.13: LD LIGAND BIDNING TO TALIN ROD DOMAIN 
A schematic of an LD-motif packing against a talin helical bundle via helix addition. 
 
Other domains within the talin rod can also bind LD-motifs including R3 which binds RIAM.  More 
recently, and discussed in this thesis, we have discovered that the R7 domain could bind to the LD-
motif in KANK (see chapter 4), this was a breakthrough for the understanding of LD-motifs and 
identifying that LD-motifs could bind to five-helix bundles in talin.  This was a critical realisation, as 
it opens up the possibility that every talin rod domain has the potential of binding to an LD-motif.  
Talin has the possibility to bind numerous LD talin-binding motifs making the talin rod act as a 





FIGURE 2.14: DOMAIN STRUCTURE OF TALIN1 SHOWING THE LOCATION OF LIGAND BINDING SITES 
Schematic diagram of talin highlighting the domain arrangement; vinculin binding sites are highlighted in red.  
Talin domain boundaries for both talin1 (UniProt: P206039) and talin2 (UniPro: B2RY15) are highlighted, if 
these domain boundaries are used then it is possible to make any fragment of talin and delete any domain 
whilst maintaining the proteins structural integrity. The ligands that can bind to talin are highlighted under 
the corresponding talin domain.   
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2.7 Layers of talin autoinhibition and mechano-sensing 
properties  
When describing vinculin binding to talin (Section: 2.6.2) it was revealed that talin had multiple 
layers of folding, and the vinculin binding site was only exposed on talin when talin was under force. 
We dubbed these multiple layers ‘talins layers of autoinhibition’ and they appear to be a vital 
feature of talin as a mechanosensor.  Talin has the ability to mask binding sites at certain times 
allowing talin to respond to different signals within the cell.  
FIGURE 2.12A shows a schematic representation of autoinhibited talin, here it maintains a compact 
globular shape and is found in the cytosol (Goksoy et al., 2008; Goult et al., 2009; Banno et al., 
2012; Song et al., 2012).  The autoinhibited state is achieved through interaction between the 
FERM F3 sub-domain and the talin rod domain R9.  The process by which the interaction between 
these two domains is relieved and talin switches into an active confirmation is not yet fully 
understood.  However, it would appear that a number of proteins are able to relieve talin 
autoinhibition including; Gα13 (Schiemer et al., 2016), RIAM and the phospholipid, PIP2 (Goksoy 
et al., 2008).  Once in an open confirmation talin takes on more of a linear confirmation as shown 
in FIGURE 2.12B.  This is crucial for the talin F3 sub-domain being able to bind to the integrin β-tail 
leading to integrin activation (Anthis et al., 2009).  Furthermore, the talin rod comprises 13 alpha 
helical bundles which when in this active confirmation all remain intact and provide binding 
surfaces for a number of ligands, including the LD-motif containing proteins: RIAM, DLC1 and 
paxillin (shown in FIGURE 2.15).    
In the activated confirmation talin still has binding sites such as VBS that are buried and inaccessible, 
which ensures talin can only bind to these ligands when mechanical force is applied.   Force exerted 
on talin causes the helical bundles to begin to unfold as shown in FIGURE 2.15B, this process also 
simultaneously destroys binding sites on the surface of helical bundles.  For example, if RIAM 
activates talin and helps translocate it to the plasma membrane, it would then no be longer 






FIGURE 2.15: DIFFERENT BINDING SITES ON TALIN REVEALED UNDER FORCE 
(A) Schematic of talin R3 folded helical domain illustrating where RIAM LD containing ligand can bind. (B) 
Schematic demonstrating what happens to the R3 domain when force is applied, the domain begins to unfold 
revealing the vinculin binding site (blue) this process destroys the RIAM binding site on R3 so it can no longer 
bind. (C) The talin R3 domain fully unfolded with vinculin binding site exposed allowing vinculin to bind (red).   
 
It has been shown that all thirteen of the talin rod domains can be unravelled when mechanical 
force is applied (Yao et al., 2016) and the structural stability of each of the helical bundles is 
different, resulting in some domains unfolding at lower force than others.  This difference is due to 
talin having both four-helix and five-helix bundles; four-helix bundles have a lower stability and can 
unravel at lower force than five-helix bundles (Yao et al., 2014; Yan et al., 2015).   Talin domains 
R2, R3, R4 and R8 are four-helix bundles and of these R3 is shown to be the ‘weakest’ domain in 
the talin rod un-folding at 5 pN (Yao et al., 2014, 2016).   
Force is exerted on talin when it binds to actin and the force of a single actomyosin contraction (5 
pN) is enough to un-fold R3 and reveal the VBS (Yao et al., 2014).  When vinculin binds to talin R3 
it prevents R3 from re-folding into a helical bundle; as more force is exerted on talin, further 
domains unfold and more vinculin binding sites become exposed.  The crosslinking of talin to actin 
via vinculin strengthens the adhesion, allowing it to withstand greater force.  Excessive forces on 
talin (~25 pN) can lead to vinculin being displaced (Yao et al., 2014).  When force is released talin 
helical bundles can re-fold and this ability for talin to un-fold and re-fold is critical for its role as a 
mechanosensor.  It also  allows talin to be a force buffer across the talin-integrin interactions 




2.8 Talin in disease 
Talin1 knockout in mice was found to be embryonically lethal (Monkley et al., 2000), this implies 
that any severe mutations or deletions of talin would also be lethal in humans.  This is evidenced 
by the fact that no disease-causing mutations have been identified in talin1 to date.  However, talin 
has a prominent role to play in cell-matrix adhesions and cell migration which has led to extensive 
research into possible roles talin may have in cancer progression.  Talin1 is located on chromosome 
9 which is observed to contain numerous mutations and deletions that have led to cancerous 
phenotypes (Gilmore et al., 1995).   Several studies have revealed that talin1 is overexpressed in 
cancer cells and particularly in metastatic cells (Desiniotis and Kyprianou, 2011). An example of this 
is where talin1 has been found to be significantly upregulated in prostate cancer compared to 
normal prostate tissue which led to greater invasion and migration of the cancerous cells 
(Desiniotis and Kyprianou, 2011).  This overexpression of talin1 led to increased activation of β1 
integrin at the membrane, which was found to promote the metastatic potential in the cells.   In 
prostate cancer it was found that phosphorylation of talin (at Ser425) was required to activate β1 
integrin (Huang et al., 2009).  Using a non-phosphorytable mutant of the Ser425 site the activation 
of β1 integrin could be blocked.  Further understanding of talin at a molecular level within 
adhesions could enable us to target drugs for specific cancer types.   
Talin1 has also been found to be at reduced levels in platelet cells, in patients suffering from 
myelodysplastic syndrome (MDS) (Fröbel et al., 2013).  MDS is a rare type of blood cancer 
developed through having a shortage of healthy blood cells.  Talin is an integral protein in activating 
the αIIβ3 integrin found in platelets, which enables aggregation and spreading of platelets.  In 
patients with MDS the critical integrin αIIβ3 is impaired and this is due to reduced talin expression 
(Fröbel et al., 2013).    
Diseases related to the talin2 isoform are not so well understood nonetheless, studies of talin 
isoforms in the heart revealed that both isoforms are tightly regulated and highly expressed in 
cardiomyocytes (Manso et al., 2017).  However, as heart cells mature talin2 becomes the 
predominant talin isoform and is found to localise to the costameres (see  
FIGURE 2.16)(Manso et al., 2013, 2017).  Costameres are part of striated muscle and are involved 
in the assembly of sarcomeres (Jaka et al., 2015).  Cardiac specific talin1 knockout mice do not 
display abnormal cardiac function (Jaka et al., 2015) however, talin1 is upregulated in a failing 
human heart (Manso et al., 2017).  The mechanism that leads to talin isoform switching in the heart 
is still not understood but it would appear the two isoforms play distinct roles in cardiac muscle.   
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A mutation in talin2, S339L, was found through exon sequencing to cause a fifth-finger 
Camptodactyly (a medical condition that causes a permanent bend in the fifth finger) (Deng et al., 
2016).  It seems likely to suggest that further sequencing will reveal additional talin2 mutations 
that are associated with disease which will shed further light on the functions of talin2.   
 
FIGURE 2.16: TALIN IN A COSTAMERE 
Diagram of a costamere which assembles to form part of the striated muscle in a heart. Talin is highlighted 
by a green box.   Figure adapted from (Jaka et al., 2015). 
 
2.9  Talin post-translational modifications 
Proteomic studies on talin have identified many post-translational modifications and 
phosphorylation sites (summarised in (Gough and Goult, 2018)).  Phosphorylation sites of talin 1 
were mapped in platelet cells (Ratnikov et al., 2005) and proteomic studies of the ‘adhesome’ (the 
network of structural and signalling proteins that assemble on integrin cytoplasmic tails) revealed 
further phosphorylation sites of talin (Robertson et al., 2015).  These sites are shown in TABLE 1.  
Phosphorylation of adhesions protein are important for cell signalling and phosphorylation of 
FERM domain proteins has been found to regulate transmembrane proteins (Tsukita and 
Yonemura, 1999).   The talin FERM domain is no exception, the three most abundant 
phosphorylation sites in talin1 are found in the talin FERM domain; Thr144, Thr150 and Ser446.  
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Thr144 and Thr150 are found in the F1-Loop; phosphorylation of these residues has been found to 
negatively regulate integrin activation (Ratnikov et al., 2005; B. T. Goult et al., 2010).   
The rod domain also has multiple phosphorylation sites a number of which are shown to be Cyclin 
Dependent Kinase (CDK) targets.   The CDK family plays a vital role in regulating the cell cycle but 
in literature they are not generally regarded as being involved with the regulation of cell adhesions 
(Robertson et al., 2015).  However, proteins within the adhesome are now being found to be 
phosphorylated by the CDK family which has led to the belief that CDKs could be regulating 
adhesions.  Talin is also phosphorylated by CDKs including; Ser425 phosphorylation by CDK5 
(Huang et al., 2009) and in this thesis I describe novel CDK1 phosphorylation sites on the talin rod 
R7 and R8 domains (see chapter 6).   These findings give the beginnings into understanding how 
adhesions are regulated and could suggest a link between the cell cycle and cell adhesions.   
A further talin PTM is calpain cleavage which is non-reversible.  Talin has three calpain cleavage 
sites as shown on FIGURE 2.14; one of which is located in the unstructured linker region between 
residues Gln433 and Gln434. Cleavage at this site results in the separation of the talin head from 
the rod domain which is a fundamental step in adhesion disassembly (Franco et al., 2004).  
Expression of non-cleavable talin in cells blocks growth, adhesion maturation and mechanosensing 
of the protein.  If the cells are rescued with talin rod fragments then these functions are rescued 
(Saxena et al., 2017).  Interestingly, cleavage of talin at Gln433-Gln434 is predominantly found in 
early adhesions, where adhesion turnover is very high.  With adhesion turnover being regulated 
through the calpain cleavage of talin it would suggest that an important function of talin is in 
control of cell cycle progression via cleavage in early adhesions (Saxena et al., 2017).  
Furthermore, when calpain cleaves the linker region a recognition site for E3 ubiquitin ligase 
SMURF1 is revealed in the talin head (Huang et al., 2009).  SMURF1 binds to this site on the FERM 
domain and this interaction leads to ubiquitination and degradation of the talin FERM domain 
(Huang et al., 2009).  This degradation can be stopped by phosphorylation of the residue Ser425 
by CDK5 which inhibits SMURF1 binding (Huang et al., 2009).  This complexity arising from talin 
PTMs hints at a complex signalling network where the cell fine-tunes talin function to regulate 
adhesion turnover, stability and cell cycle regulation.   
Evidence of mechanical regulation of PTMs across talin is evidenced via the third calpain cleavage 
site located on the talin rod domain between residues Pro1902 and Ala1905 (Zhang, Saha and 
Kashina, 2012).  This site is located within the R10 helical bundle and it is not exposed until talin is 
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under-force and the helical bundle unfolds.  This calpain cleavage site is regulated by arginylation 
(Zhang, Saha and Kashina, 2012). 
Most research on talin PTMs have been carried out with talin1; to determine if these sites are 
found in talin2, the talin1 and talin2 sequences were aligned.  Then all reported talin1 PTM sites 
were collated and searched for in the talin2 sequence, this information is shown in TABLE 1.  On 
the whole it was found that most talin1 PTM sites were found in both talin isoforms, suggesting 
that the isoforms are regulated in similar ways.  However, the sites which differed were of interest 
as it could give insight onto the differences between the two talin isoforms.  One ‘difference’ of 
interest is the acetylation site on talin1 R8 domain (Lys1544).  This site is not found on talin2 but 
interestingly, it would appear that in the same region on talin2 there is a phosphorylation sequence 
(see chapter 6).  This difference could be a way that the cell uses the talin isoforms to fine tune 
signalling.   Another difference between isoforms was the glycosylation sites found on talin1 R8 




TABLE 1: POST-TRANSLATIONAL MODIFICATIONS IN TALIN ISOFORMS 
A summary table of the known post-translational modifications found in both talin1 and talin2.  For each 
PTM the talin residue is listed along with the domain it is located and whether it is conserved in the other 
talin isoform.  Phosphorylation sites are from (Ratnikov et al., 2005; Robertson et al., 2015) acetylation sites 
(Choudhary et al., 2009), arginylation (Zhang, Saha and Kashina, 2012), glycosylation (Hagmann, Grob and 





2.9.1  Objectives of work  
Talin is a large adapter protein that provides a critical link between integrins and the actin 
cytoskeleton in cell-matrix adhesions.  Every talin domain has been conserved over evolution giving 
strong evidence that each domain has a biological purpose and function.  For some of these 
domains there are defined functions and known binding ligands however, there are still some 
domains in the talin rod such as talin R7 and R5 with no known role.  Are these domains of 
relevance to talin and do they have a function within adhesions?   
In my thesis I will be focussing on identifying novel binding partners to the talin rod domains and 
exploring the mechanism of LD-motifs binding to talin.  Through identifying new talin interactors 
we believe this will enable a deeper understanding of talin-integrin adhesions and shine a light on 
how the different assemblies in the cell link together.     
1. The first aim of the thesis is to characterise the interaction between talin and the adapter 
protein KANK by using a variety of different biochemical and biophysical techniques 
including: florescence polarisation, NMR and X-Ray crystallography.   After identifying the 
individual talin domain required for the talin:KANK interaction I used nuclear magnetic 
resonance (NMR) to define the talin surface that KANK binds to.  
 
After identifying the talin:KANK binding site I aim to obtain structural information of the 
talin:KANK interaction in order to design a series of talin point mutations that can perturb 
the interaction and allow us to study the role of the interaction in a cellular environment.  
This will enable me to further explore the talin:KANK interaction and look at how it may 
affect binding of other focal adhesion proteins.  
 
2. The identification of the talin:KANK interaction taught us more about how LD-motifs bind 
to talin, using this information I sought to design an LD talin-binding motif that can be used 
to search for other talin binding partners.  I designed and implemented a novel pipeline 
that used this motif and allowed us to identify talin binding proteins and rapidly identify 




3. From the LD talin-binding motif search one of the proteins identified was Cyclin Dependent 
Kinase 1 (CDK1).  Using biochemical and biophysical techniques I was able to identify the 
talin binding surface and design mutants both in CDK1 and talin to perturb the interaction.  
Using these mutants we sought to understand the dynamics and physiological role of the 
interaction within a cell.   
 
4. My final aim of the project was to biochemically characterise how talin binding CDK1 would 
affect CDK1 kinase activity.  Using an in vitro kinase assay we determined talin R7R8 is 
phosphorylated by CDK1 and through phosphomimetic-mutagenesis of the 
phosphorylated talin residue we sought to identify the phenotype of talin phosphorylation 
and if it links to cell adhesions.    
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All chemicals were purchased from: Fisherbrand; Sigma-Aldrich; Melford and BIO-RAD unless 
specified in TABLE 2 below.  All buffers were dissolved in dH2O and are listed in TABLE 3 below.  
Reagent Company 
Instant Blue Expedeon 
Ammonium Sulphate 
15N 
Cambridge Isotope Lab  
Glucose 13C Cambridge Isotope Lab  
TABLE 2: CHEMICAL REAGENTS 
3.1.2 Buffers 
Buffer Components  
NiNTA Buffer A 500 mM NaCl, 20 mM Imidazole and 20 mM Tris pH 8   
NiNTA Buffer B 500 mM NaCl, 1 M Imidazole and 20 mM Tris pH 8    
Q Buffer A 50 mM NaCl and 20 mM Tris pH 8  
Q Buffer B 1 M NaCl and 20 mM Tris pH 8   
S Buffer A 
20 mM Phosphate Buffer pH 6.5 (1.9 g NaH2PO4, 0.9 g Na2HPO4), 50 
mM NaCl, 2mM DTT 
S Buffer B 
20 mM Phosphate Buffer pH 6.5 (1.9 g NaH2PO4, 0.9 g Na2HPO4), 1 M 
NaCl, 2mM DTT 
S Buffer A 
(Crystallography) 
20 mM MES pH 6.5, 50 mM NaCl, 2mM DTT 
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TABLE 3: BUFFER COMPOSITIONS 
  
3.1.3 Hardware and apparatus 
  
S Buffer B 
(Crystallography) 
20 mM MES pH 6.5, 1 M NaCl, 2mM DTT 
NMR Buffer SolutionA 12.5  g  Na2HPO4 , 7.5  g  KH2PO4 Make  to  1L   
NMR Buffer  SolutionB 
4.0  g  C6H12O6, 10.0  mL H2O,  10.0  mL BME Vitamins,  2.0 ml MgSO4  
(1M), 0.1 ml CaCl2 (1M), 1.0 ml Antibiotic (1000x), 1.0 g 15NH4Cl  
NMR phosphate Buffer 50 mM NaCl, 15 mM NaH2PO4, 6 mM Na2HPO4 and 2 mM DTT pH 6.5   
PBS 137 mM NaCl, 2.7 mM KCl, 8 mM Na2HPO4, and 2 mM KH2PO4 pH 7.4 
SDS Running buffer 50 mM MOPS, 50 mM Tris Base, 0.1% SDS, 1 mM EDTA, pH 7.7 
5x Sample Buffer 
0.625 M Tris base, 40 % Glycerol, 10 % SDS, 10% 2 mercaptoethanol, 
0.005% Bromophenol Blue 
TBS 50 mM Tris-HCl, pH 7.6 ; 150 mM NaCl 
TBS Tween 0.1% Tween-20, 50 mM Tris-Cl, pH 7.6 ; 150 mM NaCl 
BSA in TBS 
10 mM Tris-HCl, pH 7.4, and 150 mM NaCl containing 0.05% (WT/vol) 
Tween-20 (TBST) 




TABLE 4: LABORATORY EQUPIPMENT 
Laboratory Equipment Company 
Advance III 600 MHz QCI cryoprobe Spectrophotometer Bruker 
5 mm Shigemi tubes Sigma Aldrich  
ÄKTA Pure GE Healthcare  
HiTrap Q HP 5 ml column GE Healthcare 
HiTrap S HP 5 ml column GE Healthcare 
HiPrep 26/10 G25 resin Desalting Column GE Healthcare 
ClarioStar Plate Reader BMG LABTECH 
black 96 well plates (Plate Reader) Nunc  
Prometheus NT.Plex Nano Temper 
7315-Spectrophotometer Jenway 
Weighing Scales VWR  
16R Megafuge Centrifuge Thermo scientific  
Microstar centrifuge  VWR 
NanoPhotometer IMPLEN 
Heat block-  Dry Block thermostat Grant-Bio  
pH-Meter Mettler Toledo 
Pipettes Gilson  
Gel Rocker Grant-Bio 
SDS-PAGE Gel tank Novex  
DNA tank Gene Flow 
Autoclave Classic Prestige Medical  




Protein Plasmid Vector Description Source 
mTalin1_R1R3 pET151TOPO 
Ampicillin Resistant 
plasmid expressing mouse 
talin1 rod domains 
R1,2,and 3. 
Dr Ben Goult 
mTalin1_R4R8 pET151TOPO 
Ampicillin Resistant 
plasmid expressing  mouse 
talin1 rod domains 
R4,5,6,7 and R8 
Dr Ben Goult 
mTalin1_R9R12 pET151TOPO 
Ampicillin Resistant 
plasmid expressing mouse 
talin1 rod domains 
R9,10,11 and 12. 
Dr Ben Goult 
mTalin1_R13DD pET151TOPO 
Ampicillin Resistant 
plasmid expressing  mouse 
talin1 rod domains R13 
and DD 
Dr Ben Goult 
mTalin1_R7 pET151TOPO 
Ampicillin Resistant 
plasmid expressing  mouse 
talin1 rod sub domain R7  
Dr Ben Goult 
mTalin1_R8 pET151TOPO 
Ampicillin Resistant 
plasmid expressing  mouse 
talin1 rod sub domain R8  
Dr Ben Goult 
mTalin1_R7R8 pET151TOPO 
Ampicillin Resistant 
plasmid expressing  mouse 
talin1 rod domains R7 and 
R8 





plasmid expressing  mouse 




plasmid expressing  mouse 




plasmid expressing  mouse 





plasmid expressing  mouse 
talin2 rod domains 




plasmid expressing mouse 
talin1 rod domains R7 and 




plasmid expressing mouse 
talin1 rod domains R7 and 




plasmid expressing mouse 
talin1 rod domains R7 and 




plasmid expressing mouse 








plasmid expressing mouse 
talin1 rod sub domain R7 




plasmid expressing mouse 
talin1 rod sub domain R7 




plasmid expressing mouse 
talin1 rod domains R7 and 
R8 with mutation A1495L. 
Gene Art 
mTalin1_R7R8_ A1495L+A1499L pET151TOPO 
Ampicillin Resistant 
plasmid expressing mouse 
talin1 rod domains R7 and 





plasmid expressing mouse 
talin1 rod domains R7 and 





plasmid expressing mouse 
talin1 rod domains R7 and 




TABLE 5: PLASMIDS 
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3.2 General microbiology techniques 
3.2.1 Bacteria strains used 
Throughout my work DH5α competent cells were used for plasmid DNA transformation to make 
large quantities of DNA needed for mammalian cell transfection, DH5α is a commonly used 
Escherichia coli (or E. coli) strain for cloning procedures (Hanahan, Jessee and Bloom, 1991).  BL21 
DE3 competent cells were used for protein purification.   
3.2.2 Making competent cells 
Competent E. coli cells were made from a bacterial overnight starter culture made from a single 
colony of DH5α or BL21 DE3 and inoculated into 10 mL fresh Lysogeny Broth (LB) and grown 
overnight at 37 °C.  The overnight culture was then diluted (1:50) into LB and grown to an OD600 
of 0.5-0.7. 
The cells were then cooled on ice for 15 minutes and pelleted at 4 °C 850 xg. For each 50 mL of 
culture, the pellets were gently re-suspended in 25 mL of ice-cold 0.1 M CaCl2 and incubated on ice 
for 30 min. Cells were collected again by centrifugation and re-suspended in 0.25 mL of 0.1 M CaCl2, 
containing 25% (v/v) glycerol. Aliquots were frozen rapidly and stored at -80 °C. 
3.2.3 Making agar plates 
Agar plates are used as a selective growth media to grow E.coli colonies with the desired plasmid, 
based on antibiotic resistance.   10 cm Agar plates are made by autoclaving 500 mL LB-Agar and 
adding the desired antibiotic (Kanamycin 50 μg/μL or Ampicillin 100 μg/μL) when the LB-agar has 
reached an approximate temperature of 40 oC.  The plates are then poured under sterile conditions 
and left to stand until set.   
3.2.4 Transformation 
50 µL of DH10-β/ BL21 competent cells were thawed on ice and 2 µL of the required plasmid DNA 
was added and gently mixed by inversion.  The cells and plasmid were incubated on ice for 20 
minutes and then heat shocked at 42 oC for 60 seconds, before being placed immediately back on 
ice for a further 2 minutes.   500 µL of autoclaved LB was added to the cells and they were left to 
grow for 90 minutes, shaking at 200rpm at 37 oC.  100 µL of this was then added to an agar plate 
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containing the appropriate antibiotic and spread using a glass spreader.  Plates were left at 37 OC 
in an incubator overnight. 
3.2.5 Plasmid DNA isolation from bacterial cells 
3.2.5.1 Small scale isolation- mini prep 
The small-scale isolation of plasmid DNA was performed by picking a single colony from agar plate 
using a sterile pipette tip and adding to 10 mL of autoclaved LB media.  The appropriate antibiotic 
is added to the culture and then it is left shaking at 200 rpm for 12-16 hours at 37 °C.  
The overnight culture is pelleted at 4000 rpm for 3 minutes.  The QIAprep Spin Miniprep kit (Qiagen) 
is used and manufacturer’s instructions were followed, and the plasmid DNA was eluted into 50 μL 
of Elution Buffer (10mM Tris/HCl, pH 8.5) or water.   
3.2.5.2 Large scale isolation- midiprep 
For larger scale isolation of plasmid DNA a midiprep was performed.  Initially a single colony was 
picked from an agar plate and added to 100 mL of autoclaved LB and left shaking at 200 rpm for 
12-16 hours at 37 °C.  The Midi prep kit (Qiagen) was used and manufacturer’s instructions were 
followed; the plasmid DNA was eluted into 150 μL of buffer Elution Buffer (10mM Tris/HCl, pH 8.5) 
or water.   
3.3 Protein purification methods 
3.3.1 Making a glycerol stock 
After transformation of BL21 competent cells with the required DNA plasmid, following the steps 
described in (section 3.3.4).  750 µL of the overnight culture were added to 300 µL of filter sterilised 
50% Glycerol and stored at -80 oC.  
3.3.2 Inoculating a liquid bacterial culture 
An overnight culture is made by taking a scraping of glycerol stock on a sterile pipette tip and 
dropped into autoclaved LB media.  The appropriate antibiotic is added to the culture (Ampicillin 
50 µg/mL or Kanamycin 100 µg/mL) and then it is left shaking at 200 rpm for 12-16 hours at 37 °C.   
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3.3.3 Protein expression 
The overnight culture is then added to an autoclaved bevelled glass flask containing 750 ml of LB 
(dilution 1:200).  Ampicillin is added to a concentration of 100 µg/ml.  The flask is placed in a 
rotating incubator 200 rpm at 37 °C, the culture is grown until cell density reaches 0.7 (this is 
measured using spectrophotometer at OD 600).  The cells are then induced with 200 µM IPTG and 
left overnight at 18 °C.   
The cells were harvested by centrifugation at 4000 rpm for 20 minutes.  The supernatant was 
discarded, and the pellet re-suspended in 30 mL of NiNTA buffer A.  This pellet was then stored at 
-20 °C or used straight away.   
3.3.4 Cell lysis by sonication 
Cell pellets were defrosted on ice and sonicated using an MSE Soniprep 150 sonicator to lyse the 
cells and release the protein into solution.  Cell pellets were placed on ice, in a 50 mL falcon tube. 
Sonicating cycles of 30 seconds ON and 30 seconds OFF were repeated for 4 minutes.  The sample 
was placed into a 30 mL centrifuge tube (Oakridge) and centrifuged for 20 minutes at 20,000 rpm.  
The supernatant, containing the soluble protein, was retained and kept on ice.  
3.3.5 Protein purification by immobilized metal affinity chromatography 
All the talin constructs were in pET-151 vectors (see Table 3), which contained a His6-tag sequence 
for protein purification by affinity chromatography.  The His6-tag has a high affinity for Ni2+ ions, 
which meant the protein could be purified using either a Ni-NTA column on the ÄKTA purifier 
system or using Ni-NTA resin beads (Thermo Fisher) in the batch method.   
3.3.5.1 Batch purification 
For the batch purification method 0.5 mL of beads was used for every 0.5 L of E.coli used in protein 
expression.  The beads were equilibrated with 20 mL Ni-NTA buffer A, by inverting the solution 3-
4 times and pelleting at 3000 rpm for 4 minutes.  The supernatant was discarded and this step was 
repeated three times.  The cell lysate from section 3.3.4 was incubated with the beads on a roller 
at room temperature for 45 minutes. They were then spun down at 3000 rpm for 4 minutes and 
supernatant was discarded (50 µL was kept for SDS-PAGE analysis).  The beads were then washed 
with 20 mL Ni-NTA buffer A, by inverting the tube 2-3 times before centrifuging at 3000 rpm for 4 
minutes and removing the supernatant, this process was repeated 6 times. The beads were then 
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poured into an empty eluting column and the protein was eluted from the beads by adding 5 mL 
of Ni-NTA buffer B.  Buffer was added 1 mL at a time and 1 mL fractions were collected and analysed 
using SDS-PAGE.   
3.3.5.2 Ni-NTA column purification 
A 5mL Ni-NTA HiTrap HP column (GE Healthcare) was used on an ÄKTA system for affinity 
purification of His6-tag proteins. Following column equilibration, using 6x column volumes of Ni-
NTA Buffer A, at a flow rate of 5mL/min, the supernatant was loaded at a flow rate of 3 mL/min, 
using a peristaltic pump. Following this, 6 column volumes of Ni-NTA buffer A were loaded (also 
using the pump) to remove any non-specific binding proteins.  An additional wash cycle was run 
on the ÄKTA main system; with 6 column volumes of Ni-NTA buffer A. The protein was eluted with 
a 30 mL linear gradient of 0-500 mM imidazole, at a flow rate of 3 mL/min and fractions were 
collected in a 96 well plate.  The fractions with a peak at A280 were collected and analysed on SDS-
PAGE.   
3.3.6 Buffer exchange 
After affinity purification using Ni-NTA resin or columns, the protein is in a high concentration 
imidazole buffer. For TEV cleavage to be successful, all imidazole must be removed from the buffer 
(Kinsland, 2010).  To buffer exchange, a G25 resin-desalting column (GE Healthcare) was used on 
the ÄKTA.  The protein sample from the Ni-NTA purification step was loaded onto the column using 
a peristaltic pump at a flow rate of 3 mL/min.  After this step, Q buffer A was used at a flow rate of 
5 mL/min to wash the column. A280 was monitored to determine when the protein fractions were 
eluting from the column, and these were collected in a falcon tube.  The protein is then in Q buffer 
A and ready for TEV cleavage.   
3.3.7 TEV cleavage 
Purified TEV was added to the protein sample, to a final concentration of 2 mg/mL and incubated 
on a roller at room temperature overnight.  A sample was taken before addition of TEV to run on 
an SDS PAGE gel.  
3.3.8 Ion exchange chromatography 
Ion exchange chromatography separates proteins based on differences in charge; there are two 
choices of columns for ion exchange - anion exchange column (Q column) or a cation exchange 
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column (S column).  The column was selected, based on the Isoelectric Point (pI) of the protein of 
interest. The pI is the pH at which the net charge of the protein is zero, all proteins are made up 
from different combinations of amino acids which gives different proteins different net surface 
charges.  The pI was determined using ExPASy’s ProtParam (Gasteiger et al., no date).  For proteins 
with a pI above 7 an S column was used and for proteins with a pI below 7 a Q column was used.   
The protein sample with added TEV was spun down at 4000 rpm and the supernatant was decanted 
into a falcon tube.  This was loaded onto either a 5 mL HiTrap HP Q column (GE healthcare) or 5 
mL HiTrap HP S column (GE healthcare) using a peristaltic pump at a flow rate of 3 mL/min. Six 
column volumes of Q/S buffer A were loaded through the pump to remove any non-specific bound 
proteins.  An additional wash cycle was run from the ÄKTA main system, with 6 column volumes of 
Q/S Buffer A, followed by a 30 mL linear gradient of 0-1 M NaCl for protein elution. All fractions 
displaying peaks at A280 were collected in a 96 well plate analysed on SDS-PAGE.   
3.3.9 Protein concentration estimation 
Purified protein samples concentration was quantified using a NanoPhotometer N60/N50 (Implen).  
The proteins molecular weight and extinction coefficient were calculated using ProtParam.  The 
protein concentration was calculated in mg/mL according to Beer-Lamberts Law.   
3.3.10 SDS-PAGE gels 
Samples for SDS-PAGE analysis were boiled with 5x sample Buffer at 95 °C for 5 minutes.  
Typically, gels were made in gel cassettes (Novex) with a 12 % separating component and a 4 % 
stacking component.  Buffers can be seen in  
 





















TABLE 6: GEL CONTENTS 
 
 
3.4 Biochemical methods 
3.4.1 Differential scanning fluorimetry 
Nano differential scanning Fluorimetry (nanoDSF) is a technique used to determine protein stability 
by looking for changes in intrinsic fluorescence from aromatic amino acid residues.  The nanoDSF 
measurements were done with Prometheus NT.48 (NanoTemper Technologies GmbH, Munich, 
Germany).  The Prometheus machine measures protein folding and thermal stability of proteins 
using a low sample volume capillary system and a dye free approach (Senisterra, Chau and Vedadi, 
2012; Muca et al., 2017).    
Purified proteins were tested in a range of buffers and at varied concentrations. A Monolith NT.115 
standard capillary tube (NanoTemper) was used to pick up 2-3 µL of sample and was placed in the 
loading tray. A starting temperature was set at 15°C and measurements were taken at 2 oC/minute 
with fluorescent readings at 350 and 330 nm wavelengths.  The ratio of fluorescence 
350nm/330nm was used to plot a curve, over the scanning temperatures of the instrument. For 
Separating Gel - 12% Stacking Gel - 4% 
40 % Acrylamide 7.5 mL 40 % Acrylamide 1.25 mL 
Separating Gel Buffer (1 M Tris-HCL 
pH 8.8) 
9.4 mL 
Stacking Gel Buffer (0.375 M Tris-HCL pH 
6.8)  
4.2 mL 
10% SDS 250 µL 10% SDS 125 µL 
50% Sucrose 4 mL Water 6 mL 
Water 3.3 mL TEMED 5 µL 
TEMED 6.25 µL Ammonium Persulphate 1 mL 
Ammonium Persulphate 625 µL   
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analysis and calculation of the protein’s melting point, the first derivative maxima or minima were 
taken and an 8th order polynomial fit was calculated for the transition region. Next, the first 
derivative of the fit was formed and the peak position (at Tm) was determined.  (Martin, Schwarz 
and Breitsprecher, 2014).  
3.4.2 Fluorescence polarisation 
Fluorescence polarization is a method in which the binding interaction between two molecules can 
be measured and the binding constant determined.  It works on the principle that there is a size 
difference between the two molecules being measured.  The smaller molecule is coupled to a 
fluorophore that can be excited by polarised light (light waves that only travel in a single direction) 
and will also then emit polarised light.  However, if this small molecule is tumbling quickly in 
solution it will ‘scramble’ the polarised light and emit light in all directions.  If this small fluorescent 
molecule binds to a target molecule the tumbling rate will decrease and the amount of polarised 
light will increase, shown in FIGURE 3.1.  This change in polarised light is measured and can be 
plotted to determine a binding constant.   
 
FIGURE 3.1: FLURESCENCE POLARISATION 
Fluorescence polarisation is a method in which the binding interaction between two molecules can be 
measured and the binding constant determined.  Diagram shows how a small fluorescent ligand not bound 
to anything will tumble quickly and scramble the polarisation of light by emitting at a different direction form 




3.4.2.1 Coupling peptides 
Synthetic peptides (shown in the TABLE 7 below) were ordered with an additional N-terminal or C-
terminal Cys, which allowed coupling to a fluorescent tag; BODIPY-TMR (ThermoFisher Scientific) 
or fluorescein (ThermoFisher Scientific).  The Cys residue forms a di-sulphide bond with the 
fluorescent tag allowing a signal for the peptide to be measured on the plate reader.  The peptides 
were coupled to the dye using: 100 μM peptide, 25 μL dye (fluorescein or BODIPY-TMR), 0.005 M 
TCEP (1 M stock), 0.05% (v/v) Triton X-100.  The coupling was performed at room temperature, in 
the dark, with stirring for 2 hours.   
To remove the excess of uncoupled dye from the reaction, a PD-10 column (GE Healthcare) was 
used.  1.5 mL of peptide mix was loaded onto the column and allowed to flow through, before 
adding 2.5 mL of PBS and collecting the flow through.  The coloured fractions were kept and stored 
in the dark at -80 oC.   
3.4.2.2 Fluorescence polarisation assay 
The assay uses a 1 mM stock solution of fluorescently labelled peptide and dilutes it to 1 µM in PBS.  
100 µL of 1µM peptide is pipetted into the first 11 wells of a black 96 well plate (Nunc).  100 µL of 
the protein of interest (PBS buffer) is added to well 11, along with 1 µL of 1 mM stock solution of 
the labelled peptide.  The well solution is mixed up and down twice with a pipette and 100 µL of 
solution removed from well 11 and pipetted into well 10.  The serial dilution was continued all the 
way down the plate until well 2; where the extra 100 µL was discarded.  The plate is then placed 
into the plate reader (BMG LABTECH, CLARIOstar) at room temperature and the settings were 
adjusted according to the fluorescence tag used.   
3.4.2.3 Calculating KD from binding curves 
In order to determine the binding constant KD the fluorescence polarisation data is entered into 
GraphPad Prism v7.00 software and data is fitted to the non-linear binding equation ‘one site total 




+ 𝑁𝑆 ∗ 𝑋 + 𝐵𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑   
EQUATION 1: ONE SITE BINDING EQUATION FOR FLUORESCENCE POLARISATION 
Equation used to determine binding constant KD.  Here Y represents the protein concentration and X 
represents the ligand concentration.  NS is the slope of nonspecific binding in Y units divided by X units and 
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Background is the amount of nonspecific binding with no added ligand.  The binding constant is defined as 
the amount of ligand needed to achieve half-maximum binding at equilibrium; the KD unit is the same as X. 
Peptide Sequence Supplier 
KANK1 (30-68) PYFVETPYGFQLDLDFVKYVDDIQKGNTIKKLNIQKRRKC Biomatik 
KANK1 (30-60) PYFVETPYGFQLDLDFVKYVDDIQKGNTIKKC Biomatik 
KANK1_4A (30-68) PYFVETPYGFQAAAAFVKYVDDIQKGNTIKKLNIQKRRKC Biomatik 
KANK2 (31-61) PYSVETPYGYRLDLDFLKYVDDIEKGHTLRRC Biomatik 
KANK3 (32-62) PYSVETPYGFHLDLDFLKYVEEIERGPASRRC Biomatik 
KANK4 (24-54) PYSVETPYGFHLDLDFLKYVDDIEKGHTIKRC Biomatik 
KANK_L43A (30-60) PYFVETPYGFQLDADFVKYVDDIQKGNTIKKC Biomatik 
CDK1 (283-297) CNHPYFNDLDNQIKKM GL Biochem 
CDK1 (206-223) GDSEIDQLFRIFRALGTPC GL Biochem 
CDK1 (206-232) GDSEIDQLFRIFRALGTP GL Biochem 
CDK1_2A (206-223) GDSEAAQLFRIFRALGTPC GL Biochem 
CDK1_4A (206-223) GDSEAAAAFRIFRALGTP GL Biochem 
CDK1_EA FitC (206-223) FITC-GDSAIDQLFRIFRALGTP GL Biochem 
CDK1_EP FitC (206-223) FITC-GDSPIDQLFRIFRALGTP GL Biochem 
CDK1 FitC (206-223) FITC-GDSEIDQLFRIFRALGTP GL Biochem 
HSF2 (519-535) CLCELAPAPLDSDMPLLD GL Biochem 
HSF2 (280-305) QYPDIVIVEDDNEDEYAPVIQSGEQNC GL Biochem 
SEPTIN2 (159-174) CGLKPLDVAFMKAIHNK GL Biochem 
DLC1 (465-489) IFPELDDILYHVKGMQRIVNQWSEKC GL Biochem 
RIAM (4-30) SEDIDQMFSTLLGEMDLLTQSLGVDTC GL Biochem 
TABLE 7: PEPTIDE SEQUENCES 
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3.4.3 Nuclear magnetic resonance- NMR 
3.4.3.1 Inoculating a liquid bacterial culture in 15N media 
Talin constructs were transformed into BL21 cell as described in section 3.2.4 and grown in a 10 
mL overnight of minimal media solution (10 mL SolutionA and 270 µL SolutionB), for 18 hours at 
200 rpm, 37 oC.  SolutionB could be adjusted according to the sample-label needed for the 
experiment; for all samples used here 15N Ammonium Sulphate was added to SolutionB.  The 
overnight solution (1:100) was added to 500 mL flasks of autoclaved NMR SolutionA and 30 mL 
SolutionB filter-sterilised through a 0.2 µM Millex filter (MerckMillipore).  Flasks were incubated 
with shaking at 37 oC, until an OD 600 density of 0.5 was reached, 0.4 mM of IPTG was added to 
the flask and the temperature changed to 18 ֯C and the flasks were left shaking overnight.  The rest 
of the purification process is the same as described in section 3.3. 
3.4.3.2 Buffer exchange 
Purified protein must be buffer exchanged into NMR buffer, so that the pH and salt concentration 
is the same for all samples and the data can be effectively compared.  Buffer exchange was carried 
out using a PD-10 column (GE Healthcare) following manufacturer’s instructions.   
3.4.3.3 1D NMR experiments  
All NMR experiments were performed on a Bruker Avance III 600 MHz NMR spectrometer 
equipped with QCI-P CryoProbe.  Purified 15N labelled protein with 5% D2O added was used for all 
experiments in a Shigemi tube (Sigma-Aldrich) final sample volume 450 µL and carried out at a 
temperature of 298 °K.    
1D spectra allowed us to assess if the water suppression was sufficient for the 2D experiment and 
to determine if the protein sample looked an adequate concentration for the experiments.  It also 
allowed us to determine that the added ligand was present in titrations.  However, 1D spectra 
signals are highly overlapped making direct interpretation of data challenging.  Instead analyse an 
additional dimension (15N) is introduced and this is measured in a 2D experiment.   
3.4.3.4 2D HSQC experiments 
The 2D experiment that was most used was heteronuclear single quantum correlation (HSQC) 
experiment (Mori et al., 1995).  The HSQC (and TROSY) experiment makes use of the fact that every 
amino acid (apart from proline) has a proton attached to the peptide bond.  The experiments 
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provide a correlation between the proton and the nitrogen atoms that are visualised as a peak in 
the spectrum; meaning every peak corresponds to an amino acid in the protein sequence.  A HSQC 
does also show the aromatic HN protons of Trp and His residues (which are shown as a second peak 
for that residue as well as the amide peak).   
To run a HSQC the sample from section 3.4.3.3 was kept in the spectrometer at 295K and then a 
2D 15N, 1H (HSQC) experiment was carried out.  Spectra were acquired using a HSQC pulse sequence 
at 600 MHz; data were acquired with 1024 points in the 1 H dimension over a sweep width of 10 
484 Hz and 124 increments in the indirect 15N dimension over a sweep width of 4600 Hz.  
3.4.3.5 2D TROSY experiments 
For larger proteins such as the talin1 R7R8 domain (32 kDa) a transverse relaxation optimised 
spectroscopy (TROSY) experiment was used (Pervushin, Wider and Wüthrich, 1998).  TROSY is 
collected in a similar way to a 1H15N HSQC experiment although; TROSY gives an increased 
resolution and better sensitivity for larger proteins compared to a HSQC experiment.  This increase 
in resolution is acquired due to the relaxation rates of non-decoupled HN multiplets in a HSQC 
experiment.  FIGURE 3.2A shows a peak multiplet (multiplet is what a peak representing a single 
chemical shift turns into when it is coupled to other nuclei) for both a large protein and a small 
protein in a coupled HSQC experiment.  The small protein (15 kDa) can be seen as four sharp signals 
whereas the larger protein (30 kDa) is shown as: one sharp peak which is dubbed the TROSY peak, 
two broadened “semi-TROSY” peaks and a broad peak named the anti-TROSY peak.  
The TROSY experiment works by only detecting the sharp TROSY peak and avoids mixing of all four 
signals (as done in a HSQC experiment).  This allows for a sharper peak and better peak dispersion 
in experiments.  FIGURE 3.2A demonstrates how there is no benefit to using a TROSY experiment 
on smaller proteins due to no increase in signal furthermore, hence where possible a HSQC 
experiment was used.  HSQC and TROSY spectrum can be compared and spectra can be overlaid, 
it is just important to remember there is a slight shift offset with TROSY experiments equivalent to  
½ 1JHN in both 15N and 1H dimension as can be seen in FIGURE 3.2B which needs to be corrected for 
before comparison.  15N, 1H (TROSY) spectra were acquired with a sensitivity enhanced sequence 
using an echo anti echo for phase discrimination and Watergate for water suppression.  
3.4.3.6 Spectra analysis  
Spectra were displayed and analysed in CcpNmr analysis version 2.5.2 (Vranken et al., 2005; 
Skinner et al., 2015).  Protein assignments could be read directly into CCPN from the Biological 
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Magnetic Resonance Bank (BMRB) allowing the identity of each peak to be determined and 
assigned a residue from the talin sequence.  In titration experiments each spectrum was assigned 
and this allowed for peak comparison between the talin spectrum and the titrations with ligand 
added.  Shift distances were measured between talin peak and titration peak using the weighted 
combination of 1H and 15N amide secondary shifts (∆(H,N)).∆(H,N).  Secondary shifts are 
determined whereby, WH and WN are weighting factors for the 1H and 15N amide shifts (WH= 0.15 
and WN= 1) (Ayed et al., 2001; Goult et al., 2009).  
 
FIGURE 3.2: DIFFERENCES IN TROSY AND HSQC EXPERIMENTS 
(A) Peak multiplet for both a large protein and a small protein in a coupled HSQC experiment.  Blue circle 
indicates TROSY peak, yellow and green identify semi-TROSY peaks and red identifies the broad peak named 
the anti-TROSY peak. (B) A 1H15 N HSQC (black) and 1H15 N TROSY experiment (blue) indicating spectrum shift 




3.4.4 X-Ray crystallography  
3.4.4.1 Crystallisation by hanging drop method 
Crystals were obtained by using the hanging drop vapour diffusion technique at 21 °C.  
Crystallisation screens: Hampton crystal screen 2 (Hampton), JCSG (Molecular Dimensions), Wizard 
(Molecular Dimensions) and Pact (Molecular Dimensions) were used and 100 µL of each condition 
was transferred into a 96 well plate (Hampton Research).  A Mosquito (TTP Labtech) robot was 
used to produce a 1:1 protein: well solution drop, which was then placed over the 96 well plates.  
Varying concentrations of protein were tried along with differing buffering conditions, furthermore 
peptide: protein ratio was also varied in order to facilitate crystal growth.   
If crystals were obtained from a screening condition further optimisation was carried out.  
Optimisation was used to increase the size of crystals and improve their quality in order to 
maximise diffraction quality.  Optimisation was carried out in a 24 well plate (HamptonResearch) 
and 500 µL of well solution was used.  In the 24 well plates differing the precipitant concentration 
and the pH across the 24 well plates further optimised the original screening condition. 
On successful growth of crystals they were harvested using a loop with a cryo-protectant (cryo-
protectants contained the well solution with additional 20% glycerol) and frozen in liquid nitrogen.  
Diffraction dataset was collected at 100 K on beamline I03 at Diamond Light Source (Didcot, UK) 
using a Pilatus3 6M detector (Dectris, Baden, Switzerland).   To solve the talin:CDK1 and talin:KANK 
structures the talin1 R7R8  in complex with DLC1 (PDB ID: 5FZT) was used as a template for 
molecular replacement.  Molecular replacement was carried out using PHASER (McCoy et al., 2007) 
and then manual model adjustment and refinement were performed with COOT (Emsley et al., no 
date) and REFMAC (Murshudov, Vagin and Dodson, 1997) respectively. 
3.4.5 Actin co-sedimentation assay 
Proteins to be used in the actin co-sedimentation assay were expressed and purified as described 
in section 3.3.  Purified F-Actin was used for experiments and for this G-Actin was purified from 
Rabbit skeletal muscle and polymerised to F-actin in 10 mM Tris, 50 mM NaCl, 100 μM ATP, 1 
mM DTT, 1 mM MgCl2, pH 7.0.   The co-sedimentation assays were performed using 20-μM talin 
R4-R8 (residues 913-1653), 60 μM KANK 30-60 peptide and 20 μM F-actin.  Samples were incubated 
at room temperature for 60 minutes and then centrifuged in an ultracentrifuge (Beckman Optima) 
for 20 minutes at 100,000 rpm at 4 0C.  The supernatant was removed and mixed at a 1:1 ratio with 
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2-mercaptoethanol loading buffer and boiled at 95 0C for 10 minutes.  The Pellet was mixed with 
co-sed buffer (10 mM Tris, 50 mM NaCl, 1 mM DTT, 1 mM MgCl2, pH 7.0) and 2-mercaptoethanol 
loading buffer in a 1:1:1 ratio and boiled at 95 0C for 10 minutes.  The supernatant and pellet 
samples were analysed on  8-12% gradient SDS-PAGE gels and stained using InstantBlue (Expedon).   
Image-J software (Rueden et al., 2017) was used to analyse SDS-PAGE gels and quantify the band 
density of the talin R4-R8 band  to determine the percentage of talin in the pellet and the 
supernatant.  
3.4.6 In vitro kinase assay 
An in vitro Kinase assay was used to quantify the amount of phosphorylation of different purified 
recombinant protein constructs by CDK1 and cyclins: A1 and B1.  Purified recombinant GST-tagged 
CyclinA2-CDK1 and His6-tagged CyclinB1-CDK1 were purchased from Invitrogen and stored in 20 
mM Tris, pH 7.5, 150 mM NaCl, 0.5 mM EDTA, 0.01% (v/v) Triton X-100, 2 mM DTT, 20% (v/v) 
glycerol.   
30 ng of each protein was mixed with 0.1 µg of substrate (talin/FMNL2) and incubated in 50 mM 
HEPES (pH 7.4), 150 mM NaCl, 5 mM EDTA, 5 mM DTT, 25 mM MgCl2, 0.02% Triton X-100 and 1 
mM ATP at 30 °C (shaking 100 rpm) for 20min. The reaction was stopped by adding 10 µL of 5x SDS 
sample buffer and boiled at 95 °C for 10 minutes.  A gradient SDS-PAGE 4-12% Bis-Tris gel (Thermo 
Fisher Scientific) was loaded with the entire sample and ran at 200 V for 45 minutes in 1x SDS 
running buffer (NuPAGE).  When finished the gel was placed in transfer buffer (see table of buffers).    
3.4.6.1 In vitro kinase analysis  
Western blotting is a technique used to isolate and identify proteins resolved by SDS-PAGE.  Protein 
bands from the SDS-PAGE gel are transferred to a Polyvinylidene difluoride (PVDF) membrane 
(Immobilon P, Millipore Inc.) before being probed with a primary antibody (selected for the protein 
of interest) and detected with a secondary antibody, raised against the primary and labelled with 
a fluorescent tag.  
The protein from the in vitro kinase assay SDS-PAGE gels were transferred to a PVDF membrane 
using a wet transfer.  After transfer the membrane was washed with 1x PBS buffer (see buffer table) 
before being incubated with blocking buffer (5% (m/v) BSA TBS Tween) for 30 minutes at room 
temperature rocking.  After blocking, the membrane was washed with TBS tween and incubated 
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with 1 µg/µL primary antibody.  The primary antibody was prepared in 1.5 mL 5% (m/v) BSA in TBS 
tween and added to the membrane in a sealed plastic wallet and left rocking overnight at 4 oC.    
The membrane was then washed thrice with 30 mL TBS tween (10 minutes each wash) before 
incubating with the secondary antibody.  The secondary antibody was prepared in 10 mL of 
blocking buffer (5% (m/v) BSA TBS Tween) and added to the membrane for 45 minutes in the dark 
to avoid any photo bleaching.  After incubation, the membrane was washed twice with TBS Tween 
and scanned using the Odyssey infrared imaging system (LI-COR Biosciences), and band intensities 
were analysed by using Odyssey software (LI-COR Biosciences).  All antibodies used in these 
experiments are listed in TABLE 8 below: 
Primary Antibody Supplier Secondary Antibody Supplier 
Anti- MPM2 (1:1000) Millipore  Mouse 800 (1:10,000) 
Cell Signalling 
Technology 
Anti- CDK1 (1:1000) 
Cell Signalling 
Technology 












Mouse 800 (1:10,000) 
Cell Signalling 
Technology 
TABLE 8: PRIMARY AND SECONDARY ANTIBODIES 
3.4.7 Identification of talin phosphorylation sites by mass spectrometry 
Phosphorylation sites of talin1 R7R8 and talin2 R7R8 were determined using Mass spectrometry.  
The in vitro kinase assay (see section: 3.4.6) was carried out with the substrates talin1 R7R8, talin2 
R7R8 and CDK1-cyclinA2.  Reaction was left for 45 minutes at 30 °C and stopped by adding 10 µL 
5x SDS sample buffer and boiling for 10 minutes at 95 °C.   
All samples were loaded onto an SDS PAGE 4-12% Bis-Tris gel (Thermo Fisher Scientific) and 
separated by running at 200 V for 60 minutes.  Gels were stained with Instant-Blue (Expedeon) for 
15 minutes, and washed in water overnight at 4°C.  The talin R7R8 bands were cut from the gel and 
processed by in-gel tryptic digest.  Peptides were analysed by LC-MS/MS by using an UltiMate 3000 
Rapid Separation LC (Dionex Corporation) coupled to an Orbitrap Elite MS (Thermo Fisher 
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Scientific).  Peptides were separated on a bridged ethyl hybrid C18 analytical column (250 mm × 
75 µm internal diameter, 1.7-µm particle size; Waters) over a 45-min gradient from 8 to 33% v/vl 
acetonitrile in 0.1% v/v formic acid.  LC-MS/MS analyses were operated in data-dependent mode 
to automatically select peptides for fragmentation by collision-induced dissociation.  For 
phosphoproteomic analyses, multistage activation was enabled to fragment product ions resulting 
from neutral loss of phosphoric acid.  Quantification was performed using Progenesis LC-MS/MS 
software.   
3.4.8 Cell culture techniques 
3.4.8.1 Media and cell culture  
The growth medium used for HEK-293T cells was DMEM (Dulbecco’s Modified Eagles Medium) 
with L-Glutamine, glucose, Pyridoxine-HCl, NaHCO3 (PAA-GE Healthcare) supplemented with 10% 
of FBS (Biosera) and 50 µg/mL gentamicin (Life Technologies-Invitrogen). All cells were maintained 
at 37°C and 5% CO2. 
3.4.8.2 Trypsinization and cell splitting  
For my studies I required the cells to grow as an adherent monolayer and required passaging when 
they were 70-80% confluent.  To re-suspend cells or split cell flasks, the cells needed to be removed 
from their adherent surface.  This was achieved using Trypsin-EDTA (Sigma-Aldrich).  To trypsinise, 
all media was removed from the cells and the surface was gently washed with 1X PBS.  Trypsin-
EDTA (sigma) was added to the cells and incubated at 37 oC for 5 minutes.   Cells were removed 
and added to 20 mL pre-warmed media.  The cells were counted, and the cell suspension was then 
centrifuged at 2000 rpm for 5 minutes. The supernatant was carefully aspirated and the cell in the 
pellet re-suspended in fresh media.   
3.4.8.3 Cell transfections  
Lenti-X HEK293T cells (Takara Bio Inc.) were used for all experimental assays.  The cells were 
transfected with the DNA constructs seen in table 2.  To transfect the plasmid DNA into the HEK 
293T cells, 5 µg of DNA pre-incubated in 500 µL of Opti-MEM (Sigma-Aldrich) was mixed to 500 µL 
of optimum pre-incubated with 25 µL lipofectamine 2000 (Sigma-Aldrich).  After 20 minutes of 
incubation, the mixture was drop-pipetted over the seeded cells in a 10 cm plate or 2x3 well plate.  




Chapter 4. Identifying and 
characterising the interaction 





The mechanism that targets microtubule (MT) plus-ends to grow towards focal adhesions (FA) at 
the cell cortex has been a long-standing question.  Here I look to find the missing link between 
these two macromolecular assemblies and characterise the interaction that can regulate adhesion 
turnover and stabilise MTs in their vicinity.   
4.1.1 Microtubules  
Microtubules form an integral part of the cell cytoskeleton and help to influence cell shape and cell 
polarity.  MTs are comprised of long profilaments that assemble together to form hollow tubes (of 
approximately 25 nm in diameter) (shown in FIGURE 4.1A).  Profilaments are made from two 
globular proteins: α-tubulin and β-tubulin, which form dimers and polymerise by arranging 
themselves in a head-to-tail fashion.  This assembly results in one end of the MT being exposed 
with β-tubulin and one end exposed with α-tubulin.  Due to this, MTs have polarity, an attribute 
that is critical for their function (Cooper, 2000).  The α-tubulin subunits provide a slow growing 
‘minus-end’ and the β-tubulin provides a fast growing ‘plus-end’.   Although growth can occur at 
either end of the MT, it is significantly more rapid at the plus-end (Cooper, 2000).  β-Tubulin binds 
GTP, which stimulates polymerisation of the MT profilament plus-end resulting in growth.  MTs are 
highly dynamic and are susceptible to catastrophe, whereby the filament breaks down.  MTs 
growth/ catastrophe rate is influenced by the rate of which GTP hydrolysis occurs; GTP at the plus-
end forms a GTP cap allowing for growth and protects the MT from catastrophe.  However, GTP 
can be hydrolysed to GDP, which prevents the tubulin subunits from binding tightly to the polymer 




FIGURE 4.1: THE STRUCTURE OF MICROTUBULES AND THE CYCLE OF GROWING AND SHRINKING 
(A) Schematic diagram showing the composition of a microtubule; α-tubulin (purple) and β-tubulin (blue).  
(B) The cycle of growing MT and shrinking MT through GTP hydrolysis.  Figure from (Rochlin, Dailey and 
Bridgman, 1999).   
 
4.1.2 Microtubules are found to localise to focal adhesions and assist in 
adhesion turnover 
MTs play a role in cells both during mitosis and interphase.  During mitosis, MTs completely 
reorganise to form the mitotic spindle, which allows the cell to divide into two daughter cells 
(Cooper et al., 2000).  Alternatively, during interphase MTs direct their growth towards the cell 
periphery via their dynamic plus-end (Howard and Hyman, 2003).   A process that from very early 
on has been recognised as a requirement for directional migration of cells (Vasiliev et al., 1970).   
These dramatic changes in MT organisation highlight the dynamic instability of these structures 
and the importance this has on cell growth and division. 
In the late 1980s it was found that, in migrating cells, MTs localise near FAs (Rinnerthaler, Geiger 
and Small, 1988).  This interaction did not appear to happen by chance, but, instead was a targeted 
phenomenon whereby MTs would change their growing direction in order to make connection 
with FAs (Rinnerthaler, Geiger and Small, 1988).  This cross-talk between FAs and MTs is important, 
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as it directs MT growth and enables MTs to exert their influence on cell shape and polarity in a 
migrating cell (van der Vaart et al., 2013).  Furthermore, the targeting of MTs to FAs encourage FA 
turnover which is critical for a cell to move forward during migration (Stehbens and Wittmann, 
2012).  Since the first identification of a link between MTs and FA turnover, researchers have been 
trying to identify the mechanism that targets MTs to FAs to understand what controls directional 
cell growth and migration in a spatially and temporally controlled migrating cell.  
The molecular mechanisms involved in adhesion disassembly are thought to be complex due to the 
number of proteins involved.  Because of the multifaceted interaction of proteins, it seems highly 
unlikely that adhesion disassembly occurs in reverse motion to that of adhesion assembly (Ezratty 
et al., 2005).  Which then questions- what does control adhesion disassembly and what are the key 
FA players in regulating disassembly?  When looking at cell-matrix interactions, two key players 
activate β integrin- talin and kindlin.  These proteins could both make a good converging point for 
adhesion disassembly and as such MTs could be targeting FAs via one of these proteins.   
Microtubules not only regulate FA turnover but also control FA dynamics through the regulation of 
endocytosis.  Endocytosis is the process in which the cell can traffic cargo into the cytoplasm via 
vesicular transport.  One way in which adhesions utilise this process is in integrin recycling.  Integrin 
recycling transports integrins from the back of the cell (cell rear end) and recycles them to the front 
of the cell (leading edge) (Caswell et al., 2008; Bridgewater, Norman and Caswell, 2012).  This 
process occurs through clathrin-mediated endocytosis and uses rab-labelled endocytic 
compartments (Ezratty et al., 2009).  Clathrin-mediated endocytosis selects its cargo through the 
use of adapter protein-2 (AP2), this protein coats the cargo and allows a clathrin cage to assemble 
around it.  Dynamin is a GTPase protein that coats around the neck of the clathrin coated pit and 
when hydrolysed causes a change in confirmation constricting the cell and allowing the break off 
of the clathrin coated vesicle (De Camilli, Takei and McPherson, 1995).   
MTs are often used in endocytosis acting as railroads to facilitate transport of endocytic adapter 
proteins (Stehbens and Wittmann, 2012).  MTs could also play a role in integrin recycling and 
subsequent disassembly of adhesions; at the point of integrin recycling it is thought MTs would 
already be attached to adhesion (Stehbens and Wittmann, 2012).  These MTs could act as railway 
tracks transporting in endocytic adapters such as AP2, Dab2, clathrin and dynamin.  However, it 
has been found that  when cells are treated with  nocodozole (a MT interfering drug) the levels of 





4.1.3 Microtubules are stabilised at the cell edge through the cortical 
microtubule stabilising complex 
MTs direct their growth towards the cell periphery, where, once the plus-end of the MT has 
reached the cell cortex, the MT can do one of the following:  
 Catastrophize and shrink 
 Promote formation of a cell protrusion 
 Continue to grow parallel to the plasma membrane 
 Get captured and stabilised at the cell cortex by MT-stabilising proteins 
 
MT capture and stabilisation at the cell cortex can be regulated by MT-stabilising proteins, known 
as ‘plus tip proteins’ (+TIP) (Akhmanova and Steinmetz, 2008).  An important +TIP is the 
cytoplasmic linker associated protein (CLASP), which acts as rescue factor and attaches MTs to the 
cell cortex through the formation of a complex with other proteins: LL5β and the ETS domain-
containing protein (ELKS) (van der Vaart et al., 2013).  These proteins are found in concentrated 
plasma membrane bound patches which are tightly associated with FAs around the cell cortex 
(Lansbergen et al., 2006; Hotta et al., 2010).   
In low motility cells, most MTs are found to terminate at the cell edge despite the high 
concentration of the +TIP protein CLASP (rescue factor) in close vicinity (van der Vaart et al., 2013).  
This is an interesting observation, as in the absence of protrusions the MTs could be predicted to 
form a bundle parallel to the cell edge due to continued growth; however, this was not the case.  
MT termination at the cell edge could also not be due to the cell membrane acting as a barrier to 
stop growth because MTs have been proven to be flexible (Brangwynne et al., 2007).  Instead, it 
was found that the protein kinesin family member 21A (KIF21A) counterbalanced CLASP’S activity 
and inhibited MT growth at the cell cortex (van der Vaart et al., 2013). KIF21A had also been 
previously found to interact with the KANK family of proteins via KANK’s ankyrin repeat domain 
(Kakinuma and Kiyama, 2009). KANK, in turn, is also known to bind to liprin-β1 and liprin-α1 at the 
cell cortex (van der Vaart et al., 2013).   KIF21A, Liprin-β1, liprin-α1 and KANK have been found to 
associate to the plasma membrane-bound patch proteins (LL5β, ELKS and CLASPs) and together 
this group of proteins form the cortical microtubule stabilising complex (CMSC) (FIGURE 4.2). 
The CMSC stabilises MT growth at the cell periphery and accumulates around FAs but with no 
overlap with FA proteins (van der Vaart et al., 2013).  Further evidence shows that KANK protein 
64 
 
was found very close to the FA assemblies, raising the question of whether it could be interacting 
with any FA proteins.  
 
 
FIGURE 4.2: THE CORTICAL MICROTUBUE STABILISING COMPLEX 
A schematic diagram of the proteins involved in the CMSC (cortical microtubule stabilising complex).  KANK 
binds to liprin β1 via its C1 coiled coil domain, completion of the CMSC occurs with further clustering of liprins 
and the KANK ankyrin repeat domain binding to KIF21A, which captures the microtubules and allows ELKS, 
CLASP, LL5β all to cluster around the focal adhesion.   
 
4.1.4 KANK protein family 
The KANK family of proteins are comprised of four members KANK1-KANK4. KANK stands for ‘KN 
motif and ankyrin repeat domains’ and the KANK1 gene was originally identified as a candidate 
tumour suppressor gene in analysis of renal cell carcinoma (Zhu et al., 2008).  Subsequent 
homology search across the human genome identified three other proteins in the family KANK2, 
KANK3 and KANK4 (Zhu et al., 2008).  All four KANK isoforms have a similar domain structure as 
shown in FIGURE 4.3.  Each isoform has a conserved N-terminal KN domain which spans around 38 
amino acid residues, which until recently had no known function (Zhu et al., 2008).  Our work here 
demonstrates that the KN domain plays a critical role in binding the adhesion protein talin and 
through collaboration with the Akhmanova group, we describe that this interaction is the 
mechanism that links FAs to cortical microtubule stabilising complexes (CMSC). 
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The KANK C-terminus comprises a series of five ankyrin repeats, preceded by an additional ankyrin-
0 domain shown in FIGURE 4.3; the ankyrin repeats are well conserved across the KANK family and 
across species and are important for binding to KIF21A (van der Vaart et al., 2013), a key 
component of CMSC complexes.   
The middle region of KANK is the region than differs most between the KANK isoforms ans is largely 
unstructured apart from coiled-coils regions.  KANK1 has 3 predicted coiled-coils, KANK 2 and 
KANK3 have two coiled-coils and KANK4 has just one single coiled-coil.  KANK1 and KANK2 coiled-
coil 1 region (CC1) is required to bind to liprin α1 and β1 (van der Vaart et al., 2013).   
 
FIGURE 4.3 SECONDARY STRUCTURE OF KANK FAMILY PROTEINS 
Domain structure of human KANK family proteins the domain regions are predicted using secondary 
structure prediction (PSIPRED(Jones, 1999)).  KANK domains highlighted: KN domain (green), coiled coil 





4.1.5 Identifying talin as a KANK binding protein  
To address the question of whether KANK can bind to adhesion proteins, Anna Akhmanova’s group 
from the University of Utrecht, carried out a proteomics study for KANK1, using full-length GFP-
KANK1, in HEK239T cells. The top hits for this study are shown in FIGURE 4.4B.  One of the top hits 
was talin1, the only FA protein present in the proteomics dataset. This suggested that talin is the 
FA protein involved in the KANK:FA interaction.  In parallel to this, we found that a talin1 
proteomics set previously obtained by Ben Goult in a collaboration with Martin Humphries’ group  
(unpublished data) identified KANK as one of the most abundant proteins bound to GFP-talin1 in 
human fibroblasts (shown in FIGURE 4.4A).   
In order to identify the region of KANK responsible for talin binding, the Akhmanova lab used pull-
downs from HEK293T cells, combined with mass spectrometry, to show that only the N-terminal 
region of KANK1 (1-339) interacts with talin.  Taken together, these studies suggest that talin might 
be the FA mechanosensitive protein linking the FA and the CMSC (via KANK).  
 
FIGURE 4.4: GFP-TALIN1 AND GFP-KANK1 PROTEOMIC DATA SETS. 
(A) Data from the Goult and Humphries lab showing identified GFP-tagged talin1 binding partners using mass 
spectrometry. (B) Data from the Akhmanova lab showing identification of the binding partners of Bio-GFP-
tagged KANK1 from a series of pull-down assays from HEK293T cells.  Proteins were identified using mass 
spectrometry and data was analysed using Mascot.   
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4.1.6 Identifying the region of KANK involved in interaction talin 
To further define the region of KANK involved in talin binding, the Akhmanova group used deletion 
mapping of KANK1.  This revealed that the KN domain is essential for KANK1 to localise to the FA 
rim.   The KN domain was identified in KANK1 as a conserved region spanning residues 31-72 (Zhu 
et al., 2008).  Previously, and despite its high conservation, the region had no known function other 
than harbouring a potential nuclear export sequence (NES) and nuclear localisation signals (NLS) 
which were found to contribute to nucleo-cytoplasmic shuttling of KANK1 (Zhu et al., 2008).  
The KANK1 KN domain boundary was slightly refined to 30-68 and used to make a series of GFP-
KANK constructs.  These GFP-KANK constructs were then transfected into HeLa cells along with 
mCherry-paxillin (FA marker). FIGURE 4.5 shows both full-length KANK1 and KANK1_KN constructs 
localise to FAs, whereas the KN deletion (KANK1_∆KN) is, instead, found to be diffuse around the 
cell cortex.   These data strongly indicate that the KANK KN domain is required for FA targeting. 
Combined with the data obtained through proteomics whereby KANK1 binds to talin, it is possible 





FIGURE 4.5: KANK1 KN DOMAIN IS RESPONSIBLE FOR LOCALISATION TO FOCAL ADHESIONS 
TIRFM images of live HeLa cells transiently expressing GFP-tagged KANK1 constructs: KANK1, KANK1_KN and 
KANK1_∆KN along with mCherry-paxillin (focal adhesion marker). In these experiments, endogenous KANK1 






With strong evidence that the KANK KN domain binds to talin, I sought to explore the interaction 
by employing a series of biochemical and biophysical techniques, including: Fluorescence 
Polarisation (FP), Nuclear Magnetic Resonance (NMR) and X-Ray Crystallography.  After identifying 
the individual talin domain required for the talin:KANK interaction, I used NMR to define the talin 
surface to which KANK binds to.  From this I aim to obtain structural information of the talin:KANK 
interaction in order to design a series of talin point mutations that can perturb the interaction.  This 
is of importance, as it would allow the study of the interaction in a cellular environment and 
improve our understanding of the combined function of talin and KANK1 in the context of FAs. I 
also look at how the interaction between talin and KANK1 affects binding of other FA proteins to 
talin.   
4.2.1 Designing KANK1 KN domain peptide 
The cell biology experiments from the Akhmanova lab, in section: 4.1.6, identified that the N-
terminal region of KANK contains the region responsible for binding to talin.   In light of this, we 
designed a KANK1 synthetic peptide for binding experiments.  To design the KANK1 KN peptide, a 
secondary structure prediction software (PSIPRED (Jones, 1999)) and a KANK1 sequence alignment 
across different  species was carried out. PSIPRED is a two-stage neural network  that can be used 
to predict protein secondary structure based on position-specific scoring matrices generated by 
PSI-BLAST(Jones, 1999).   PSIPRED gives a predicted secondary structure: α-helix , β-sheet or 
disordered.  The predicted secondary structure is given a confidence score, which is depicted as a 
series of blue bar graphs; the higher the bar, the higher the confidence of the predicted structure.  
The results of the PSIPRED analysis on human KANK1 have been over-laid on the sequence 
alignment on FIGURE 4.6 to highlight the region of the sequence with predicted structure. The 
algorithm shows that the N-terminal of  KANK1 is unstructured, except between residues 38-50, 
where it predicts an α-helix (with 50-60% confidence).      
To highlight the areas of high conservation in the KANK1 sequence across species, a BLAST search 
using the KANK1 human sequence (Uniprot: Q14678) was performed.  A BLAST query highlights 
proteins from different species sequences that have regions of similarity.  This search enabled 
identification of KANK1 sequences from a range of species including: Horse; Sheep; Chicken; Mouse 
and Human.  The N-terminal region of KANK1 across all species had a patch of high conservation 
between residues 30-68 (human KANK1).  In contrast, the sequence conservation for the regions 
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either side of 30-68 was much lower.  Furthermore, inspection of the highly conserved 30-68 
sequences revealed the presence of a putative LD-motif. 
 
FIGURE 4.6: CONSERVATION ALIGNMENT OF KANK1 TO DESIGN A KANK PEPTIDE 
Conservation of KANK1 N-terminal residues using sequences from: human, gorilla, chimpanzee, gibbon, 
green monkey, marmoset, horse, sheep, Chinese hamster, guinea pig, mouse, rabbit, chicken and zebrafish.  
Sequences were aligned in UniProt and all had similar secondary structure predictions (PsiPred), which is 
shown above the sequence in blue.  Conserved residues are highlighted by a *, semi-conserved amino acids 
(with similar properties) are shown by a :. Sequence alignment of talin biding motifs: paxillin LD2 (UniProt: 
P49023); RIAM (UniProt: Q7Z5R6); DLC1 (UniProt: Q96QB1); KANK1 (UniProt: Q14678) and KANK2 (UniProt: 
Q63ZY3).  The sequences were aligned via the Lei-Asp residues in the LD, interacting hydrophobic residues 
are highlighted orange and additional hydrophobic residues are highlighted in purple.   
 
4.2.1.1 KANK proteins contains an LD-Motif 
LD-motifs are short helical protein–protein interaction motifs that are crucial in connecting cell 
adhesion with cell motility and survival (Alam et al., 2014).  LD-motifs were first discovered over 
20 years ago in the paxillin family of scaffolding proteins (Bellis, Miller and Turner, 1995), with the 
sequence LDxLLxxL (where x is any residue).  The N-terminus of paxillin was found to contain five 
of these LD-motifs which are highly conserved both across species, and across the paxillin 
superfamily (Tumbarello, Brown and Turner, 2002).   
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LD-motifs are recognized by LD binding domains (Zacharchenko et al., 2016) (LDBDs).  LD-motifs 
bind to LD binding domains via helical addition, whereby the LD-motif forms a helical structure 
which packs against the side of a helical bundle as shown in FIGURE 4.7.  The core LD-motif 
sequence LDxLLxxL binds to the LD recognition box via its Asp residue, which forms a salt bridge 
with a negatively charged residue on the LDBD.  In some cases, the same LD recognition box can 
recognize multiple different LD-motifs and the mechanism that distinguishes how LD-motifs are 
selective for their target molecule is still not fully understood.  Fully understanding this mechanism 
is important, as dysfunction in LD-motifs often contributes to diseases, such as cancer metastasis 
and viral infections (Mitra and Schlaepfer, 2006).  A more detailed discussion of LD-motif 
recognition is given in Chapter 5. 
 
FIGURE 4.7: TALIN1 R8 DOMAIN IS LD RECOGNITION BOX 
A schematic of the LD recognition box on the talin R8 domain. Purple cylinder represents an LD-motif showing 
how the Asp residue would bind to a charged amino acid on the LDBD via the recognition box.  Further down 
the LD-motif a second charged residue makes contact with talin in what is known as the specificity region 
(Zacharchenko et al., 2016).   
 
4.2.1.2 Talin can bind LD-motifs 
The first realisation of LD-motif binding to talin was found when looking at the interaction between 
the protein DLC1 (Deleted in Liver Cancer 1) and talin (Zacharchenko et al., 2016).  This interaction 
was mapped to the R8 domain of talin, and since then R8 has become recognised as an LDBD that 
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forms a hot spot for LD binding proteins with: DLC1, RIAM, and Paxillin all binding to the domain.  
The best studied mode of LD-motif recognition is via binding to four helix bundles (Hoellerer et al., 
2003).  FIGURE 4.6 shows an alignment of the known talin binding LD-motif proteins identified to 
date and aligns the KANK1 KN domain with the canonical LDxLLxxL motif.  This analysis was 
interesting as it shows that the KANK1 region does not quite fit the consensus LDxLLxxL motif of 
other LD binding proteins; the KANK sequences have an additional charged Asp residue in place of 
the hydrophobic residues found in the other sequences.  This extra Asp residue comes because of 
an LDLD motif found in KANKs sequence, which has not been found in other LD containing proteins.  
We were not sure if the charged residue would prevent the region from binding to the LD 
recognition box.  However, the rest of the KANK sequence looked to fit the LD-motif pattern and 
so we concluded the KANK KN domain did include an LD-motif.  This led us to hypothesize that 
KANK would bind to the talin R8 domain where the other LD-motifs have been found to bind to 
talin.  A series of KANK1 peptides were designed encompassing the potential LD-motif predicted 
to bind to talin.  The constructs differed slightly in length with the hope they would narrow down 
the talin-binding site; peptides are shown in FIGURE 4.8. 
 
FIGURE 4.8: BIOCHEMICAL CHARACTERISATION OF KANK BINDING TO TALIN 
(A-B) Binding of BODIPY-TMR labelled KANK1(30–68)C peptide to talin1 R7R8 (1357–1653), talin2 R7R8 
(1360-1656) and Talin1 R7 (1357-1653 Δ1454-1586) was measured using fluorescence polarization.  BODIPY-
TMR labelled TFS258 peptide was used as a negative control.  Dissociation constants ± SE (μM) for the 
interactions are indicated in the legend.  All measurements were performed in triplicate.  ND, not determined.  
(C) helical prediction of KANK peptide based on the DCL1 peptide (PDB ID: 5FZT) KANK1 30-60 residues were 
threaded onto the DLC1 helix using PyMOL and the designed peptides for FP: KANK1 30-60C, KANK1 30-68C 
and KANK1 41-68C. (D) Structural model of the talin rod domains highlighting R7 and R8 talin domains.  
73 
 
4.2.2 Determining the region of talin involved in the talin:KANK 
interaction 
To investigate if talin R8 was the binding domain for KANK1, we used the designed human KANK1 
synthetic peptide (KANK1 30-68C), shown in FIGURE 4.8C.  A C-terminal cysteine residue was added 
to the peptide to allow coupling to a fluorescent label.  To test the relative binding affinities, an in 
vitro fluorescence polarization (FP) assay was used.  In the assay, the KANK1 30-68C peptide was 
coupled to BODIPY-TMR (see material and method Chapter 3) and titrated against an increasing 
concentration of talin1 (residues 1357-1653) or talin2 (residues 1360-1656).  An increase in FP 
signal generates a binding curve that corresponds to binding of the peptide and protein, the FP 
binding curve was fitted to a binding equation (see materials and method Chapter 3) to obtain 
dissociation constant, KD.  FIGURE 4.8 shows the binding data for talin1 R7R8 domain with the 
KANK1 30-68C peptide.  FIGURE 4.8A, shows that talin1 binds KANK1 with a KD of 0.75 μM and 
talin2 with KD 1.2 μM.  Interestingly, this sub-micromolar affinity of KANK1 for talin makes KANK 
the strongest talin-binder identified so far.   
To confirm if talin R8 was the KANK binding domain, the same FP assay was used with individual 
domains R7 (residues 1359–1653 Δ1454–1586) and R8 (residues 1461-1580) (FIGURE 4.8B).  This 
gave a surprising result - KANK1 bound to talin1 R7 with a KD of 1 μM only barely to the R8 domain 
(KD nd, data not shown), revealing that it is actually the talin R7 domain that contains the major 
KANK binding site.  The fact that KANK1 bound with lower affinity to the R8 domain indicates that 
there is a weak interaction (possibly between the LD residues and the LD recognition box in R8).  
This was unanticipated because evidence of LD-motifs binding to 5-helix bundles had not yet been 
reported.  This finding shows KANK is binding to talin in a novel-binding site, and talin R7 could be 
a new talin LD binding domain (LDBD).   
4.2.3 Chemical shift mapping of talin1 R7R8 domain with KANK peptide 
To explore the talin:KANK1 interaction further, NMR chemical shift mapping was used. Chemical 
shift mapping is a technique that follows the changes in chemical shifts of a protein when a ligand 
is added, these shifts can be used to determine the binding site and in some cases the affinity of 
the ligand.  Typically for chemical shift mapping 1H15N HSQC or 1H15N TROSY experiments are used 
(see materials and methods 3.4.3.4) and the protein is expressed with an 15N label such as 15N 
ammonium sulphate.  The HSQC and TROSY experiment makes use of the fact that every amino 
acid (apart from Pro) has a proton (hydrogen) attached to the peptide bond see FIGURE 4.9.  The 
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experiments provide a correlation between the proton and the nitrogen atoms which are visualised 
as a peak in the spectrum; meaning every peak correlates to an amino acid in the protein sequence.   
 
FIGURE 4.9: 1H15N HSQC CORRELATION BETWEEN THE PROTON AND THE NITROGEN ATOM 
Schematic diagram showing the correlation between nitrogen and proton atoms in a amino acid that a HSQC 
and TROSY measure. 
15N-labeled talin1 R7R8 (residues 1357-1653) were expressed and purified for NMR see materials 
and methods 3.4.3.1.  A 15N TROSY spectrum of talin1 R7R8 (80 µM) (black FIGURE 4.10) showed 
good peak dispersion indicating the talin1 R7R8 domain was folded as reported previously (Gingras 
et al., 2010).  The addition of the KANK1 peptide 30-68C to talin1 R7R8 at a ratio of 3:1 (blue FIGURE 
4.10) caused large peak changes in the NMR spectra; the peaks were still well dispersed, indicating 
that the overall structure of the R7R8 talin domain had been maintained.  A significant number of 
peaks that shifted upon addition of KANK1 were found to be in slow exchange, which on the NMR 
shift timescale is indicative of a tight interaction, complementing the 1 μM KD measured with the 
FP assay.   Slow exchange is where the protein is found to be in two states: free protein and protein 
bound to the ligand.  Because the exchange between these two forms is happening slowly the NMR 
is capturing both states that is visualised as two peaks.  These two peaks will disappear and become 
one when the interaction is saturated enough to only see the bound form.   
To determine which talin peaks had shifted when KANK peptide was added the talin:KANK 
spectrum was overlaid with talin1 R7 spectrum (data not shown).  This showed that the large 
majority of the peaks that shifted were h the talin R7 peaks, there were some smaller shifts 
recorded on R8 talin peaks.  The chemical shift changes on the R8 domain were in fast exchange, 
which on the NMR timescale is indicative of a weak binding interaction, thus supporting the finding 




FIGURE 4.10: 15N TROSY NMR TITRATION TALIN1 R7R8 AND KANK1 30-68C PEPTIDE 
(A) 1H,15N TROSY spectra of 80 uM 15N-labelled talin1 R7R8 (residues 1357–1653) in the absence (black) or 
presence of KANK1(30–68)C peptide (blue) at a ratio of 1:3. (B) Shows a zoomed in region of spectra (A) 
(highlighted by the black box) showing slow exchange of peaks when the KANK1 peptide has been added.  
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4.2.4 Chemical shift mapping of talin1 R7 domain with KANK peptide 
To identify where on the R7 domain the KANK was interacting a 15N HSQC titration was carried out 
on the single talin1 R7 (1359–1653 Δ1454–1586).  15N-labelled talin1 R7 was titrated against 
increasing concentrations of the KANK1 30-68C peptide.  The overall spectra are shown in FIGURE 
4.11A, with talin1 R7 on its own (black) and KANK1 titrated at a ratio 1:2 (talin:KANK) (blue).  The 
peak shifts were much clearer to analyse compared to the double R7R8 domain due to less overlap 
of individual peaks, allowing the tracking of each individual peak.  The peaks are in slow exchange 
on the NMR timescale after the addition of the KANK1 30-68C peptide, confirming the high affinity 
between talin1 R7-KANK1.   
Evidence of an R7 peak in slow exchange is shown in FIGURE 4.11B.  Talin1 Asp1362 (black) is found 
as a single peak when not bound to KANK1.  When KANK1 is added at a 0.5:1 ratio (talin: KANK1) 
(green) half the talin R7 molecules are bound to KANK1 and half are in the free form which gives 
rise to two Asp1362 peaks.  In contrast, if the interaction were in fast exchange we would see a 
single peak at the average position of free and bound.  When KANK1 is then added to talin at a 
ratio of 1:1 (pink) the entire population of talin in the sample is now bound to KANK1 and so the 
Asp1362 signal appears as a single peak again but in a different position to when not bound to 
KANK1.   
A region of the R7 spectrum is shown in FIGURE 4.11C and D.  FIGURE 4.11C shows talin1 R7 (black) 
with KANK1 30-60C added at a ratio 1:0.5 (green) and FIGURE 4.11D KANK1 30-68C added at a ratio 
1:1 (purple).  FIGURE 4.11C has more peaks than FIGURE 4.11D as it is showing both the bound 
and non-bound forms of talin.  Mapping which peaks shift upon addition of KANK allows us to 
understand which talin residues are involved in the interaction and define the interacting surface 
on talin.   
In order to determine which peaks have shifted, amide chemical shift assignments from the 
Biological Magnetic Resonance Bank (BMRB) of talin1 R7 were downloaded (BMRB: 19139).  The 
assignments were used to assign the corresponding residue number to each peak in the talin1 R7 
HSQC spectrum.  For each peak the chemical shift changes on addition of KANK1 were measured 
between talin1 R7 on its own and talin1 R7:KANK1 (at a ratio 1:2).  This however was harder than 
anticipated, as it was not clear for every talin peak where it had shifted upon the addition of KANK1 





FIGURE 4.11: 15N HSQC NMR TITRATION TALIN1 R7 AND KANK1 30-68C PEPTIDE 
(A,C,D) 1H,15N HSQC spectra of 150 µM 15N-labelled talin1 R7 (residues 1357–1653 Δ1454-1586) in the 
absence (black) or presence of KANK1(30–68)C peptide (blue/green/purple).  Blue peaks shows a 1:2 ratio of  
talin:KANK1, green peaks 1:0.5ratio and purple peaks 1:1 ratio. Black box highlights residue Asp1362.  (B) 
Shows the peak corresponding to Asp1362: black peak is on its own, green is with KANK1 30-68C peptide 
added at a ratio of 1:0.5 and pink is KANK1 peptide added at a ratio of 1:1.  The peak splitting is evidence 
that the interaction is happening in slow exchange. 
78 
 
To solve this problem, we needed to find a way to put the talin:KANK interaction into fast exchange 
on the NMR timescale.  Fast exchange binding has a distinct peak tracking pattern; peaks shift in a 
line upon addition of binding ligand.  This is because the ligand is binding on and off the protein 
quickly resulting in an average position being taken, so as more ligand is added the average peak 
position will be closer to fully bound resulting in a linear line of peaks.  This line of peak shifts allows 
for more confident tracking and recognition of where each peak has shifted.   
In preliminary characterization of the talin:KANK interaction a KANK1 peptide- KANK1 42-68 was 
designed.  The KANK1 42-68 peptide did not encompass any residues before the LD-motif unlike 
the longer KANK1 30-68C peptide.  Instead, the first residue was Leu48, which was likely to have 
reduced helical propensity of the region reducing its ability to bind to talin R7.   
The FP assay showed this peptide had a much weaker binding KD (data not shown) to talin R7R8 
then the 30-68C peptide.  The reduced affinity to talin worked to our advantage, as it changed the 
talin:KANK interaction to a fast exchange regime on the NMR timescale.   
A point in the 15N HSQC titration with talin1 R7 (black) is shown in FIGURE 4.12A.  KANK1 42-68 
peptide was added to talin1 R7 at a ratio of 6:1 (blue).  The addition of KANK peptide caused the 
talin peaks to shift.  Talin1 R7 amide chemical assignments (BMRB: 19139) were used to determine 
which peaks in the HSQC had shifted and peak distances were measured using EQUATION 2:. 
∆(𝐻, 𝑁) =  √∆𝐻𝑊𝐻
2 + ∆𝑁𝑊𝑁
2  
EQUATION 2: WEIGHTED COMBINATION OF AMIDE SECONDARY SHIFTS 
Chemical shift changes are determined using the weighted combination of 1H and 15N amide secondary shifts 
(∆(H,N)).  ∆(H,N).  Secondary shifts are determined whereby, WH and WN are weighting factors for the 1H and 
15N amide shifts (WH= 0.15 and WN= 1) (Ayed et al., 2001). 
 
The shift differences for each peak in talin1 R7 are shown in FIGURE 4.12B; residues where the 
peak shifted over 0.005 ppm are highlighted in red on the graph and also on the talin1 R7R8 
structure (PDB ID: 5FZT) shown in FIGURE 4.12D.  Shifts over 0.005 ppm were chosen to be mapped 
because it represented a significant peak shift when KANK1 was added which likely correlates to 
the peak being involved in binding or can also be due to induced conformational change upon 
binding.  Shifts below this range were not deemed significant in the talin:KANK interaction.  The 
shift changes mapped to the surface of talin R7 between helices 2 and 5 of the R7 5 helix bundle 





FIGURE 4.12: CHEMICAL SHIFT MAPPING OF TALIN1 R7R8 AND KANK1 42-68C 
(A) KANK1 30-68C and KANK1 42-68C peptides aligned.  (B) 1H,15N HSQC spectra of 150 µM 15N-labelled talin1 
R7 (residues 1357–1659 ∆1454–1586) in the absence (black) or presence of KANK1(42–68)C peptide (blue) 
at a ratio of 1:6.  (C) Mapping the chemical shift distances of the KANK142-68 peptide with talin1 R7 as 




FIGURE 4.13: CHEMICAL SHIFT MAPPING OF THE KANK1 BINDING SURFACE ON TALIN1 R7 
Mapping of the KANK1 binding site on R7 as detected by NMR using weighted chemical shift distances, 






4.2.5 Structural characterisation of the talin:KANK complex 
We wanted to gain an atomic structure of the talin:KANK1 interaction in order to determine which 
KANK1 residues were interacting with talin R7.  Through doing so we hoped to design both a KANK 
mutant to disrupt talin binding and a talin mutant to disrupt KANK binding. 
4.2.5.1 Crystal trials of talin1R7R8:KANK1 structure 
To get an atomic structure of talin1:KANK1 crystallography trials were set up with talin1 R7R8 
(residues 1357-1659) and the KANK1 30-60C peptide.  Talin1R7R8 and KANK1 were incubated 
together at varying ratios (1:1,1:2,1:4) and then plated onto a number of different crystallography 
screens including: Hampton crystal screen 2 (Hampton), JCSG (Molecular Dimensions), Wizard 
(Molecular Dimensions) and Pact (Molecular Dimensions).  All screens were plated at a 1:1 ratio of 
protein: well solution and left at both 4 °C and 20 °C.  No crystals were found in any condition at 
either temperature.   
4.2.5.2 Predicted talin:KANK1 structure 
To design KANK and talin mutations in the absence of an atomic structure of talin:KANK1, a 
structural model was generated by docking the talin1 R7R8 and the KANK1 30-68C  peptide 
together.  This was achieved using the known talin1 R7R8:DLC1 structure (PDB ID:5FTZ), where the 
DLC1 forms a short alpha helix when bound to talin.  The DLC1 helix was used as a base and the 
KANK1 peptide 30-68C was threaded onto the DLC1 helix using PyMOL to create a helical KN 
domain structural coordinates.  The DLC1 helix was docked onto the R7 helices 29 and 36 based on 
the NMR chemical shift mapping data.  Multiple binding models were initially created; switching 
which end of the talin bundle the KANK LD-motif docked, i.e. with the KN domain flipped 180° along 
the domain axis.  After structural analysis of the residues involved it was decided that the most 
plausible model had the KANK Asp42 and Asp44 forming salt bridges with talin Arg1652 and 
Lys1401 (respectively).  We know from previous studies in the lab that the formation of a salt bridge 
with the Asp residue in an LD protein is essential for talin binding (Zacharchenko et al., 2016).  The 





FIGURE 4.14: STRUCTURAL MODEL OF THE TALIN1 R7R8: KANK1 INTERACTION 
(A) Talin1 R7R8 structure showing the predicted binding site of KANK 30-60 (green) on the talin1 R7 surface.  
(B) Highlights talin1 R7 residues Trp1630 and Tyr1389 that act as molecular rulers separating helices 29 and 
36.   
 
4.2.6 Designing KANK mutations to perturb talin:KANK1 interaction 
The talin binding site (TBS) on KANK1 is unusual, it contains an LDLD motif, which has not been 
seen before in an LD-motif.  In order to further investigate and confirm that the LDLD residues were 
integral for talin binding, we designed a KANK1 mutant that removed the LDLD residues and 
mutated them to alanine’s (KANK_4A mutant).   
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We anticipated that the substitution to alanine residues would perturb KANK binding to talin.  The 
talin:KANK model shows KANK residues Asp42 and Asp44 form salt bridges with talin Arg1652 and 
Lys1401 (respectively).  FIGURE 4.15 shows how aspartate interactions position the KANK peptide 
in relation to talin and allow the KANK1 hydrophobic residues to be directed between the talin 
helices to form hydrophobic interactions.  Mutating Asp42 and Asp44 to a non-charged residue 
such as alanine would prevent the ability of KANK to form salt bridges with talin.   
 
FIGURE 4.15: STRUCTURAL REVIEW KANK_4A MUTANT 
(A) Talin1 R7 structure with predicted KANK1 30-60 (green) bound; KANK1 Asp42 and Asp44 residues are 
highlighted and the talin residues predicted to form salt bridges which are integral for KANK binding.  (B) 
Talin1 R7 with KANK1_4A peptide, KANK LDLD residues mutated in PyMOL which demonstrates how Ala 
mutations prevent the formation of salt bridges with talin1 R7 and thus would prevent talin:KANK binding.    
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4.2.7 Biochemically characterisation of the KANK1_4A mutant 
To determine if KANK_4A mutation would prevent binding to talin a KANK1_4A 30-68C peptide 
was designed FIGURE 4.16A, the peptide was designed to be the same length as the KANK1 30-68C 
peptide and contain a C-terminal cysteine residue that would allow it to be coupled to a fluorescent 
label.   
Using the FP assay, both KANK1 30-68C and KANK1_4A 30-68C peptides were titrated against 
increasing concentrations of talin1 R7R8 (residues: 1357–1653) and talin2 R7R8 (residues: 1360-
1656) the relative binding affinities measured are shown in FIGURE 4.16B.  The binding between 
talin and KANK1 was completely abolished in both talin isoforms when the KANK_4A peptide was 
used, highlighting that the KANK LDLD residues are required for binding to talin.   
 
 
FIGURE 4.16: KANK_4A MUTANT PERTURBS BINDING TO TALIN 
(A) Alignment of KANK1 peptides used in FP assays green highlights LD-motif and red highlights mutation 
added to sequence. (B) Binding of BODIPY-TMR labelled KANK1 (30–68)C and KANK1_4A (30-68)C peptides 
to talin1 R7R8 (1357–1653) and talin2 R7R8 (1360-1656).  Dissociation constants ± SE (μM) for the 




4.2.7.1 NMR analysis of the KANK1_4A mutant 
NMR was used to further investigate the effect of the KANK1_4A mutation on talin:KANK binding 
and to look for the presence of weaker binding events that may not be detectable by FP. A 15N 
TROSY titration of 15N labelled talin1 R7R8 (residues 1357-1653) (black) shown in FIGURE 4.17 with 
addition of KANK1_4A 30-68C peptide (orange) and addition of KANK1 30-68C (blue).  No shifts 
were observed with the addition of KANK1_4A peptide confirming the absence of binding events.  
Interestingly, there was also no peak movement on the talin R8 residues when the KANK_4A 
mutant was added unlike with the KANK 30-68C peptide, supporting the idea that the weak KANK1 
binding to talin R8 is via its LD domain.   
To further confirm the KANK_4A mutant was effective, a 15N HSQC was carried out with the single 
R7 talin domain.  FIGURE 4.17 shows talin1 R7 (black) with KANK1 30-68 (blue) and KANK1_4A 30-
68 (orange) added.  No shifts were observed when the KANK1_4A mutant was added confirming 





FIGURE 4.17: KANK_4A MUTANT PERTURBS BINDING TO TALIN1 R7R8 
(A) 1H,15N TROSY spectra of 80 µM 15N-labelled talin1 R7R8 (residues 1357–1653) in the absence (black) or 
presence of KANK1(30–68)C peptide (blue) at a ratio of 1:3.  (B) Shows 1H,15N TROSY spectra of 80 uM 15N-
labelled talin1 R7R8 (residues 1357–1653) in the absence (black) or presence of KANK1_4A mutant peptide 




FIGURE 4.18: KANK_4A MUTANT PERTURBS BINDING TO TALIN1 R7 
(A) 1H,15N HSQC spectra of 150 μM 15N-labelled talin1 R7 (residues 1357–1659 Δ1454-1586) in the absence 
(black) or presence of KANK1(30–68)C peptide (blue) at a ratio of 1:2.  (B) 1H,15N HSQC spectra of 150 μM 
15N-labelled talin1 R7 (residues 1357–1659 Δ1454-1586) in the absence (black) or presence of KANK_4A 




4.2.8 Designing talin1 R7 mutants to perturb the talin: KANK1 interaction 
A major aim of the biochemical characterisation of the talin:KANK interaction was to design and 
validate mutations that perturb the interaction, so to be able introduce them into cells and 
ultimately animals, to explore the physiological role of the interaction.  Having already designed a 
successful KANK_4A mutant we wanted to design a point mutation on talin R7.  The mutation 
needed to perturb the interaction between talin and KANK, but also maintain talins structural 
integrity so as not to perturb its mechanical properties or other interactions with adhesion proteins.   
The distance between the talin R7 helices 29 and 36 (FIGURE 4.19) is larger than between other 
adjacent helices, both within R7 but also in other talin bundles.  Helices 29 and 36 are separated 
by a distance of 8-10Å, compared to the other helices in R7 that are only 5-6Å apart.  Analysis of 
the structure revealed that two residues, Trp1630 on helix 36 and Tyr1389 on helix 29, are the 
reason for this helix separation.  These residues act as “molecular rulers” and fix the distance 
between the two talin helices. This is due to the large size of Trp and Tyr side chains forcing the 
talin helices apart.   
The space between the two helices is enhanced further due to smaller residues Ser1400, Gly1404 
and Ser1411 on helix 29 and Ser1637 and Ser1641 on helix 36 (FIGURE 4.19).  These residues are 
located on the inner helical surfaces and their small side chains create two conserved pockets 
midway along the KANK1 binding site.  We predict that these pockets create space for the KANK1 
peptide to fit and allow KANK1 bulky hydrophobic residues to point in between the talin helices. 
A key KANK1 residue that looks to be burying in between the talin helices is Tyr48.  Our structural 
talin:KANK1 model shows the Tyr48 residue binding in the talin binding pocket described above.  It 
looks as though when bound, the KANK1 Tyr48 residue is in close proximity to talin Gly1404.  We 
therefore rationalized that if Tyr48 could be prevented from engaging R7 it might disrupt the 
talin:KANK1 interaction.  To achieve this the talin Gly1404 residue was mutated to a leucine residue.  
Leucine residues have big side chains, we predicted that it would fill the gap between the two-talin 





FIGURE 4.19: STRUCTURAL ANALYSIS OF TALIN1 R7 TO DESIGN TALIN MUTANTS TO PERTURB KANK 
INTERACTION 
(A) KANK 30-60 peptide (green) binding to talin R7 highlighting the Tyr and Trp residues acting as molecular 
rulers and keeping helices 29 and 36 at a fixed distance apart. (B) Talin R7 helices 29 and 36 surface showing 
acidic residues (red) and basic residues (blue); black dotted box indicates the conserved pockets on the talin 
surface important for KANK binding.  (C) Talin1 R7 surface with KANK 30-60 (green) peptide docked onto the 
side.   
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Additionally, on the opposite helix to Gly1404 (helix 36) is the residue Ser1641 (helix 29).  Ser1641 
was of particular interest as it was identified in the 2005 paper by Ratnikov et al. as a 
phosphorylation site on the talin R7 domain; this residue was predicted to be phosphorylated by 
CKII (casein kinase 2), PKC (protein Kinase C) and RSK (ribosomal S6 Kinase)(Ratnikov et al., 2005).  
With the location of this phosphorylation site being close to the KANK binding site we hypothesized 
that phosphorylation of Ser1641 may serve as a kinase dependent regulation of talin:KANK binding.  
To further investigate this, a phosphomimetic mutant, S1641E was designed. 
Lastly, a triple talin mutation was designed; Lys1401Glu, Lys1645Glu and Arg1652Glu (KKR).  The 
KKR mutant replaced three positively charged residues is shown in FIGURE 4.20, the talin Lys1401 
and Arg1652 residues are predicted to form salt bridges with KANK Asp42 and Asp44.  Through 
mutating the positively charged talin residues to negatively charged Glutamates it was predicted 
to repel the KANK Asp and prevent the talin:KANK interaction.   
These observations lead us to designing a series of talin1 R7 mutants: 
i. G1404L - Filling the gaps between helices 29 and 36 preventing KANK Tyr48 from binding 
into talin groove. 
ii. W1630A - Removing the ‘molecular ruler’ that is holding the two talin helices 29 and 36 
apart. 
iii. S1640E - A phosphomimetic of the phosphorylation site. 
iv. KKR (K1401E, K1645E and R1652E) - Trying to disrupt electrostatic interactions between 
the KANK LD Asp42 and Asp44 residues binding to talin.   
 
The mutants were introduced into talin1 R7R8 (residues 1357-1653) for protein solubility purposes 
as creating them in the R7 domain alone might be disruptive to the helical bundle and prevent 
appropriate folding of the protein.  The constructs were cloned into apET-151 expression vector 





FIGURE 4.20: STRUCTURAL ANALYSIS OF DESIGNED TALIN MUTANTS TO PERTURB KANK INTERACTION 
(A) Talin1 R7 bound to KANK1 indicating the talin residues selected for mutation to perturb the talin:KANK 
interaction.  The slat bridges between Asp residues on KANK and talin Lys1401 and Arg1652 are indicated on 
the structure. (B) Talin1 R7 indicating the mutated talin residues for mutants; G1404L, S1641E,W1630A and 




4.2.9 Validating the structural integrity of the talin1 R7R8 mutants 
The validation and analysis of the talin mutants is essential in ensuring that the domain integrity is 
not compromised by the modification, and a combination of techniques was used, including: NMR, 
CD and Nanoscale Differential Scanning Fluorimetry to assess this.   
To determine the structural stability of the talin1 R7R8 mutants: G1404L, W1630A, S1640E and 
KKR, the proteins were recombinantly expressed and purified (gel shown in FIGURE 4.21).  Thermal 
stability was measured using Nanoscale Differential Scanning Fluorimetry (Nano Temper 
Technologies GmbH) see materials and methods Chapter 3. 
Thermal unfolding of R7R8 mutants was followed through changes in intrinsic fluorescence (ratio 
at 350/330 nm) as a function of temperature (temperature gradient from 20 to 90 °C) and plotted 
as shown in FIGURE 4.21.  The maxima and minima of the first derivatives these curves were used 
as the midpoints (Tm) of the thermal unfolding  and the values are summarized in the table in 
FIGURE 4.21.  Whilst WT talin1 R7R8 has a Tm of 47.6 oC, the thermal stability of the different 
mutants were mixed.  W1630A had a similar unfolding temperature to the WT, indicating that this 
particular mutation had no major effect on the overall stability of the helical bundle.  The G1404L 
mutation also had negligible effect on the stability of R7R8.   
Intriguingly, the S1641E mutant appeared to stabilize the R7R8 domain, increasing the Tm to 50.3 °C.  
The KKR mutant, however, was surprisingly unstable in solution and appeared to undergo two 
unfolding events, the first being at 36.5 oC; this suggests that the KKR mutation may have disrupted 
the integrity of the domains and the separate unfolding events could represent the different talin 
domains unfolding: R7, where the mutation lies, could unfold at the lower temperature before the 
final unfolding of the R8 domain.   
Protein aggregation midpoints were also calculated for all versions of the R7R8 domains, by 
measuring light scattering as a function of temperature – the values used represent the maxima or 
minima of the first derivatives of the scattering curves.  Whilst most mutants had aggregation 
temperatures close to the WT R7R8 domain, the aggregation temperature for KKR mutant was 
much lower, confirming its instability and indicating that this would not be a useable mutant for 
either biochemical analysis or for cell work, as it wouldn’t be stable and could affect more than the 




FIGURE 4.21: THERMAL STABILITY OF TALIN R7R8 MUTANTS 
(A-B) Thermal stability of a series of talin R7R8 (1357-1653) constructs (Talin1, Talin2, S1641E, G1404L, 
W1630A and KKR) was determined.  The unfolding temperature was calculated using the first derivative of 
thermal unfolding curves obtained using Prometheus NT.plex instrument (NanoTemper Technologies GmbH).  
(C) A table of all unfolding temperatures and aggregation temperatures, aggregation temperatures 
calculated from first derivative of scattering data.  (D) SDS-page gel of all talin R7R8 constructs used in the 
thermal stability measurements.   
4.2.10 Measuring the binding affinity of KANK1 to the talin mutants 
To determine if the talin mutants were effective in disrupting the talin:KANK interaction, the 
relative binding affinities of the talin mutants and the KANK1 30-68C peptide were measured using 
in vitro FP assays (FIGURE 4.22).  The KANK1 30-68C peptide was coupled to the fluorescent label 
BODIPY-TMR and titrated with an increasing concentration of the talin1 R7R8 mutants. 
The relative binding constant showed that the S1641E mutation had a small effect on the binding 
of KANK1 to talin with a measured KD of 2.1 μM compared to the talin1 R7R8 WT KD 0.5 μM, 
suggesting that the proposed phosphorylation of the Ser1641 residue may be playing only a minor 
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role in regulating the binding of KANK1 to talin.  However, this still represents a four-fold change 
in affinity, which may be of importance and it is also possible that the Glu1641 was not a sufficient 
phosphomimetic.  In the cell, phosphorylation may have a larger effect on the R7 surface properties 
an effect that is not being mimicked completely by a single Glu substitution. 
 
FIGURE 4.22: TALIN R7R8 MUTANTS BINDING TO TALIN 
Binding of BODIPY-TMR labelled KANK1(30–68)C peptide to talin1 R7R8 (residues 1357–1653), talin1 R7R8 
G1404L(residues 1357–1653), talin1 R7R8 S1641E (residues 1357–1653),  and talin1 R7R8 W1630A (residues 
1357–1653).  Relative binding affinities were measured using fluorescence polarization and dissociation 
constants ± SE (μM) for the interactions are indicated in the legend.  All measurements were performed in 
triplicate.  ND, not determined.   
 
The W1630A and G1404L mutations both had striking effects on the talin:KANK interaction, 
abolishing any binding and therefore a KD could not be determined.  This gives further confidence 
in the talin:KANK structural model we predicted, as it confirms the importance of the Gly1404 for 
the KANK1 Tyr48 to dock.  G1404L and W1630A were taken forward for further biochemical 
analysis. 
NMR was used to further validate the G1404L and W1630A mutants.  Initially a 15N TROSY spectrum 
of talin1 R7R8 WT, G1404L and W1630A mutants were run and are shown in FIGURE 4.23.  Each of 
the mutant spectra look well dispersed and similar to the R7R8 WT, indicating the R7 helical bundle 




FIGURE 4.23: 15N TROSY SPECTRA OF THE R7R8 TALIN MUTANTS 
(A) 1H,15N TROSY spectra of 80 μM 15N-labelled talin1R7R8 (residues 1357–1653)(black).  1H,15N TROSY 
spectra of 80 μM 15N-labelled talin1R7R8 G1404L (red) (residues 1357–1653).  1H,15N TROSY spectra of 80 
μM 15N-labelled talin1R7R8 W1630A (green) (residues 1357–1653)(black).      
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 To look at the binding of KANK1 30-68C with talin1 R7R8 G1404L mutant a 15N TROSY NMR titration 
(shown in FIGURE 4.24) of talin1 R7R8 (residues 1357-1653) (black) and talin1 R7R8 G1404L (black) 
were titrated against increasing concentrations of the KANK1 30-68C peptide (WT blue, G1404L 
red).  The addition of the KANK1 30-68C peptide caused shifts in the WT R7R8 spectra consistent 
with binding occurring, however, there were also some small shifts in the G1404L mutant spectra.  
Further analysis showed these shifts could be mapped to the talin R8 domain, showing that the 
KANK1 peptide could still bind weakly to the talin1 R8 domain. 
To further characterize the effects of the point mutations on R7 binding to KANK, the G1404L and 
W1630A mutations were introduced into the single talin1 domain R7 (1359–1653 Δ1454–1586), 
recombinantly expressed and purified.  15N HSQC of talin1 WT R7, G1404L and W1630A were run 
to determine if the mutants affected the overall structure of the talin1 R7 domain.  The spectra 
(G1404L red, W1630A green) shown in FIGURE 4.25 confirm the mutations did not affect the 
folding of the five-helix bundle; the peaks were well dispersed and looked similar to the WT spectra 
(shown in black), although a number of residues shifted in the mutants in comparison to the WT, 
presumably close to the mutation site.  The 2D NMR spectra nicely highlights the tryptophan 
mutation in W1630A - talin1 R7 only has one tryptophan residue and the indole peak from the 





FIGURE 4.24: TALIN G1404L MUTANT PERTURBS BINDING TO TALIN R7 
(A) 1H,15N TROSY spectra on the left 80 µM 15N-labelled talin1 R7R8 (residues 1357–1653) in the absence 
(black) or presence of KANK1(30–68)C peptide (blue) at a ratio of 1:3.  Right spectra shows 1H,15N TROSY 
spectra of 80 μM 15N-labelled talin1 R7R8 G1404L mutant (residues 1357–1659) in the absence (black) or 




FIGURE 4.25: 15N HSQC SPECTRA OF THE TALIN R7  MUTANTS 
(A) 1H,15N HSQC spectra 80 µM 15N-labelled talin1 R7 (residues 1357–1653 ∆1454-1586. (B) 1H,15N HSQC 
spectra 80 µM 15N-labelled talin1 R7 G1404L (red) (residues 1357–1653 ∆1454-1586). (C) 1H,15N HSQC 
spectra 80 µM 15N-labelled talin1 R7 W1630A (green) (residues 1357–1653 ∆1454-1586).  Red circle indicates 
Trp1630 residue indol peak.  
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Having determined that the mutations do not affect the talin R7 structurally 15N titrations with 
talin1 R7 WT, G1404L and W1630A mutants and increasing amounts of KANK1 30-68C peptide 
were carried out and shown in FIGURE 4.26.  The talin1 R7 WT peaks shifted when the KANK1 
peptide was added, as previously shown, demonstrating the tight interaction between KANK1 and 
talin1 R7 WT.  In contrast, the two talin mutants showed only very slight changes in their spectra 
when the KANK1 peptide was added (G1404L green, W1630A red), indicating lack of interaction.  
The presence of slight changes in the spectra for the R7 mutants with KANK1 are likely to represent 
weak residual interactions as NMR can detect very weak interactions down to the mM KD range.   
The NMR titrations do confirm that the talin G1404L and W1630A mutants successfully perturb the 





FIGURE 4.26: TALIN R7 MUTANTS PERTURB BINDING TO KANK1 
(A)1H,15N HSQC spectra: 150 μM 15N-labelled talin1 R7 (residues 1357–1653 ∆1454-1586) in the absence 
(black) or presence of KANK1(30–68)C peptide (blue) at a ratio of 1:2.  (B) 1H,15N HSQC spectra: 150 μM 15N-
labelled talin1 R7 G1404L mutant (residues 1357–1653 ∆1454-1586) in the absence (black) or presence of 
KANK1(30–68)C peptide (red) at a ratio of 1:2.  (C) 1H,15N HSQC spectra: 180 μM 15N-labelled talin1 R7 
W1630A mutant (residues 1357–1653 ∆1454-1586) in the absence (black) or presence of KANK1(30–68)C 




4.2.11 Investigating talin binding to different KANK isoforms 
All our initial experiments aimed to characterise the interaction between talin and KANK1.  
However, the proteomics data set (from fibroblast cells) for talin1, suggested that talin could also 
bind to KANK2.  Therefore, we sought to test whether the other KANK isoforms were also capable 
of binding to talin.  As described earlier FIGURE 4.3, all four isoforms of KANK have a KN domain.  
To predict whether they could bind to talin, human KANK isoforms were aligned to determine if 
the LD region was conserved; this is shown in FIGURE 4.27.  When all four human isoforms were 
aligned, not all of the 30-68 residues that make up the KN domain were fully conserved.  Only 
residues 30-60 were conserved across all four isoforms, shown in red on FIGURE 4.27, with KANK3 
being the most divergent.  KANK3 had 58% sequence homology to the KANK1 KN domain whereas 
KANK2 and KANK4 had 73% and 77% sequence homology (BLAST results), respectively, raising the 
question of whether KANK3 will bind more weakly than the other isoforms to talin.   
Due to low conservation of residues 60-68 across all KANK isoforms I wanted to determine if 
residues 60-68 (shown in blue on FIGURE 4.27) were important for talin binding.  To achieve this a 
shorter KANK1 KN peptide, with only residues 30-60, was designed shown in FIGURE 4.28.  The 
relative binding affinities of KANK1 30-60c and KANK1 30-68C to talin R7R8 were measured, using 
the in vitro FP assay.  The KANK1 30-60C peptide coupled to the fluorescent label BODIPY-TMR, 
was titrated with an increasing concentration of the talin1 R7R8.  The results are shown in FIGURE 
4.28; there was not a noticeable difference in relative affinities between KANK1 30-60 and KANK1 
30-68C, revealing that the 60-68 residues do not play a major role in the talin interaction.  
  
FIGURE 4.27: KANK KN DOMAIN ALIGNMENT 
Alignment of Human KANK proteins (KANK1 Q14678, KANK2 Q63ZY3, KANK3 Q6NY19, KANK4 Q5T7N3) LD 
residues highlighted in green.  Conserved residues are highlighted by a *, similar property amino acids are 
shown by a :. Red box indicates the region highly conserved 30-60 residues across all four KANK isoforms and 





FIGURE 4.28: CHARACTERISING THE KANK1 KN DOMAIN BOUNDARY 
Binding of BODIPY-TMR labelled KANK1(30–68)C and KANK1 (30-60)C peptides to talin2 R7R8 (1360-1656).  
Dissociation constants ± SE (μM) for the interactions are indicated in the legend.  All measurements were 
performed in triplicate.  ND, not determined. 
 
As residues 30-60 are highly conserved across the isoforms of KANK, narrowing down the TBS on 
KANK1 to residues 30-60 strongly suggested that the other isoforms of KANK may also bind talin.  
To determine if the other KANK isoforms could bind to talin R7R8 via the KN domain, synthetic 
peptides of the other KANK isoform KN domains were designed, encompassing the ’30-60’ residues 
of KANK1 as shown in FIGURE 4.29. 
Relative binding affinities of the different KANK isoforms (KANK1 30-60, KANK2 31-62, KANK3 32-
62 and KANK4 24-54) and talin1 and 2 R7R8 were determined using FP assays, and the results are 
shown in FIGURE 4.29.  It is apparent that all the four KANK KN domains can bind to talin1.  KANK1 
and KANK2 have similar binding affinities to both talin isoforms, whereas KANK4 shows a stronger 
affinity to talin2 than talin1.  KANK4 24-54 bound to talin1 with a KD 2.55 μm and talin2 with a KD 
of 0.6 μM.  The measured KD of KANK3 and talin1 R7R8 was 1 μM the same affinity as KANK1 and 
talin1.  It was unexpected that the KANK3 binding affinity was same as KANK1 due to the biggest 
sequential difference was between KANK1 and KANK3.  The similarity in binding highlights the 




FIGURE 4.29: CHARACTERISING KANK ISOFORMS 1-4 BINDING TO TALIN1 R7R8 AND TALIN2 R7R8 
(A-D) Binding of BODIPY-TMR labelled KANK1(30–60)C, KANK2(1-61)C, KANK(32-62)C and KANK4(24-54)C 
peptides to talin1 R7R8 (1357–1653) and talin2 (1360-1656) measured using fluorescence polarisation.  
Dissociation constants ± SE (μM) for the interactions are indicated in the legend.  All measurements were 




4.2.12 Does the binding of KANK to talin R7 increase thermal stability? 
Our structural model of talin:KANK shows KANK1 binding to the talin R7 domain through a helix-
addition interaction, where the KN domain peptide packs on the side of R7 between helices 29 and 
36.  This would imply that, when KANK1 is bound to R7 (a five-helix bundle) it would become like a 
six-helix bundle.  In literature there is little evidence of six-helix bundles in nature other than those 
found in virus proteins such as HIV (Hu et al., 2012).   
We know that talin is a mechanosensitive protein and if enough force is applied then the talin R7R8 
domain can be unfolded and the helical bundle formation is lost (Yan et al., 2015; Yao et al., 2016).  
If the talin R7 bundle is unfolded by force, then the KANK1 binding site would be lost and KANK1 
would no longer be able to bind to talin.  Does KANK1 binding to talin increase the stability of 
bundles and prevent their unravelling, by reducing susceptibility to force?    
To begin to address this question we initially looked at the thermal stability of talin R7R8 domain 
with both KANK1 and KANK2 30-60C peptides.  Although thermal stability does not directly link to 
mechanostability it would give an indication of whether KANK binding was altering the talin R7R8 
domains.  Thermal unfolding was measured using the Prometheus software and the results are 
shown in FIGURE 4.30.  For both KANK1 and KANK2 peptides, binding to talin increases the thermal 
stability of talin1 and talin2 R7R8 domains; Tm values in talin1 and KANK2 were increased by 10 oC, 





FIGURE 4.30: KANK EFFECTS STABILITY OF TALIN HELIX 
(A-B) 141 μM Talin1 R7R8 and Talin2 R7R8 thermal stability measured in the presence and absence of KANK1 
and KANK2 (150 μM) peptides.  (C-D) The unfolding temperature was calculated using  the first derivative of 
thermal unfolding curves obtained using Prometheus NT.plex instrument (NanoTemper Technologies GmbH).  
(E) A table of all unfolding temperatures and aggregation temperatures.  Aggregation temperatures 




4.2.13 Can KANK influence the interaction between talin and actin? 
As mentioned in the introduction (Chapter 2) talin has three actin binding sites; ABS1, ABS2 and 
ABS3, which all play different roles in adhesions(Atherton et al., 2015).  ABS2 is positioned across 
talin domains R4 and R8 (shown FIGURE 4.31C) at the centre of the talin rod and provides the 
tension-bearing actin connection which has been found to be crucial for focal adhesion maturation 
and generating maximum traction force (Atherton et al., 2015; Kumar et al., 2016).   
Talin ABS2 is present in both talin isoforms and the main binding surfaces for actin have been 
narrowed down in previous actin pull-down experiments, showing R4 and R8 domains to be the 
key helical bundles involved in the interaction (Atherton et al., 2015).  Both R4 and R8 domains 
have atypically high isoelectric point (pI) values, compared with the other talin rod domains, 
causing the surface of these domains to be positively charged at physiological pH.  A positive 
binding surface enables the domains to form an interaction with the negatively charged actin; 
these high pI values are also shown on the actin binding helices in ABS1 and ABS3 (Atherton et al., 
2015).   
The R7 domain is only weakly involved in actin binding but is crucial in correctly positioning the R8 
domain in the ABS2 site.  Since we show that KANK binds weakly to the R8 helical bundle, we 
questioned whether KANK binding to talin R7R8 could have an overall effect on the affinity of actin 
to talin ABS2.   
To observe the effects that KANK had on the interaction between actin and talin1 ABS2, a series of 
actin pull-down experiments were carried out using talin1 R4R8 (residues 913-1580), filamentous 
actin and KANK1 30-68C peptide.  Initially the percentage of actin pulled down with talin1 ABS2 
was measured (see materials and methods Chapter 3) and visualised using SDS PAGE.  Image J was 
used to measure grey-scale value of the talin bands in the pellet and supernatant (Rueden et al., 
2017).  The intensities were converted into a percentage of overall talin in the supernantent and 
pellet and are shown above the band on the gel in FIGURE 4.31. 
The difference in talin R4R8 co-sedimentation with actin, compared to KANK:talin R4R8 co-
sedimentation with actin was measured and is shown in FIGURE 4.31.  The KANK1 30-68C peptide 
is 3 KDa in molecular weight so could not be visualized on an SDS-PAGE gel.  The experiment was 
carried out in triplicates and a re-producible difference in the amount of talin in the actin pellet 
when KANK1 was present compared to when it was absent is noticeable.  More talin was pulled-
down when KANK1 was present 41% compared to 29%. 
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The increased amount of talin in the pellet, when KANK1 is present, could be due to KANK1 binding 
the talin1 R7 domain and opening up the R7R8 structure allowing the R8 domain to be in a more 
open confirmation to bind actin.  The negative effect on talin:actin binding predicted if KANK bound 
to talin R8 was not seen, this could be due to not enough KANK1 being added, saturation of the R7 
domain had not been reached meaning that there was no KANK1 bound to talin1 R8.  
 
FIGURE 4.31: TALIN1:KANK1 INTERACTION INCREASES ACTINS AFFINITY TO TALIN ACTIN BINDING SITE 2 
(A) Recombinant talin domain ABS2 (residues 913-1580) was incubated with F-actin and KANK1 peptide, 
actin was then pelleted and the supernatant (S) and pellet (P) were analysed via SDS-PAGE, the percentage 
of talin found in either the S or P is shown above the band.  Actin co-sedimentation assay shows that actin 
binding to ABS2 is increased when KANK 30-68C peptide is present.  (B) A schematic of talin actin binding 
site 2, blue highlights bundles involved in the interaction and yellow shows neighbouring domains.  (C) A full 
length talin schematic highlighting the three talin actin binding sites ABS1-ABS3 across the protein, green 




4.3 Testing the physiological role of KANK mutants in a cellular 
context 
Having designed and biochemically characterised both a successful KANK mutant (KANK_4A) and 
a talin mutant (G1404l and W1630A) to perturb the talin:KANK interaction it was paramount to 
next understand the significance the talin:KANK interaction in conjunction with the rest of the cell.  
In order to achieve this our collaborator Anna Akhmanova from the University of the Utrecht 
carried out cellular experiments using our designed talin and KANK1 mutants.  The following 
sections describe the cell biology results generated with the reagents generated in this chapter.   
4.3.1 Characterisation of KANK1_4A mutant in mammalian cells 
In collaboration with Anna Akhamanovas’ group, the KANK_4A mutant was transfected into 
mammalian HEK293T cells to explore the importance of the talin:KANK interaction within the cell .  
The Utrecht group also generated: a full-length KANK1 ∆coiled-coil (∆CC), a ∆coiled-coil_4A 
(∆CC_4A) and a KN domain 4A (KN_4A).  The ∆CC mutant corresponds to the coiled-coil region of 
KANK1, designed to test if KANK1 requires binding to liprin β1 in order for the KN domain to bind 
to talin.  The hybrid mutant ∆CC_4A was designed with both the coiled-coils missing and the 4A 
mutation in the KN domain incorporated. 
To determine if the KANK1 mutants perturbed the talin1:KANK1 interaction bioGFP-tagged: KANK1 
WT, KANK_4A, ∆CC, ∆CC_4A and KN_4A constructs were co-transfected with GFP-talin1 into 
HEK293T cells.  Streptavidin pulldown assays were performed, as shown in FIGURE 4.32, and these 
showed that both the KANK1_4A and the KN_4A mutants reduced the interaction between KANK 
and talin1.  This corroborated my biochemical finding that the KANK_4A mutant disrupted the 
interaction between talin and KANK.  Whilst the ∆CC mutant did not appear to affect the talin:KANK 
interaction, the ∆CC _4A mutant had a stronger inhibitory effect than the full length 4A mutant on 
its own.   The deletion of the coiled-coil region in the ∆CC _4A mutant prevented KANK1 from 
localising to the cell cortex and binding to liprin β1, which can account for the difference observed 
between this form of the protein and the KANK_4A mutant.   
To investigate effects of the different mutations on KANK1’s localisation in the cell, HeLa cells were 
depleted of endogenous KANK1 and KANK2 using siRNA.  KANK1 and KANK2 were targeted, as they 
were the two isoforms the Utrecht group found to be present in HeLa cells in previous proteomic 
studies (van der Vaart et al., 2013).  Rescue experiments were performed with GFP-KANK1 WT and 
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mutants.  FIGURE 4.32B shows images taken using total internal reflection fluorescence 
microscopy (TIRFM) live imaging.  The FL-KANK1 WT strongly accumulates in cortical patches that 
cluster around the edge of FAs, as expected. However, this clustering is absent when cells are 
transfected with the FL-KANK1_4A and instead KANK1 is dispersed throughout the cell cortex. 
Whilst the ∆CC mutant of KANK1 localised almost entirely around FAs in the shape of tight rings, 
the ∆CC_4A mutant was completely dispersed around the cell with no localisation to FAs or the cell 
cortex.  For the KN domains, the WT version localised to focal adhesions but did not accumulate 
around the edge of FA assemblies; instead, it entered into focal adhesion assemblies, possibly due 
to the small size of the domain.  The KN_4A mutant, however, was completely diffused across the 
cell.   
The KANK1 mutants provided further evidence that the KANK1 KN domains interaction with talin 
provides an essential link for KANK1 to be recruited to focal adhesion assemblies.  The different 
KANK1 mutations also highlighted the importance of the different KANK domains.  They showed 
that the coiled-coil region is essential for KANK to accumulate in the cell cortex, where it interacts 
with liprin β1, and that the KN domain is critical to create a link with talin and cluster KANK around 





FIGURE 4.32: CHARACTERISATION OF KANK LOCALISATION IN MAMMALIAN CELLS 
(A) Streptavidin pull-down assays with the BioGFP-tagged KANK1 or the indicated KANK1 mutants, co-
expressed with GFP-talin1 in HEK293T cells, analysed by Western blotting with the indicated antibodies.  (B) 
TIRFM images of live HeLa cells depleted of KANK1 and KANK2 and co-expressing the indicated 
siRNAresistant GFP-KANK1 fusions and TagRFP-paxillin.  Data from (Bouchet et al., 2016).   
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4.3.2 Characterisation of talin1 G1404L mutant in mammalian cells 
Our biochemistry data identified two talin1-R7 point mutants that could abrogate the talin1:KANK1 
interaction: W1630A and G1404L.  To further our understanding of talins’ role in recruiting KANK1 
to focal adhesion assemblies one of the talin mutants was chosen for transfection in mammalian 
cells.   
Biochemically both the W1630A and G1404L mutations perturbed talin binding to KANK.  However, 
for the cellular studies G1404L was chosen over W1630A.  G1404L changes the talin binding surface 
and not the domain structure whereas, removal of Trp1630 would remove the ‘molecular ruler’ 
that is holding apart the two talin helices making up the KANK binding site; this structural change 
could have an off target effect of disrupting the mechanostability of the talin R7 domain, which is 
known to be important for protecting talin R8 from force induced extension (Yao et al., 2016).   
4.3.2.1 Does the G1404L mutant effect focal adhesion formation? 
To determine if the G1404L talin mutant had any off-target effects on focal adhesion formation or 
maturation, the Akhmanova lab used HeLa cells and depleted them of both endogenous talin1 and 
talin2 before rescuing with mouse GFP-talin1 or the GFP-talin1_G1404L mutant.  The depletion of 
talin1 and talin2 resulted in near total loss of FAs and caused detachment from coverslips, which 
supports the well-established role of talin1 in focal adhesion formation (del Rio et al., 2009; 
Calderwood, Campbell and Critchley, 2013; Yao et al., 2014; Yan et al., 2015).  Therefore, only cells 
expressing the GFP-talin1 could be imaged, since they exhibit normal attachment and spreading.  
FIGURE 4.33A shows HeLa cells expressing GFP-talin1 and GFP-talin1-G1404L.  FIGURE 4.33B-D 
also show that talin-G1404L can fully support normal cell attachment and spreading.  Further the 
number or size of focal adhesions is not significantly different between talin1 WT and G1404L.  This 
leads to the conclusion that the talin1 G1404L point mutation did not interfere with talins’ 




FIGURE 4.33: G1404L TALIN1 MUTANT DOES NOT AFFECT TALINS ABILITY TO FORM FOCAL ADHESIONS 
(A) Fluorescent F-actin staining (red) in HeLa cells co-depleted of talin1 and talin2 transfected with the 
indicated GFP-talin1 fusions.  (B) Cell area (C) Focal Adhesion number per cell (D) Focal Adhesion area in cells 
treated the same way as (A).  (n=12 cells, 577–664 FAs analysed).  In all plots: error bar, SEM; ns, non-




4.3.2.2 Does the G1404L mutant perturb talin:KANK interaction in cells? 
To investigate the impact of the talin mutant G1404L on the talin:KANK1 interaction, the 
Akhmanova group used bioGFP-tagged talin1, talin1-G1404L, talin1 R7 and talin1 R7 G1404L 
constructs for co-transfection with HA-KANK1 in HEK293T cells.  Streptavidin pull-down assays 
were performed and Western Blots against GFP and HA are shown in FIGURE 4.34A.  The assays 
show that both the talin1-G1404L and talin1 R7 G1404L mutants abrogated the interaction with 
KANK.  This finding fully supports our biochemical evidence where we observed that recombinant 
talin1 R7 G1404L stops binding with KANK.   
Following pull-down assays, the Akhmanova group used HeLa cells with knock-downs of both talin1 
and talin2 for rescuing with GFP-talin1 WT and GFP-talin-G1404L.  Following transfection, cells 
were immunolabelled for endogenous KANK1 and imaged (shown in FIGURE 4.34B and D).  KANK1 
localises around the rim of adhesions when WT talin is present but in cells expressing talin-G1404L, 
KANK1 is no longer localised to FAs and appears to be diffuse across the cell.   
Overall, our biochemical data and the Utrecht group’s cell data leads to the conclusion that it is 
possible to perturb the talin:KANK1 interaction with a single point mutation in the approximately 
2500 amino acid long talin1 protein.  As previously discussed, the point mutation does not disrupt 
talin’s role in focal adhesion formation; however, it abolishes KANK1s’ ability to cluster around the 




FIGURE 4.34: CHARACTERISATION OF THE TALIN1 G1404L MUTANT IN CELLS 
(A) Streptavidin pull-down assays with the BioGFP-tagged WT talin1 or the indicated talin1 mutants, co-
expressed with HA-KANK1 in HEK293T cells, analysed by Western blotting with the indicated antibodies.  (B) 
Widefield fluorescence images of HeLa cells depleted of endogenous talin1 and talin2, rescued by the 
expression of the wild type GFP-tagged mouse talin1 or the G1404L mutant and labelled for endogenous 
KANK1 by immunofluorescence staining.  (C) Quantification of peripheral clustering of KANK1 in cells treated 
and analysed as in (E) (n=12, 6 cells per condition).  Error bar, SEM; *** *p<0.001.  (D) HeLa cells co-depleted 
of talin1 and talin2 transfected with the indicated talin1 fusions and stained for the endogenous KANK1.  
Data taken from (Bouchet et al., 2016).   
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4.3.3 How does mislocalisation of KANK1 due to perturbed talin1:KANK1 
binding affect other CMSC components? 
Disruption of the talin:KANK interaction prevents KANK from being recruited to the rim of FA 
assemblies and, instead, KANK is distributed across the cell.  Following this finding, we wanted to 
explore what happens to CMSC components when KANK is no longer localised to the cell cortex or 
adhesions. 
For this, the Akhmanova group knocked-down KANK1 and KANK2 in HeLa cells,  which resulted in 
the complete abolishment of clusters of CMSC components such as LL5β and KIF21A around the 
cell cortex.  Rescue experiments with GFP-KANK1 showed that cortical clustering of these proteins 
could be restored upon expression of KANK1 WT (shown in FIGURE 4.35).  However, clustering of 
LL5β and KIF21A could not be fully restored with the addition of either GFP-KANK1-4A, GFP-∆CC or 
GFP-∆CC_4A mutants.  Importantly, although the KANK_4A mutant did not localise to adhesions, 
it could still be found to co-localise with LL5β across the cell due to KANK-liprinβ1 binding.  The 
KANK ∆CC mutant localised around FA assemblies in ring like structures, but could not bind LL5β 
due to mutually exclusive localisation with liprin β1 and LL5β.   
The CMSC component, KIF21A, binds to KANK1 via the ankyrin repeat domain.  In contrast to LL5β, 
KIF21A could still localise with the KANK ∆CC mutant at the FA assembly rim.  However, overall 
KIF21A localisation at the cell periphery was significantly reduced in both KANK ∆CC, KANK ∆CC_4A 
and KANK_4A compared with KANK1 WT (FIGURE 4.35).  Furthermore, all the KANK mutants 
prevented efficient accumulation of CLASP2 (MT binding protein) at the ell cortex, which confirms 




FIGURE 4.35: KANK1 MUTANTS AFFECT ON CMSC COMPONENTS CLUSTERING AROUND FOCAL 
ADHESIONS 
(A) Wide field fluorescence images of HeLa cells co-depleted of KANK1 and KANK2 then transfected with 
indicated GFP-KANK mutants (∆CC_4A, ∆CC and KANK_4A) (green) and stained for endogenous LL5β or 
KIF21A (red), magnification bars represent 3 µM.  (B) Quantification for cell edge clustering of both CMSC 
proteins LL5β (black) and KIF21A (red) in cells with indicated KANK1 mutant. Error bars, SEM; ***p<0.001, 




To determine if disrupting the talin:KANK interaction from the ‘talin side’ would have a similar 
effect on CMSC localisation as the KANK mutants, HeLa cells depleted of talin1 and talin2 were 
rescued with either GFP-talin1 or GFP talin1 G1404L.  FIGURE 4.36 shows that the cells rescued 
with talin1 WT had both MSC components, LL5β and KIF21A, clustered around the adhesion.  
However, cells rescued with GFP-G1404L talin1 (deficient in KANK binding) were no longer able to 
recruit LL5β and KIF21A to FA clusters.   
 
FIGURE 4.36: TALIN G1404L MUTANT STOPS CLUSTERING OF CMSC COMPONENTS TO FOCAL ADHESIONS 
(A) Wide field fluorescence images of HeLa cells co-depleted of talin1 and talin2 then transfected with 
indicated GFP-talin1 construct (green) and stained for endogenous LL5β or KIF21A (red), magnification bars 
represent 3 µM.  (B) Quantification for cell edge clustering of both CMSC proteins LL5β (black) and KIF21A 
(red) in both cells with GFP-talin1 and GFP-talin1 G1404L Error bars, SEM; ***p<0.001, Mann-Whitney U test. 




4.3.4 Disruption of talin1:KANK1 leads to microtubules plus-end 
disorganisation at the cell periphery 
To understand the importance of the focal adhesion and cortical microtubule stabilising complex 
crosstalk, we investigated the effect of disruption of the talin:KANK interaction on microtubule 
organisation at the cell periphery, using our talin1 G1404L and KANK_4A mutants.  
For the MT study the Akhmanova group used Hela cells due to their stereotypically round shape 
(van der Vaart et al., 2013).  In Hela cells, MTs are found to grow rapidly in central parts of the cell 
whereas at the cell margin (where CMSCs group in the vicinity of FAs), MT plus-ends are tethered 
to the cortex and exhibit much slower growth rate due to MT regulators; CLASP and KIF21A 
(Mimori-Kiyosue et al., 2005; Drabek et al., 2006; van der Vaart et al., 2013).  These regulators are 
important as they prevent MT overgrowth at the cell edge, which causes disorder.   
The Utrecht group knocked-down both endogenous KANK1 and KANK2 from HeLa cells before co-
transfecting GFP KANK1 WT or GFP KANK1_4A with EB3-mRFP (a microtubule plus-end marker).  
Additionally, knock-downs of talin1 and talin2 were also performed in HeLa cells, before co-
transfection with GFP-talin1 WT or GFP-talin1 G1404L and EB3-mRFP.  TIRFM live imaging was used 
to image cells, as shown in FIGURE 4.37B and C.  The plus-ends of MTs, in cells expressing talin1 
and KANK1, grew at a 60-80° angle and approximately 2.5 times slower than the central region of 
MTs.  However, when either the KANK_4A mutant or the talin1 G1404L mutant were expressed, 
the MT central regions were not affected but the growth rate of plus-ends increased and the 
characteristic growth at 60-80° angles was no longer observed. Instead, MTs grew at oblique angles 




FIGURE 4.37: DISRUPTION OF THE TALIN:KANK INTERACTION DISORDERS MICROTUBULE PLUS END 
ORGANIZATION AT THE CELL PERIPHERY 
(A) Schematic representation of the pattern of microtubule growth in control HeLa cells and in cells with 
perturbed CMSCs, based on (van der Vaart et al., 2013).  (B) TIRFM images of live HeLa cells depleted of both 
KANK1 and KANK2 then co-expressed with siRNA-resistant GFP-KANK1 and EB3-mRFP, magnification bars 
represent 5 µM.  (C) TIRFM images of live HeLa cells depleted of talin1 and talin 2 and then co-expressed 
with GFP-talin1 and EB3-mRFP. Magnification bars represent 5 µM (D) Ratio of microtubule growth rate in 
the cell centre and at the cell edge for the cells treated with varying talin and KANK mutants described in B 




This phenotype observed with the GFP-talin1 G1404L mutant fully supports our biochemistry data.  
This single point mutation, G1404L in talin1, presents a powerful tool for exploring the connections 
between adhesion and the microtubules as it does not interfere with adhesion formation but is 
sufficient to perturb CMSC clustering and through doing so induces complete disorder of the 
microtubule plus ends at the cell cortex.   
4.4 Conclusion  
4.4.1 Does talin nucleate CMSC assembly?  
In the cell, CMSC proteins have not been found to coalesce around the FAs, so what is driving them 
to accumulate around the focal adhesion rim?  CMSC complexes form through an intricate network 
of interactions, and at the heart of this network is a trio of core proteins: KANK; LL5β and liprins 
(Lansbergen et al., 2006; van der Vaart et al., 2013; Astro and De Curtis, 2015).  These core 
components can be independently recruited to the plasma membrane.  The KANK mutant ∆CC 
(FIGURE 4.38) was unable to support proper clustering of CMSC components at the cell cortex 
despite being able to co-localise around FA assemblies.  These data suggest that the liprinβ1-KANK1 
interaction is required for CMSC recruitment along with the talin:KANK1 interaction.   
It would seem that the talin:KANK interaction initiates the platform for assembly of CMSC 
components.  Talin acts as the seed for KANK1 to bind via the KN domain and in turn KANK serves 
as a platform to bind liprin β1 at the cell cortex (via KANK coiled-coil domain).  This then allows 
CMSC proteins to assemble forming CMSC ‘patches’.  These patches can remain stable for around 
10 minutes at a time, whilst individual CMSC proteins are dynamic and have much shorter turnover 
rates (van der Vaart et al., 2013).  Additional proteins then bind to these ‘patches’, including KIF21A 
and CLASPS, MT-binding proteins that ultimately capture MTs at the CMSC (FIGURE 4.38A).   
We speculate that increasing the KANK concentration at the FA rim helps nucleate CMSC assembly 
(FIGURE 4.38B).  Through this nucleation, large macromolecular assemblies form around the 
adhesions, attracting different membrane bound proteins to bind such LL5β (Bouchet et al., 2016) 
and, in turn, concentrating the number of CMSC proteins in the region.  This model correlates with 
data indicating that CMSC accumulation is reduced but not abolished when PI3 kinase is inhibited 
(Lansbergen et al., 2006).  Most importantly this model provides the answer to a key unanswered 




FIGURE 4.38: TALIN NUCLEATES CMSC ASSEMBLY BY INITIATING A SEEDING COMPLEX WITH KANK1 
(A) Model of how talin1 directs the assembly of the cortical microtubule-stabilizing complex in three stages.  
1) KANK1 binds to talin R7, 2) KANK1 coiled-coil domain binds to liprin β1, 3) this allows LL5β to bind and the 
final CMSC proteins to assemble including ELKS, CLASP and KIF21A.  (B) KANK1 binds to the rim of adhesion 
complexes and acts as a ‘seed’ for the CMSC proteins to bind, which generates a macromolecular assembly 
around the FA rim.  Figure taken from (Bouchet et al., 2016). 
4.4.2 Why is KANK kept at the rim of focal adhesions? 
The cell images from the Akhmanova group showed that KANK1 was able to bind to talin and 
localise to focal adhesion assemblies.  Interestingly though, KANK1 formed a belt around the edge 
of the adhesion and was not found distributed through the adhesion; this was also observed in 
another KANK study (Sun et al., 2016).  FIGURE 4.39 shows the different KANK mutants and their 
abundance (shown as a measure of fluorescence) across a cross section of an adhesion.  FIGURE 
4.39 show that the only KANK1 construct able to enter the adhesion was the small KN domain.  
What is keeping KANK at the rim of adhesions and is it biologically important that KANK doesn’t 
enter the adhesion? 
A logical answer is that steric hindrance prevents KANK from doing so, whilst the smaller KN domain 
can easily penetrate the dense actin core of the adhesion.  This steric hindrance would be further 
compounded due to binding of CMSC proteins to KANK and the formation of large macromolecular 
assemblies.   
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This however, may be a slightly too simplistic model.  Unpublished data from the Akhmanova lab 
shows that when ROCK1 inhibitors are introduced in the cell there is more of an overlap between 
KANK1 and FA markers.  ROCK1 is a key regulator in actin cytoskeleton organisation and is found 
to be involved in stress fibre and adhesion formation (Maekawa et al., 1999). Because ROCK1 
inhibitors would reduce the tension across the cell and at adhesions, a higher overlap with FA 
markers suggests that the interaction between talin and KANK1 is mechanosensitive.  
 
FIGURE 4.39: TALIN:KANK INTERACTION IS REQUIRED FOR KANK TO BE RECRUITED TO FOCAL ADHESIONS 
RIM. 
Fluorescence profile of GFP-tagged KANK1 and KANK mutants: KANK_4A, ∆CC, 4A_∆CC, KN and KN_4A and 
TagRFP-paxillin (adhesion marker) based on line scan measurement across the FA area in TIRFM images. 
 
As mentioned in Chapter Chapter 2, talin is a mechanically sensitive protein (Yan et al., 2015; 
Kumar et al., 2016; Yao et al., 2016).  The helical bundles in the rod domain can unfold under force.  
Unfolding of the R7 helical bundle would lead to the loss of the KANK binding site.  The KANK1 
binding site overlaps with the ABS2 on the talin rod (between R4-R8) (Atherton et al., 2015).  Actin 
binding puts talin under force and with multiple actin binding sites across talin it is possible to 
hypothesise that different talin molecules are under differing amounts of force across the adhesion.  
This results in KANK1 only binding at the periphery of the adhesion, where talin is not fully 
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embedded into the adhesion and not under tension, allowing the R7 domain to maintain helical 
bundle formation. 
Finally, post-translational modifications on or surrounding the KANK1 binding site may prevent 
KANK1 from binding talin.  A recognised phosphorylation site Ser1614 was found in the KANK1 
binding site (Gough and Goult, 2018) and our FP data showed that a phosphomimetic S1641E 
caused a four-fold decrease in binding affinity for KANK1.  Even though this did not abolish binding, 
it does weaken the interaction and it is certainly rational to suggest a PTM in this region could 
disrupt binding. It will be important in the future to test a phosphomimetic and non-
phosphorylatable mutant of this site in cells and look to see if a similar phenotype to the G1404L 
mutant is observed.    
4.4.3 KANK proteins in disease 
Mutations and deletions within the KANK proteins have been implicated with a number of rare 
genetic human diseases.  A large deletion of KANK1 has been found to lead to cerebral palsy: a four 
generation family with congenital cerebral palsy were found to have a 225 Kb deletion of the 
ankyrin repeat domain in KANK1 (Lerer et al., 2005).   
Inactivation of genes by mutations and loss of heterozygosity (gene locus containing two different 
alleles) often lead to carcinomas (Kakinuma et al., 2009).  Loss of heterozygosity in the KANK gene 
locus has been found to be linked to renal cell carcinomas (RCC); this has also been reported in 
other cancers including lung cancer, breast cancer, pancreatic carcinoma and bladder cancer 
(Kakinuma et al., 2009).  These studies give a clear indication that loss of KANK1 function within 
the cell can lead to disease.  Reduced expression of KANK has also been reported in 
myeloproliferative disorders a group of  slow-growing blood cancers, whereby abnormal red blood 
cells are produced and accumulate in the blood (Kakinuma et al., 2009).  Other diseases where 
KANK is mis-regulated obsessive compulsive disorder (Willour et al., 2004) and autism (Vinci et al., 
2007). 
4.4.4 Expression of KANK family members 
TABLE 9 highlights information of the different KANK isoform expression levels across different 
tissues.  These data would suggest that KANK1 and KANK2 are the most dominant KANK isoforms 
and have been found in all tissues tested whereas; KANK3 and KANK4 appear more tissue specific.  
KANK1 is shown to be the predominant isoforms expressed in the heart, liver and kidney (Zhu et 
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al., 2008).  KANK2 was shown to also have high expression in kidney cells but in contrast, KANK3 
and KANK4 were shown to have low expression levels (Zhu et al., 2008).  Current evidence reveals 
slight differences in expression between the different KANK isoforms in tissues and could these 
differences reveal differences in functions between the isoforms?  We are still yet to determine 
the functional differences between KANK1-4 and in the future it would be interesting to introduce 
knockouts of the individual KANK isoforms into mice and study the effects.  Furthermore, with the 
advancement in super-resolution microscopy it could now be possible to study the KANK isoforms 
localisation in cells and determine functional aspects of the different isoforms. 
 
TABLE 9: EXPRESSION LEVELS OF KANK1,2,3 AND 4 GENES 
Table indicating (*) expressed and (**) highest level of expression of the different KANK isoforms from 
different tissues.  Data collated from Human protein atlas (Uhlén et al., 2015) and (Zhu et al., 2008). 
 
4.4.5 Why do humans have four KANK isoforms? 
As described earlier humans have four KANK isoforms KANK1-4, the originally identified member 
was KANK1 and through a homology search across the human genome three further KANK isoforms 
(KANK 2, 3 and 4) were identified (Kakinuma et al., 2009).  These four KANK proteins all have a very 
conserved C-terminal ankyrin repeat domain and a conserved N-terminal KN domain.  The only 
major difference in terms of structure between the four isoforms is the coiled –coil region (CC) in 
the middle of the protein.  KANK1 has three CC regions, KANK2 has two CC, KANK3 has two CC and 
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KANK4 has one CC region as shown in FIGURE 4.40.  These differences between the isoforms might 
be providing a clue into the different functions the KANK isoforms have within the cell.  The first 
coiled coil  (CC1) in KANK1 binds to liprinβ1 (van der Vaart et al., 2013) this interaction is crucial for 
LL5β binding and the co-localisation of the other CMSC components.  KANK2 is also shown to have 
a strong association with liprinβ1 (Luo et al., 2016).  After aligning the KANK CC regions of all KANK 
isoforms in Clustal Omega, it was clear that KANK1-3 contained a similar sequence (shown in 
FIGURE 4.40). This suggests that KANK3 would also be able to bind to liprinβ1 and could be helping 
to regulate the assembly of the CMSC. I also showed that the KANK3 KN domain could bind to talin1 
R7 and, therefore, it is feasible to suggest that KANK3 could be playing a similar role to KANK1.  
KANK4 does not contain this potential liprinβ1 binding sequence and, as a consequence, cannot 
recruit CMSC components to FA.   
 
FIGURE 4.40: HUMAN KANK ISOFORMS COILED COIL ALIGNMENT 
Schematic of the human KANK isoforms 1-4.  Highlighted in red boxes are the regions of sequence aligned 
using Clustal Omega that can be seen in the bottom panel.  Residues not be recruiting CMSC components to 




4.4.6 What is the role of the talin:KANK interaction in organisms? 
So far, KANK proteins have been poorly studied due to their unknown function and structure.  This 
is beginning to change with the recent emerging role of KANK1 as a microtubule targeting protein 
(Bouchet et al., 2016) and a possible connection to the regulation of force transmission across 
adhesions (Sun et al., 2016).  Although the KANK family is becoming more studied both in vitro and 
in vivo the main study on KANK1 function comes from studies in C.elegans.  Unlike humans, 
C.elegans have only one isoform of KANK named VAB19, which was found to localise to muscle-
epidermal attachment sites (Ding, 2003).  For interaction with epidermal attachment structures 
both the KN motif and the coiled-coil domains are required for localisation.  VAB19 mutants are 
defective in epidermal elongation (growth from embryo to larva) and muscle attachment to the 
epidermis, which results in developmental arrest and subsequent embryonic lethality  (Ding, 2003).   
Furthermore, the VAB19 is required for normal epidermal actin reorganisation and VAB19 mutants 
caused abnormal actin cytoskeletal reorganisation, preventing attachment structures to develop 
beyond a certain stage (Ding, 2003).   
KANK knock-down experiments have been reported in zebra fish, where the authors looked at the 
roles of both KANK2 and KANK3.  In this particular study, Knock-down of KANK2 showed a nephrotic 
syndrome phenotype (a kidney disorder that leads to progressive renal function decline) (Gee et 
al., 2015).  Knock-down of KANK3 in zebra fish was shown to enhance cell migration and invasion 
however, whilst overexpression of the protein inhibited these characteristics (Kim et al., 2018).  
Cell work of the KANK1 family in mammals is also still very limited. Our work with the Akhmanova 
group found strong phenotypes in HeLA cells when the talin:KANK interaction was removed,  MT 
growth at the cell cortex was no longer co-ordinated and MTs grew at an accelerated rate in 
random directions.  CMSC components were no longer able to recruit to focal adhesions and form 
macromolecular assemblies around adhesions helping to regulate the turnover of adhesions 
(Bouchet et al., 2016).  These data suggest that if a KANK knock-out was introduced into a mammal 
it would have severe effect and possibly lead to death.   
Further experiments need to be carried out to determine the importance of MT localisation to FAs 
in determining cell polarisation.  If the link between FAs and MTs was found to be critical in 
determining cell polarity, then this would give more weight to the hypothesis that a KANK1 knock-
out would be fatal in a model organism, as cell polarity is essential in determining direction of 
migration and co-ordinating the migration and formation of tissues and organs during 
embryogenesis (Campanale, Sun and Montell, 2017).   
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A good indication of how important KANK1 is in the cell is to look at known mutations found within 
the KANK gene.  Extensive mutational studies of KANK1 have been carried out and, to date, whilst 
missense variants and single nucleotide polymorphisms (SNPs) can be found in KANK1, no KANK1 
deletions or nonsense mutations have been found.  Although, interestingly, no SNPs have been 
found in  the KANK1 KN domain (Kakinuma et al., 2009), indicating that a mutation in this region 
could also be lethal.   
To investigate if there are human mutations found on the talin KANK1 binding site (talin R7) the 
human 1000 genome project (Gibbs et al., 2015) and the Catalogue Of Somatic Mutations In Cancer 
(COSMIC) (Bamford et al., 2004) were used.  FIGURE 4.41 shows the SNPs across the KANK1 binding 
site on talin1.  Across R7 helices 29 and 36 that form the KANK binding site, there are three SNPs, 
one of which is of particular interest: the mutation of residue Tyr1389.  This residue was one of the 
residues identified (along with Trp1630) to hold the helices 29 and 36 at a fixed distance apart and 
was found to be crucial for talin-binding.  In humans, SNPs where the Tyr residue is replaced by a 
His or Ile can occur.  The His residue is less hydrophobic and would not disrupt the hydrophobic 
core of the domain, likely pushing the helices apart, potentially leading to KANK1 no longer being 
able to bind talin. SNPs for this residue (Tyr1389) are very rare since this is highly conserved residue 
across species, and this particular mutation was found in patients with carcinoma.  The next most 
critical KANK1 experiments are to explore the effect of KANK1 knock-out in a model organism.  This 
will determine the importance of the interaction and start to unlock some of the questions around 






FIGURE 4.41: SINGLE NUCLEOTIDE POLYMORPHISMS FOUND IN THE KANK BINDING SITE ON TALIN R7 
Talin1 R7 structure (PDB: 5FZT) residues highlighted in red indicate the found human SNPs from either 
COSMIC or the Human 1000 genome identifier.   
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Chapter 5. Defining an LD  





In Chapter 4, the interaction between talin and the adapter protein KANK was biochemically 
characterised and we identified KANK bound to talin R7 via an LD-motif in the KANK KN domain.  
This KANK LD-motif was the first LD-motif found to bind to a talin five-helix bundle (aside from 
potentially RIAM binding to R11) and subsequently identified talin R7 as a new LDBD.  Biochemical 
characterisation of this interaction has increased our understanding of LD-motifs binding to talin 
and has raised the question: can any of the other 11 five-helix bundles on the talin rod bind LD-
motifs?   
In this chapter a strategy was developed to search for novel talin interactors from proteomics data 
sets in the view that identifying novel LD-motif interactions with talin will give new insight into 
talins role in regulating adhesion assemblies.  
5.1.1    What are Leucine-Aspartic acid motifs 
Leucine-Aspartic acid (LD) motifs are short helical interaction motifs that have been found in a 
number of adhesion proteins and mediate protein:protein interactions; they have been identified 
as crucial players in connecting cell adhesion with cell motility and survival (Alam et al., 2014).   LD-
motifs are identified through the canonical sequence LDxLLxxL (where x is any amino acid) and 




   
FIGURE 5.1: PAXILLIN DOMAIN STRUCTURE AND KNOWN BINDING PARTNERS. 
Schematic diagram of paxillin showing the proteins domain structure and highlighting the five LD-motif 
domains (highlighted by red boxes) and LIM domains. LD1 has been expanded and the protein sequence is 
shown in black box, the corresponding LDxLLxxL motif has been highlighted in red.  Green circles highlight 
the multiple; tyrosine (PY), serine (PS) and threonine (PT) residues that are phosphorylated along the protein 
also shown in grey are some of the current recognised paxillin binding partners and where they bind on the 
paxillin structure.  Diagram adapted from: (Brown, 2004). 
5.1.1.1 Paxillin LD-Motifs  
Paxillin is a large 68 kDa focal adhesion adapter protein, and its biological function is to regulate 
cell spreading and motility through its involvement in the integrin-mediated signalling pathway 
(Schaller, 2001).  The protein has multiple domains which encompass a number of different 
protein-binding motifs.   
FIGURE 5.1 shows the five N-terminal LD-motifs (highlighted by red boxes) and four C-terminal 
double zinc finger LIM (lin-a, isl-1, mec-3) domains.  The protein also contains multiple 
phosphorylated tyrosine (PY), serine (PS) and threonine (PT) residues that can be phosphorylated 
in response to cell adhesion (highlighted on FIGURE 5.1 by green circle).  Phosphorylated tyrosine 
residues generate docking sites for SH2 domain containing proteins to bind  (Brown, 2004).   
Furthermore, FIGURE 5.1 shows the multiple binding partners that can interact with the paxillin 
domains including LD-motif binding proteins, focal adhesion kinase (FAK) and vinculin (Schaller, 
2001).   
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The five LD-motif domains are named LD 1-5, these domains are well conserved across all members 
of the paxillin superfamily (paxillin, Hic-5, paxB and Leupaxin) and across species (Brown, 2004).   
The paxillin LD-motifs contain a short leucine rich sequence; LDxLLxxL (where x is any residue) 
which has been defined as the canonical LD-motif (Alam et al., 2014).  This sequence is found in all 
five of the paxillin LD domains, apart from LD3, (which has a conserved Val-Glu instead of the Leu-
Asp).   The motif has been shown to be important in mediating interactions between several 
proteins central to the regulation and co-ordination of the actin cytoskeleton including proteins 
FAK and vinculin  (Schaller, 2001).   
Interestingly, each of the paxillin LD-motifs can bind multiple proteins for example, paxillin LD2 and 
LD4 can bind FAK and paxillin; LD1, LD2,LD4 could bind to vinculin (Turner et al., 1999).  This started 
to raise questions around how the LD-motifs could dictate specificity.  To further investigate how 
LD binding partners are interacting with LD domains the FAK:paxillin interaction was more closely 
studied (Hoellerer et al., 2003).  Hoellerer et al; corroborated that FAK could only bind to paxillin 
via LD2 and LD4 domains and this selectivity could be due to modulated affinity of side chain pairing 
between the paxillin LD domain and FAK.  It was also thought that the length and helical propensity 
of the paxillin LD-motif determined binding affinity to an LD-binding ligand.  Overall it was 
concluded that the LD-motif is a fairly promiscuous recognition sequence.   
5.1.2 Leucine-Aspartate binding domains (LDBDs) 
Molecular recognition of LD-motifs comes through Leucine-Aspartatic acid binding domains 
(LDBDs).  The common binding mechanism of LD-motifs to the corresponding LDBD is through 
helical addition as shown in FIGURE 5.2.  Several different proteins have been shown to contain an 
LDBD including the already been discussed proteins, FAK and vinculin.  Other proteins include 
parvins, which are an actin binding protein directly responsible for the initial nucleation of actin at 
FAs (Nikolopoulos and Turner, 2000), and PV E6 protein from the papilloma virus.  PV E6 has 
specifically evolved to recognise the LD-motifs on paxillin (LD1, LD2 and LD4) it is thought the 
interaction disrupts the actin cytoskeleton which in turn disrupts migrating cells (Wade, Brimer and 
Vande Pol, 2008).  This demonstrates how  pathogens have learnt to exploit the ‘promiscuous’ LD 






FIGURE 5.2: LD-MOTIF BINDING TO AN LDBD 
Schematic of an LD-motif (purple) forming an interaction with corresponding LDBD (green).  LD-motif binds 
via a helix addition to the side of the helical bundle on the LDBD.     
 
5.1.3 Talin can bind LD-motifs 
More recently, talin has been found to be bind LD-motifs with the R8 domain being an important 
LDBD.  The R8 domain binds the deleted in liver cancer (DLC1) protein between helices 32 and 33 
(Zacharchenko et al., 2016), this same region also binds to paxillin LD1 (Zacharchenko et al., 2016) 
and to Rap1 –interacting adaptor molecule (RIAM) (Goult, Zacharchenko, et al., 2013).   
Furthermore, our recent findings have found the R7 domain to be an LDBD and can bind the KANK 
LD-motif between helices 29 and 36.  This was a breakthrough in terms of identifying talin as a 
protein with multiple LDBDs.  Previous literature has shown only four-helix bundles to bind LD-
motifs and in the talin rod only four domains contain four-helix bundles: R2, R3, R4 and R8.   KANK 
binding to R7 raised the intriguing possibility that every talin rod domain could be an LDBD and thus 
could suggests a role for talin as a signalling platform.   
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5.1.3.1 DLC1 an LD-motif  
DLC1 is a tumour suppressor gene which is frequently inactivated during cancer and it encodes a 
Rho-GAP focal adhesion protein needed for GTPase activation; negative regulation of RhoGTPases 
are required but not entirely sufficient for tumour suppression (Li et al., 2011).  The structure of 
talin1 R7R8 and the DLC1 LD-motif (residues 467-489) show DLC1 binds to talin1 R8 domain 
between helices 32 and 33 (Zacharchenko et al., 2016) (shown in FIGURE 5.3B).   
 
 
FIGURE 5.3: TALIN R8 DOMAIN IS AN LD BINDING DOMAIN 
(A) Schematic of an LD-motif i.e RIAM or DLC1 binding to the LDBD (talin R8) (B) structure showing binding 
of LD-motif DLC1 (green) to talin1 R8 (grey) via the LD recognition box (PDB ID: 5FZT).  (C) Structure showing 
the binding of LD-motif RIAM (orange) to talin1 R8 (grey) (PDB ID: 4W8P).   
5.1.3.2 RIAM- a previously unrecognised LD-motif 
RIAM is a Rap1 effector protein and is a member of the MRL (Mig10/RIAM/lamellipodin family) 
adaptor proteins (Lee et al., 2009).  RIAM has been found to have a central role in integrin 
activation through its ability to bind to both talin and Rap1 (Lee et al., 2009; Goult, Zacharchenko, 
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et al., 2013; Chang et al., 2014). Integrin activation by talin is instigated by a Rap1-induced signally 
pathway, these integrin activation pathways initiated from inside the cell are known as inside-out 
signalling  (Bivona et al., 2004; Banno and Ginsberg, 2008) (see section 2.5.2).    
Rap1 is a small plasma membrane bound GTPase that recruits RIAM which then in turn recruits 
talin via its TBS between residues 1-30 (Lee et al., 2009).  Talin then activates integrin via the F3 
sub-domain in the FERM head (Critchley & Gingras, 2008; J.  H.  Wang, 2012), mutations introduced 
in the RIAM 1-30 region prevented talin binding and in turn prevented the activation of integrin 
(Lee et al., 2009).   
RIAM was found to bind to talin by Goult et al along multiple sites across talin one of which was 
talin rod domain R8 (Goult, Zacharchenko, et al., 2013).  RIAM has not been classed as an LD-motif 
but it does contain a very similar sequence to the other LD-motifs that bind to talin R8, although 
instead of the Leu-Asp at the beginning of the motif it contains an Ile-Asp.  Like the other talin R8 
binding proteins, RIAM also binds between the hydrophobic groove of talin helices 32 and 33 via 
helix addition (Goult, Zacharchenko, et al., 2013) (shown in FIGURE 5.3C).   
For my study into talin binding LD-motifs I agree with the findings of Zacharechenko et al and have 
classed RIAM to be an LD-motif (Zacharchenko et al., 2016).  This classification is for two reasons.  
Firstly, the RIAM sequence binds to talin R8, a known LDBD, and the RIAM LD motif closely fits the 
canonical paxillin LDxLLxxL pattern.  Secondly, RIAM binds to talin R8 through helical addition and 
via similar residues as other talin binding LD-motifs.  
5.1.3.3 LD-motif Binding mechanism  
The best characterised mode of LD-motif recognition is by binding to four-helix bundles via helix 
addition (as shown in FIGURE 5.3A).  LD-motifs can have helical propensity before binding to an 
LDBD or can form a helical structure upon interaction with the LDBD (Alam et al., 2014).  The 
charged Asp residue is thought to make the initial connection with the LDBD and form an 
electrostatic interaction with a conserved basic residue (Lys/Arg/His) (Zacharchenko et al., 2016).    
Talin R8 has been found to bind multiple LD-motifs: DLC1, RIAM, Paxillin.  These LD-motifs all bind 
to talin R8 using the same mechanism whereby the initial aspartate residue (in the LD-motif)  binds 
to a basic residue on talin in what had been named the initial LD binding site (Zacharchenko et al., 
2016) (shown in FIGURE 5.3A).  On talin R8 this charged residue is Lys1544 and it forms a salt bridge 
with the aspartate on the LD-motif.  This initial interaction then positions the LD-motif along the 
furrow of the talin R8 helices 32 and 33 allowing the hydrophobic Leucine residue to from 
hydrophobic interactions with talin.  Zacharchenko et al proposed in their talin:DLC1 structure that 
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there is then a second binding site along the talin R8 LDBD called the specificity region shown in 
FIGURE 5.3A.  The residues in the specificity region differ between the LD-motifs and this allows 
for difference in specificity of binding to LDBD surfaces.  The specificity region is thought to be a 
way that helps to regulate which LD-motif can bind when (Zacharchenko et al., 2016). 
5.1.4 Searching for additional non-paxillin LD-motifs  
To identify LD-motifs in proteins other than paxillin, the canonical LDxLLxxL motif was used as a 
query to search protein data bases.  This method only identified three LD-motif containing proteins, 
Gelsolin, Deleted Liver Cancer 1 (DLC1) and RoXaN (Alam et al., 2014).   Gelsolin is a cytoplasmic 
protein that is important for actin cytoskeletal organisation in multiple cell types including 
osteoclasts (Wang et al., 2003) and RoXaN (rotavirus X protein associated with NSP3) is a rotavirus 
interacting protein (Vitour et al., 2004).   
The limitation with searching for LD-motifs by sequence alone is that the sequence is so similar  to 
other motifs such as transcriptional regulation sequences (LxxLL) and Nuclear export sequences 
(Alam et al., 2014).  In order to have a better chance at identifying genuine LD-motifs a structural 
characterisation could also help to reduce the number of false positives identified.   
5.2 Results 
The structure of talin domain is highly conserved across evolution. This provides compelling 
evidence that every domain within talin has an important functional role.  Furthermore, the 
talin:KANK interaction gives us some insight into how the five helix domains in the talin rod can 
bind LD motifs.  Altogether, this gives us reason to suggest that every talin rod domain has the 
potential to be an LDBD and bind multiple LD motifs.  
Previously, the Goult group produced a talin1 proteomics data set (unpublished data); the data set 
contains over 800 potential talin binding partners and, from this, only KANK had been confirmed 
and characterised as a talin binding protein.  Interrogating this vast data is an important step into 
uncovering further talin binding proteins; however, due to large size of talin, it is difficult to narrow 
down the binding sites on both talin and the putative talin binding protein.  
To overcome this, we used the current knowledge of LD motifs and, in particular, the LD motifs 
that have been found to bind to talin, to design an LD talin-binding search motif (LD-TBM) that 
could be used to search through the proteomics dataset and identify new talin binding partners 
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with LD motifs.  This method has the advantage of having the binding site on talin already identified, 
allowing for an easier characterisation of the interaction.   
5.2.1 Designing a search query to identify novel LD talin-binding motif (LD-
TBM) containing proteins 
As discussed previously, LD motifs were initially found in paxillin, where they follow the consensus 
sequence LDxLLxxL.  Previous attempts to search for proteins containing LD motifs using this 
sequence (LDxLLxxL) uncovered only three hits: DLC1, RoXan and Gesolin (Alam et al., 2014).  On 
the other hand, further attempts to search for LD motifs using a ‘more relaxed’ search sequence 
has led to the identification of many false-positives.  Searching for LD motifs is a challenging task 
due to the lack of common features in the known LD motifs that would allow them to be 
distinguished from other helical motifs. 
To combat these problems and define a LD talin-binding motif (LD-TBM) that could accurately 
determine potential talin binding proteins, a common set of features needed to be identified.  To 
search for common sequence features, all the known talin binding LD-motifs were aligned (as 
shown in FIGURE 5.4).  From this alignment any differences between the talin-binding LD-motifs 
and the paxillin LD-motifs were identified.   Position numbers were given to the residues; 0 was 
given to the first Leu residue in the (LDxLLxxL) sequence and 1 to the Asp residue, ect.  The residues 
were also coloured based on their properties; acidic (red), basic (blue) and hydrophobic (green).    
 
FIGURE 5.4: SEQUENCE ALIGNMENT OF KNOWN OF LD TALIN-BINDING MOTIFS 
(A) Sequence alignment of: paxillin LD1, LD2 and LD4 (UniProt ID:  P49023); RIAM (UniProt ID: Q7Z5R6); DLC1 
(UniProt ID:  Q96QB1); KANK1 (UniProt ID:  Q14678) and KANK2 (UniProt ID:  Q63ZY3).  Red highlights acidic 
residues, blue basic residues and green hydrophobic residues.  Known talin binding sequences are 
highlighted with an *.  (B) The designed LD talin-binding sequences which were entered into the PROSITE 
scanning tool.   
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The first difference noted between the LD-TBM and paxillin LD motifs is that, in position 0, the 
residue can be an Ile (as found in RIAM) or a Leu (paxillin LD motifs only contain a Leu at position 
0). Additionally, from the alignment it appeared that the residue in position -1 was important to 
the sequence.  In both paxillin LD motifs and LD-TBM, a charged residue (either Asp or Glu) was 
present, possibly allowing an interaction with the LDBD surface. From the alignment, it was also 
clear that whilst Leu residues always occupied positions 3, 4 and 7 in the paxillin sequences, the 
same was not true for talin-binding LD proteins.  Instead, in the latter case, position 3 could be any 
hydrophobic residue and position 4 could occupied either by a charged or hydrophobic residue. 
This information was taken into consideration when designing the LD-TBM.   Finally, position 6 in 
the paxillin LD consensus sequence is defined as x (any amino acid); however, from the alignment 
we observed that the talin-binding LD proteins all contained a hydrophobic amino acid.   
From these findings two new LD talin-binding sequences were designed:   
 
Sequence 1:  Asp/Glu-Leu/Ile-Asp-x-(ɸ)-(ɸ)-(ɸ)-x-(ɸ)   
Sequence 2:  Asp/Glu-Leu/Ile-Asp-x-(ɸ)- (+/-)-(ɸ)- (ɸ)-(ɸ)  
(where ɸ is a hydrophobic residue, x is any residue and +/- indicate a charged residue)  
Sequence 1 and sequence 2 are similar but differ in positions 6 and 7.  In some of the talin-binding 
LD sequences a charged residue was found at position 6 whereas in others it was a hydrophobic 
residue.  Designing two sequences with more-specific residues rather than one sequence with a 
more generalised approach was thought to lead to less false positives. 
5.2.2 Searching for LD talin-binding motifs  
When searching for LD-TBMs two different approaches were used: a manual approach and a 
bioinformatics approach.  The manual method allowed the manual search of proteins containing 
either sequence 1 or sequence 2 from the top 20 proteins identified in the talin1 proteomics data 
set. The bioinformatics approach utilised the programme PROSITE (Sigrist et al., 2002), with 
sequences 1 and 2 used as search queries to analyse the entire talin1 proteomics dataset for 
potential LD-TBMs.   
5.2.2.1 Manually searching for LD talin-binding motifs  
The manual search was used initially as a proof of concept to determine if the LD-TBM would be 
recognised in any protein sequences.  The sequences for the twenty highest scoring proteins from 
the talin1 proteomics dataset, were manually screened to identify any  motifs similar to the 
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designed sequences 1 and 2 (section: 5.2.1).  From this search, two proteins were identified to 
contain the LD-TBM: cyclin dependent kinase 1 (CDK1) and septin2 (SEPT2).   
The CDK1 sequence appeared to have two possible LD-TBM: one in the middle region of the protein 
(residues 206-223) that fitted the designed LD-TBM sequence 1 exactly and one at the very C-
terminus of the protein that closely fitted the LD-TBM sequence.  The sequence for SEPT2 had one 
LD-TBM that closely fitted the LD-TBM sequence but not exactly.    
5.2.2.2 Searching for LD talin-binding motifs using PROSITE 
The bioinformatics approach used the programme PROSITE which is a protein data base tool that 
allows an imputed query sequence to be searched against a chosen protein database.  The query 
sequence used both the designed sequences.  These were written using the PROSITE parameters, 
square brackets surrounding groups of amino acids such as hydrophobic amino acids [AVILMFYW] 
and X representing any amino acid (shown in FIGURE 5.5B).   
All UniProt identities from the 800 proteins identified in the talin proteomics were submitted to 
PROSITE and this formed the protein database.  The dataset was then searched using the imputed 
sequences and any matching hits were listed as shown in FIGURE 5.5C.  The PROSITE software 
identified multiple proteins that contained the LD-TBM the first of which was the protein CDK1.  
The PROSITE software only identified one LD-TBM in the CDK1 sequence and this matched the 206-
223 sequence also identified using the manual approach.  The other sequences included RIAM and 




FIGURE 5.5: PROSITE SOFTWARE USED TO IDENTIFY LD TALIN-BINDING MOTIFS  
(A) An overview of the protein sequences imputed into the PROSITE software from talin1 proteomics 
database. (B) The LD talin-binding motif (sequence 2) imputed to the ScanProsite software. (C) The first hit 
identified, cyclin dependent kinase 1 (highlighted green box), to contain a potential LD talin-binding motif.  
 
5.2.3 Validating the potential LD talin-binding motifs  
The manual and bioinformatics-based approaches identified nine proteins that contained potential 
LD-TBMs.  From the proteins identified, CDK1 (which was identified as a LD-TBM in both the manual 
and bioinformatics searches), and SEPT2 (identified in manual search), were chosen for further 
analysis, as both had high scoring in the talin proteomics.   
Past searches for LD-motifs found that sequence searching alone identified many false positives.  
In order to further validate the LD-TBMs identified through a sequence search, a structural 
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evaluation was also carried out. This involved analysing both the structural position, secondary 
structure and sequence conservation of the LD-TBM. 
5.2.3.1 Structural evaluation of septin2  
Septins are a family of GTP-binding and membrane interacting proteins that were first discovered 
in yeast, where they were found to have a role in cytokinesis and cell morphology (Hartwell et al., 
1974).  Septins are found in all eukaryotes and, in mammals, thirteen isoforms have been identified: 
septin 1-12 and septin 14 (Neubauer and Zieger, 2017).  Septins are highly conserved through 
evolution with a common domain structure consisting of:  an N-terminus region, central core 
domain with a GTP-binding domain and a coiled coil region (as shown in FIGURE 5.6A).  In most 
isoforms a short polybasic region (PBR) can bind directly to phosphatidylinositol bisphosphate 
(PIP2) in the cell membrane (Neubauer and Zieger, 2017).  Septin isoforms can be split into four 
sub groups as shown in FIGURE 5.6B, and septin isoforms within these subgroups can assemble 
into multimeric complexes of two or more subunits (Neubauer and Zieger, 2017; Xu et al., 2018).   
 
FIGURE 5.6: SEPTIN ISOFORMS DOMAIN STRUCTURE AND SUBGROUPS 
(A) Schematic representation of septin domain structure.  (B) Human Septin isoforms SEPT1-12 and SEPT14 
subgroupings -based on homology sequence and coiled-coil domains. Figure from: (Neubauer and Zieger, 
2017). 
These complexes can form hexamer and octamer-like structures, which are believed to be stable 
within the cell (Neubauer and Zieger, 2017).  Human septins predominantly form hetero-hexamers 
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and hetero-octamers composed of SEPT2, SEPT6, SEPT9 and SEPT7.  The composition of septin 
complexes is cell type specific and is essential in determining the proteins function within the cell 
(Neubauer and Zieger, 2017).   
It has been shown that mis-regulation of septin expression is associated with human tumorigenesis 
(Xu et al., 2018).  High expression levels of SEPT2 and SEPT7 have been detected in breast cancers 
and in particular down regulation of SEPT2 has been shown to supress hepatoma cell growth (Xu 
et al., 2018).  In the talin1 proteomics SEPT2 was the most abundantly found septin; but, SEPT7 
and SEPT9 were also present.   
To further determine if the LD-TBM found within the SEPT2 sequence was likely to bind to talin; 
structural position, secondary structure and sequence conservation were all considered.  FIGURE 
5.7 shows a SEPT2 sequence alignment of different vertebrate species from  residues 150-
195(inclusive of the LD-TBM).  This alignment shows good conservation across species not only in 
this region but also in the region immediately before the Leu-Asp (position -1 - -4).   
The crystal structure of SEPT2 has been solved (PDB ID: 2QA5) and is shown in FIGURE 5.7B and C.  
The LD-TBM region is highlighted in green and has a helical structure giving greater confidence that 
it could bind to talin via helical addition in a similar way to the known LD-motifs DLC1 and RIAM.  
Importantly, the motif appears to be exposed, enabling a possible interaction with talin.  This 
binding site, however, could potentially be restricted if a hexamer or octamer structure is formed.  
After evaluating the structure and sequence of SEPT2, I would predict that it could form an 
interaction with talin via potential LD-TBM between residues 164-170.   
To determine if SEPT2 can bind to talin, we designed a synthetic peptide.  The peptide 
encompassed the core LD-TBD between residues 164-170 and also included a few residues on both 
sides; to allow the peptide to adopt the correct helical fold.  The inclusion of residues before 
position 0 is an important step learnt from designing the KANK1 peptides (section: 4.2.1), where 
the shorter KANK1 peptide (KANK1 42-68) started on the Leu residue (position 0) which 
significantly impaired binding to the talin LDBD.    
The final SEPT2 peptide designed encompassed the residues 159-174 and an additional N-terminus 





FIGURE 5.7: STRUCTURAL EVALUATION OF SEPTIN2 159-174 PEPTIDE 
(A) Sequence alignment of septin2 proteins from different vertebrates, the septin2 159-174 peptide 
highlighted in green.  (B-C) show the structure of septin2 (PDB ID:2QA5) with the peptide residues coloured 
in green, (C) highlights the residues that are on the potential talin binding surface (Asp164 and Leu163).  (D) 
Shows the PSIPRED predicted secondary structure for the peptide residues (highlighted by a green box) in 




5.2.3.2 Structural evaluation of Cyclin Dependent Kinase 1 
CDK1 is part of a large family of Ser/Thr kinases, whose kinase activity is dependent of the addition 
of a regulatory subunit called cyclin (Malumbres et al., 2009).  CDKs regulate many cellular 
functions, including the cell cycle, transcription, mRNA processing, stem cell self-renewal and 
spermatogenesis (Lim and Kaldis, 2013).  CDK1 is largely involved in regulating progression through 
the cell cycle and, in yeast, is the only cyclin-dependent kinase required to drive the cell cycle 
(Santamaría et al., 2007). 
CDK1 was identified as containing an LD-TBM in both the manual and bioinformatics searches, 
where the protein sequence appeared to have not one but two potential LD-TBMs.  Both the 
manual and PROSITE search identified an LD-TBM within residues 210-220 and the manual search 
identified a second potential LD-TBM between residues 283-290.  To determine if the site(s) were 
structurally viable to bind to talin and examine if these regions were conserved across species, we 
analysed CDK1’s structure and performed protein sequence alignments.  
5.2.3.3 CDK1 206-223 sequence evaluation  
CDK1 residues 210-220 were identified in both the manual and PROSITE search, FIGURE 5.8A shows 
a sequence alignment of CDK1 from a number of vertebrates and single cellular organisms.   The 
predicted LD-TBM (between residues 210-220) is highlighted in green and shows that the region is 
highly conserved across all species, further suggesting that the region is functionally important.   
The crystal structure of CDK1 is shown in FIGURE 5.8B and again the LD-TBM (210-220) is highlighted 
in green.  The LD-TBM is located in an accessible region of the structure and the region does not 
clash with the cyclin binding site on CDK1.  The region has a clear helical structure that as previously 
discussed is important for the binding of an LD-motif to an LDBD.  FIGURE 5.8B also highlights both 
the Leu210 and Asp211 residues on the structure (positions 0 and 1, respectively).  The Asp residue 
points out into space, which could allow formation of a salt bridge with talin.   
After evaluating both the conservation and the positioning of the LD-TBM on the CDK1 structure, 
we predicted that the CDK1 210-220 region would to bind talin.  In a similar fashion to SEPT2, a 
synthetic CDK1 peptide encompassing the LD-TBM was designed.  The peptide was designed to 
include residues 206-223 with a Cys at the N-terminus to allow coupling of a fluorescent tag.  The 




FIGURE 5.8: STRUCTURAL EVALUATION OF CDK1 206-223 PEPTIDE 
(A) Sequence alignment of CDK1 proteins from different vertebrates with the CDK1 206-223 peptide 
highlighted in green.  (B) Models the structure of CDK1 (PDB ID:4YC6) with the peptide residues coloured in 
green and the potential talin binding residues are also highlighted (Asp211 and Ile210.  (C) Shows the human 
CDK1 PSIPRED predicted secondary structure for the peptide residues (highlighted by a green box); the 
peptide looks to be in a helical region.  (D) shows the residues in the final ordered peptide with a C-terminal 
cysteine residue synthetically added. 
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5.2.3.4 CDK1 283-297 sequence evaluation  
The additional LD-TBM identified within residues 287-297 of CDK1 was only identified in the 
manual search as this method is less stringent and does not fit strictly to sequence1 or sequence2 
(section 5.2.1).  To determine if this region could bind talin, the same structural evaluation process 
was carried out as with the CDK1 210-220 region.   
FIGURE 5.9A shows the sequence alignment of CDK1 across different species highlighting the 290-
297 region in green.  This revealed that the LD-TBM is not conserved across species and that the 
Leu-Asp residues (position 0 and 1, respectivley) are not found in all species.  Residues 287-297 are 
highlighted on the CDK1 structure in FIGURE 5.9B and unlike with the SEPT2 and CDK1 210-220 
region there is no helical propensity but instead the region is disordered.  This was also confirmed 
when the sequence was run through the secondary prediction software PSIPRED (D.  T.  Jones, 
1999).   The results of the secondary structure prediction correlate with the CDK1’s crystal structure 
and indicate a low level of confidence in helical formation (shown in FIGURE 5.9D).    
The sequence is however, located in an accessible region of CDK1 meaning that talin could 
potentially bind without hindrance.  Furthermore, Asp288 in position 1 points out into space 
allowing the possible formation of a salt bridge with talin.   
After evaluating the structure and sequence of CDK1’s 287-297 region, it appeared unlikely the 
possibility of an interaction with talin. In spite of this, the region was ordered as a synthetic peptide 
to confirm this and thus determine how accurate and relevant the structural analysis of the LD-
TBM was.  A synthetic peptide of residues 283-297 was designed and an N-terminal Cys was added 





FIGURE 5.9: STRUCTURAL EVALUATION OF CDK1 283-297 PEPTIDE 
(A) Sequence alignment of CDK1 proteins from different vertebrates with the CDK1 283_297 peptide 
highlighted in green. (B-C) show the structure of CDK1 (PDB ID:4YC6) with the CDK1 283_297 peptide 
residues coloured in green, (C) highlights the residues of the potential talin binding motif Leu and Asp 
residues.  (D) PSIPRED secondary structure prediction for the peptide residues (highlighted by a green box) 
in human CDK1; the peptide looks to be in an unstructured region. (E) shows the residues in the final ordered 




5.2.4 Determining if the LD talin-binding motifs bind talin   
Through the design of a novel LD-TBM and the use of structural evaluation methods, we were able 
identify two potential proteins that could bind to talin.  From these hits, three synthetic peptides 
were designed encompassing three potential LD-TBM in proteins SEPT2 and CDK1.   
I. SEPT2: 159-174  CGLKPLDVAFMKAIHNK 
II. CDK1: 206-223  GDSEIDQLFRIFRALGTPC 
III. CDK1: 283-297  CNHPYFNDLDNQIKKM 
The synthetic peptides are predicted to bind to talin via helical addition to a folded helical bundle 
in the talin rod.  The talin rod is comprised of 13 helical bundles (as shown in FIGURE 5.10) and so 
to determine which bundle(s) the peptide can bind, a talin-screening assay was developed.   
Talin is a large 250 kDa protein and although the full-length protein can be purified from E. coli, 
only very low yields can be produced, making many of the available biochemical assays unfeasible.  
Furthermore, using the whole talin protein would allow us to gauge if the peptide binds but it 
would not enable the refinement of the binding site.  To overcome these issues, the talin rod was 
broken down into four large fragments: R1-R3 (residues 482-911), R4-R8 (residues 913-1653), R9-
R12 (residues 1461-2294) and R13-DD (residues 2300-2541).  These regions are shown in FIGURE 
5.10 and all can be expressed with high yields from E. coli, allowing the use of biochemical assays 
such as FP allowing us to screen for multiple ligands in quick succession against different regions 
of the rod domain.   







FIGURE 5.10: THE TALIN ROD DIVIDED INTO FOUR BIG FRAGMENTS 
Schematic diagram of talin rod domains.  Talin rod has been separated into the four talin fragments the blue 
box indicates R1-R3 fragment (residues 482-911), green box indicates R4-R8 fragment (residues 913-1653), 
red box indicates R9-R12 fragment (residues 1461-2294) and yellow box indicates R13-DD fragment (residues 
2300-2541).   
 
5.2.4.1 Fluorescence polarisation with talin1 ‘big fragments’  
The synthetic peptides (CDK1 206-223, CDK1 283-297, SEPT 159-174) were each coupled to the 
fluorescent tag, BODIPY-TMR, to be used in the FP assay (see methods section: 3.4.2).  The four 
talin fragments (R1-R3, R4-R8, R9-R12 and R13-DD) were all concentrated to 200 µM and increasing 
amounts of each fragment were titrated against each of the synthetic peptides. The binding of the 
KANK1 30-60C peptide (from Chapter 4) was also tested against each of the four talin fragments 
as a positive control for the R4-R8 fragment of talin.        
The binding affinity of each peptide for the talin fragments are shown in FIGURE 5.11.  As expected 
KANK1 30-60C bound to the talin1 R4-R8 domain region but displayed no binding to any of the 
other large fragments.  Of the remaining peptides, only the CDK1 206-223 peptide was bound to 
talin. In this case, the peptide appeared to bind in multiple places within the talin rod, as there was 
binding affinity for talin1 R9-R12 and talin1 R4-R8.  Neither the SEPT2 159-174 or the CDK1 283-




FIGURE 5.11: BIOCHEMICAL CHARACTERISATION OF LD TALIN-BINDING MOTIFS TO TALIN ROD 
FRAGMENTS 
(A-D) Binding of BODIPY-TMR labelled; CDK1 206-223C, CDK1 283-297, SEPT2 159-174, KANK1 30-60 
peptides to talin domains; R1-R3 (residues 482-911), R4-R8 (residues 913-1653), R9-R12 (residues 1655-2294) 
and R13-DD (residues 2300-254).  Binding affinities were measured using a Fluorescence Polarization assay.  
Dissociation constants ± SE (μM) for the interactions are indicated in the legend.  All measurements were 




5.2.4.2 Refining the talin binding site of CDK1 206-223  
The binding curves shown in FIGURE 5.11 indicate that CDK1 206-223 could bind to both talin 
fragments, R4-R8 and R9-12, with an equal affinity of ~15 µM.    However, through optimisation of 
the assay with the large talin fragments, we noticed that talin1 R9-R12 can bind to BODIPY-TMR 
(data not shown) leading to potential artifacts on the FP data.  To overcome this problem, the talin1 
R9-R12 fragment was split into two smaller domains: R9-R10 (residues 1655-1973) and R11-R12 
(residues (1974-2294).  These seemed to be a good compromise, as both double-domains were 
easily expressed and do not bind to BODIPY-TMR. 
The same FP assay was then carried out with the two smaller fragments, R9-R10 and R11-R12.   The 
binding affinity of CDK1 206-223 peptide to the five talin fragments is shown in FIGURE 5.12C.  This 
time no interaction was observed between the peptide and talin domains R9-R10 or R11-R12.  This 
leads to the conclusion that CDK1 206-223 can only bind to talin1 R4-R8 and does so with an affinity 
of 14 µM.   
 
FIGURE 5.12: BIOCHEMICAL CHARACTERISATION OF CDK1 206-223 PEPTIDE 
(A) Talin rod domains predicted structure highlighting the rod fragments used in the corresponding FP assay, 
red box highlights the splitting of the R9-R12 fragment into smaller R9-R10 and R11-R12 fragments.  (B-C) 
Binding of BODIPY-labelled CDK1 206-223C peptide to talin domains; R1-R3 (residues 482-911), R4-R8 
(residues 913-1653), R9-R10 (residues 1655-1973), R11-R12 (residues 1974-2294) and R13-DD (residues 
2300-254).  Binding affinities were measured using a Fluorescence Polarization assay.  Dissociation constants 
± SE (μM) for the interactions are indicated in the legend.  All measurements were performed in triplicate.  




5.3.1 Identifying future talin binding partners  
Of the chosen LD-TBMs identified in the manual and bioinformatics approaches only the CDK1 206-
223 peptide was found to have a binding affinity to talin.  The SEPT2 159-174 and CDK1 283-297 
peptides were not identified to bind to talin.  Can the lessons from this initial screening help refine 
the LD-TBM sequence and enable us to search for further talin binding proteins?   
Initially, it was believed that all the chosen peptides fitted the LD-TBM closely enough to bind to 
talin. However, a structural evaluation was carried out on each peptide whereby the secondary 
structure of the peptide, sequence conservation and structural positioning were analysed.  The 
structural evaluation determined that, the CDK1 206-223 and the SEPT2 159-174 peptide would be 
likely to bind talin and the CDK1 283-297 peptide would be unlikely to bind talin.  This was due to 
the CDK1 283-297 peptide not having a helical structure and also not being conserved across 
species, implying the region was not of functional importance.  From the structural analysis it was 
not a surprising to determine the CDK1 283-297 peptide had no binding affinity to talin.  It was 
however, a surprise that the SEPT2 159-174 peptide had no binding affinity to talin.   
 
FIGURE 5.13: SEQUENCE ALIGNMENT AND EVALUATION OF LD TALIN-BINDING MOTIFS 
Sequence alignment of: paxillin LD1 (UniProt ID: P49023); RIAM (UniProt ID: Q7Z5R6); DLC1 (UniProt ID: 
Q96QB1); KANK1 (UniProt ID: Q14678); KANK2 (UniProt ID: Q63ZY3); CDK1 (UniProt ID: P06493) and SEPT2 
(UniProt ID: Q15019).  Red highlights acidic residues, blue basic residues and green hydrophobic residues.  
Known talin binding sequences are highlighted with an *. 
 
To determine why the SEPT2 peptide did not bind to talin, the tested LD-TBM peptides were 
aligned alongside known LD-TBMs (shown in FIGURE 5.13).  The alignment indicates the only 
difference between the SEPT2 159-174 peptide and the other successful talin binding peptides is 
the residue found in the -1 position.  Earlier analysis determined the -1 position to be important 
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for binding talin and a charged Asp needed to be present, the SEPT2 peptide had a Pro in this 
position not fitting the criteria.  Enforcing the -1 position in the LD-TBM to be of high importance.  
The alignment also highlighted a slight variation in the CDK1 283-297 peptide compared to other 
known LD-TBMs; the Gln residue at position +3 (highlighted by yellow box) is not a hydrophobic 
residue like the other LD-TBM in this position.  Glutamine is a polar residue and could disrupt 
binding, potentially indicating that the +3 position is also of importance in the LD-TBM sequence.      
This preliminary screening of talin proteomics hits, with a designed LD-TBM sequence has proved 
successful and the LD-TBM has identified a novel talin binding protein, CDK1.  Using the results of 
successful and non-successful talin binding sequences the eight residue LD-TBM has been refined 
and important residues (-1,0,1, +3) have been identified.  Furthermore, it has been established that 
‘sequence searching’ for LD-TBMs is not enough on its own to identify talin binding partners, 
further structural analysis helps to reduce the number of false positives identified.   
Further analysis of new LD-motifs binding to talin will give a better understanding of the binding 
mechanism to talin and in the future it is hoped that the designed LD-TBM can be used to search 
larger databases of proteins helping to identify future talin binding proteins.   Furthermore, 
proteomics with talin1 in different cell types would give more information on talin binding partners 
in different cell types and different conditions.  Equally, it would be interesting to determine if 
there is any difference in LD-motifs binding the two talin isoforms in order to further understand 
the functional differences between the two isofroms.     
5.3.2 LD-motifs can bind to multiple LDBDs 
LD-motifs can be recognised by multiple LDBDs with different three-dimensional structures.  For 
example,  paxillin can bind to both vinculin and talin which both have different binding surface 
residues (Tumbarello, Brown and Turner, 2002).   This research identifies that LD-motifs do not 
have to adhere to the strict LDxLLxxL consensus sequence to bind LDBDs and this sequence 
adaptability would suggest that the LD-helix is malleable and the hydrophobic side chains on the 
LD-motif are able to adjust to binding to different surfaces. 
This promiscuity between LD-motifs and LDBD raises questions around how LD-motifs are being 
correctly directed to their target molecule and prevented from forming non-specific interactions.  
Specificity is important, as an LD-motif binding to the wrong LDBD can trigger the incorrect cellular 
response (Alam et al., 2014).  Understanding this specificity would lead to further understanding 
of the biological processes LD-motifs are involved in and understand how dysfunction in these 
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relationships can lead to disease.  Our research has identified that the specificity of LD-motifs is 
incredibly sensitive to sequence, and a single point mutant at the -1 or +3 position can change 
whether it binds talin or not. Therefore, the specificity between LD and LDBD interactions, whilst 
not fully understood is likely driven by similar alterations to the sequence of the surrounding 
residues of the LD-motif.  
5.3.3 Talin LDBD specificity  
Talin1 R8 is a LDBD that has been shown to bind multiple different LD-motifs including: DLC1, RIAM 
and Paxillin (Goult, Zacharchenko, et al., 2013; Zacharchenko et al., 2016).  The talin R8 domain can 
also bind to multiple non-LD proteins such as actin, α-synemin and vinculin making it a major 
signalling hub in the talin tail.   
As previously discussed in the introduction (Chapter 2) the positioning of talin R8 is unlike any  of  
the other talin rod domains.  In the talin rod, each helical bundle provides a link to the next rod 
domain via a short unstructured linker, talin R8  however, is inserted into  the  five  helical  bundle  
R7 domain, between helices 30 and 36 as shown in FIGURE 5.14 (Yao et al., 2016).  This domain 
insertion protects the four-helix R8 domain from being ‘unravelled’ by mechanical force  (Yan et 
al., 2015; Yao et al., 2016).  The talin four-helix bundles are less mechanically stable than five-helix 
bundles; talin1 R8 on its own can be unfolded at 5 pN (Yao et al., 2016).  Whereas a five-helix 
bundle such as R7 is not unfolded until a higher force of 15 pN (Yao et al., 2016).   When R8 is 
inserted into the R7 domain the four-helix R8 domain does not unfold until after the R7 domain 
unfolds at 15 pN, allowing the R8 domain to remain stable and keep its helical bundle structure.  
The helical bundle forms the binding site for LD-motifs and other ligands which when bound can 
help regulate focal adhesion maturation.  
With talin R8 acting as a signalling hub and binding many crucial ligands, how are the interactions 





FIGURE 5.14: TALIN R8 DOMAIN STRUCTURE IN RELATION TO THE TALIN TAIL 
A schematic representation of the talin R7-R8 domain structure.  Talin R8 (blue) shown to be inserted into 
the talin R7 domain (green) via unstructured linkers.  The arrows showing the direction of the adjacent 
domains R6 and R9 and the applied force.  Figure from: (Yao et al., 2016).   
 
5.3.3.1 Talin auto-inhibition  
One way in which the talin could regulate when an LD-motif can bind to the R8 domain is through 
talin autoinhibition.  Talin can form homodimer complexes which are able to adopt a compact auto 
inhibited conformation in the cytosol (Goult, Xu, et al., 2013).  The two talin molecules wrap around 
each other in a doughnut like confirmation with both talin head domains buried in the centre.  In 
this confirmation the talin R8 domain is hidden (as shown in FIGURE 5.15) meaning that the helices 
are not exposed to bind to LD-motifs.  This conformation could be a way to prevent LD-motifs 






FIGURE 5.15: TALIN AUTOINHIBITION 
(A) Front view of the talin1 dimer in compacted doughnut like confirmation. (B) Top view of the talin dimers 
the two monomers are coloured either white (rod), blue (head) and pink (rod), red (head) respectively.  In 
both A and B the talin R8 domain is highlighted by a red box.  Figure adapted from: (Goult, Xu, et al., 2013). 
 
Furthermore, it was described how talin has many layers of autoinhibition (section 2.7) and that 
individual talin domains can become unfolded when subjected to force.  When the helical bundles 
are unfolded the binding sites for LD-motifs are destroyed thus, preventing LD-motifs from binding 
to talin.  This prevention of LD-motifs binding under high force could be a mechanism in which the 
cell prevents LD ligands binding and allow other ligands such as vinculin to bind.   
5.3.3.2 Binding affinity of LD-motifs to talin  
LD-motifs bind to talin with micro molar affinity; RIAM and DLC1 ligands bind to talin R8 with an 
affinity around 4 µM and paxillin binding is found to be much weaker (Zacharchenko et al., 2016).   
The KANK LD-TBM was the tightest binding talin LD-motif found to date with a binding affinity of 1 
µM.   The weakness of the binding between talin and the LD-motif could be functionally important 
as it could prevent non-specificity between LD-motifs and LDBDs.  In order to have an interaction 
between the LD-motif and talin there would need to be a high concentration of the LD-motif in the 
vicinity of talin or equally a high concentration of talin around the LD-motif.  This could prevent 
interactions between talin and LD-motifs from occurring when not at adhesions. 
Spatial and sequential binding of LD-motifs and talin could result indirectly from co-expression and 
co-localisation of LD-motifs and/or talin proteins.  It could also rely indirectly on clustering from 
their recruiting factors such as integrin clusters at focal adhesions or CMSC clusters.   
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5.3.3.3 Post-translational modifications  
Post-translational modifications could also be a way to regulate binding of LD-motifs to talin.  When 
looking at the paxillin LD-motifs binding to LDBDs, phosphorylation of the LD-motif has resulted in 
weakening of binding to the LDBDs.  Phosphorylation of paxillin LD4 weakened the helical 
propensity of the LD-motif and consequently reduced binding to the FAK FAT domain by a factor 
of ~2.5 (Schmalzigaug et al., 2007).   
No PTMs have been yet found on the sequences of LD-TBMs: DLC1, RIAM and KANK however, the 
CDK1 206-223 LD-TBM does appear to contain a phosphorylation site at residue Ser206 
(information form PhosphoSitePlus (Hornbeck et al., 2015)).  This residue is located in position -2 
of the LD-TBM, there is also another phosphorylation site found in the CDK1 206-223 LD-TBM at 
Thr222.  Phosphorylation at either of these sites, but in particular Ser206, could prevent or weaken 
the interaction between talin and CDK1 through a change in binding surface or the LD-motif loosing 
helical propensity. 
Furthermore, PTMs on the surface of talin could have an impact on the binding of LD-motifs.  
FIGURE 5.16 shows some of the known PTMs on talin R7R8.  In our review, we catalogued the 
published the known talin PTMs and found that Ser1508 (talin R8) and Ser1641 (talin R7) can be 
phosphorylated and Thr1487 (talin R8) has been reported to be acetylated (Gough and Goult, 2018).  
These PTMs on talin could have an effect on the binding of LD-motifs.  In the characterisation of 
the talin:KANK interaction (chapter 3) a phosphomimetic mutant S1641E was used to disrupt the 
binding of talin:KANK interaction.  This mutant did not completely perturb binding but did result in 
a four-fold weakening in binding affinity between talin R7R8 and KANK; a similar finding to that in 




FIGURE 5.16: TALIN R7R8 POST-TRANSLATIONAL MODIFICATIONS  
Talin1 R7R8 KANK1 30-60 and DLC1 predicted structure, with highlighted PTMs in red (data from 






Chapter 6. Identifying and 
characterising the interaction 





In the previous chapter, I described how a designed LD talin-binding motif was used to screen 
through talin proteomic datasets in order to identify novel talin binding partners.  Sequence 
conservation and structural characteristics of these potential talin-binding proteins were further 
assessed and, from this the protein known as cyclin dependent kinase1 (CDK1) stood out as an 
interesting talin binding protein.  In this chapter, I describe the biochemical characterisation of the 
interaction between talin and CDK1 and look at how talin affects the phosphorylation activity of 
CDK1, to determine whether there is a link between the cell cycle and adhesion regulation.   
6.1.1 The cell cycle  
The cell cycle is a tightly regulated process that orchestrates gene duplication and accurate 
segregation of DNA and other factors into two daughter-cells.   The cell cycle is split into four 
distinct phases G1, G2, S phase and M phase (mitosis) (see FIGURE 6.1).  In the G1 phase metabolic 
changes prepare the cell for DNA replication, S phase involves the duplication of genetic material 
to create sister chromatids.  G2 prepares the cell for division and assembles all cytoplasmic 
components needed for entry into the M phase, where nuclear division also known as mitosis, 
occurs,  which creates two daughter-cells (Lim and Kaldis, 2013).  Before entry into each phase of 
the cycle, the cell has a series of checkpoints it must pass in order to prevent incorrect chromosome 
replication.  When these checkpoints fail and the cell cycle progresses incorrectly, this can lead to 
disease and is  often recognised as a  hallmark of cancer (Sherr and Bartek, 2017).   One group of 
molecules used to ensure regulated progression through each of the phases is the family of cyclin 




 FIGURE 6.1: THE CELL CYCLE  
A schematic diagram of the cell cycle highlighting each of the four phases involved G1 phase, S phase, G2 
phase and M phase (mitosis). 
6.1.2 Cyclin Dependent Kinases  
CDKs are a large family of serine/threonine kinases that partner with regulatory subunits known as 
cyclins, which control the kinase activity and substrate specificity of CDKs (Lim and Kaldis, 2013).  
The first CDK discovered was in budding yeast, CDC28 (known as CDK1 in mammalian cells, see 
FIGURE 6.2, and was revealed to play a crucial role in controlling cell cycle progression through 
interactions with different cyclins (Beach, Durkacz and Nurse, 1982).  Yeast became a working 
model to study both CDK proteins and the cell cycle, and it was shown that CDC28 (CDK1) was the 
only CDK needed to drive cell division in yeast models (Santamaría et al., 2007).  
In contrast to yeast, the mammalian cell cycle has several different CDK proteins which aid 
regulation of entry into each cycle phase although, similarly to yeast, CDK1 is the only CDK required 
to drive the cell cycle (Santamaría D1, Malumbres M et al., 2007).  Humans have twenty identified 
CDK proteins, named CDK1-CDK20, categorised into two classes: cell cycle related CDKs (these can 
bind to multiple cyclins), and transcriptional CDKs (these can bind to single cyclins) (Malumbres, 
2014) (shown in FIGURE 6.2).   The main required CDKs for cell cycle are CDK1, CDK2, CDK4 and 
CDK6 (Malumbres, 2014); these CDKs mediate the cell cycle through association with different 




FIGURE 6.2: CDKS AND CORRESPONDING CYCLINS  
A list of human CDKs and their partnering cyclin, the CDKs are spilt into two categories cell cycle-related and 
transcriptional CDKs. Figure is taken from: (Malumbres, 2014).   
 
6.1.3 Cyclin-dependent kinase activation 
Cyclins are small proteins that bind to CDKs to activate their kinase ability; they are named cyclins 
because they undergo a cycle of synthesis and degradation over the course of the cell cycle (Yang, 
2018).  CDK1 can be partnered with either cyclinA, B or E (shown in FIGURE 6.2) and the cyclin to 
which CDK1 is bound, determines the phase of the cell cycle.  As such, CDKs could be considered 
as the ‘engine’ that drives the cell cycle and cyclins as the ‘gears’ that have to be changed to aid 
the transition between the cell cycle phases.    
In the first phase, cyclinE is bound to CDK2 which promotes entry to S phase (Pines and Hunter, 
1990).  Subsequently, cyclin A levels begin to rise driving the binding of CDK1-cyclinA and, by late 
S phase, there is a detectable level of CDK1-cyclinA in the cell (Malumbres, 2014).  This aids entry 
into G2 phase, where levels of cyclinA slowly decrease and cyclinB levels rise (see FIGURE 6.3).  The 
binding of cyclinB to CDK1 promotes the cells entry into M phase and is known as the ‘mitosis 





FIGURE 6.3: LEVELS OF CYCLIN AND CDK COMPLEXES IN THE DIFFERENT PHASES OF THE CELL CYCLE 
A model to show the levels of cyclin-CDK complexes at the different phases of the cell cycle.  cyclin E-CDK2 
triggers S phase, cyclin A-CDK2 and cyclin A-CDK1 regulate the completion of S phase, and CDK1-cyclin B is 
responsible for mitosis.  Figure from: (Hochegger, Takeda and Hunt, 2008). 
 
To prevent early entry into mitosis, the activity of CDK1-cyclinB is regulated by several feedback 
loops.  When in early G2 phase, inactive CDK1-cyclin B is maintained in the cytosol through 
phosphorylation of CDK1 at residue Tyr15, by Wee1 kinase and related kinases (Gould and Nurse, 
1989).  
The activity of cyclinB then progressively increases once the cell enters prophase and active cyclinB-
CDK1 can translocate to the nucleus, triggering several mitotic events such as cell rounding, nuclear 
envelope breakdown and spindle formation (Gavet and Pines, 2010).  Cell rounding is an important 
stage for entry into mitosis.  Throughout the cell cycle, anchorage to a matrix is important requiring 
both integrin–ECM interactions and the formation of actin-associated complexes.  As the cell 
enters M phase cell rounding occurs (see FIGURE 6.4) and adhesion complexes are rapidly 
disassembled allowing for the cell to retract from the surface and round up to divide (Jones et al., 
2018).  Cell rounding is required for accurate spindle formation and chromosome capture (Carreno 
et al., 2008).  Integrin mediated adhesion is required for orientation of cell division and efficient 




FIGURE 6.4: CELL ADHESIONS RETRACT BEFORE ENTRY INTO MITOSIS 
A schematic diagram showing cell-matrix adhesions on entry into mitosis.  During the onset of mitosis levels 
of CDK1-cyclinB rise and cell adhesions are lost. Figure adapted from: (Ramkumar and Baum, 2016) 
6.1.4 CDK1 Phosphorylation 
CDK1 has a ‘two lobed’ structure consisting of an N-terminal lobe and a C-terminal lobe, the kinase 
also has an important active site found in a cleft between these two lobes (as shown in FIGURE 
6.5).  CDKs have to bind to cyclins in order to become ‘activated’, when not bound to a cyclin they 
are completely inactive for two reasons.  Firstly, the active site is blocked by the activation loop (a 
flexible loop region shown in FIGURE 6.5) and secondly, several important amino acids in the active 
site are not correctly positioned for the kinase reaction.  Binding of a cyclin induces conformational 
change in the activation loop exposing the active site.  However, for full kinase activity to occur 
phosphorylation of a conserved threonine residue on the activation loop has to follow.   
The CDK family is different to other kinases as it is unable to auto-phosphorylate this site on their 
activation loop and instead rely on being phosphorylated by other kinases.  A key kinase that 
phosphorylates the CDK1 activation loop at residue Thr160, is CDK Activating Kinase protein (CAK) 
(Enserink and Kolodner, 2010).  CAK is comprised of three subunits’ CDK7, cyclin H and MAT1 
making it a member of the CDK family (Lolli and Johnson, 2005).  CAK phosphorylates the conserved 
Thr160 residue on the activation loop of CDK1 (shown in FIGURE 6.5) resulting in a conformational 
change of the protein and the exposure of the substrate binding region (Enserink and Kolodner, 
2010).   Furthermore, phosphorylation of this site increases the number of contacts between the 
cyclin and CDK1 leading to a stronger binding interaction.  Both activation loop phosphorylation 







FIGURE 6.5: STRUCTURE OF CDK2 
The structure of monomeric CDK2 (PDB ID: 1HCK) (silver).  CDK2 is composed of a smaller N-terminal lobe 
formed from a twisted anti-parallel β-sheet and a larger C-terminal lobe.  The activation loop (red) runs from 
residues 145-172 and the Thr160 residue is marked.  Figure adapted from: (Wood and Endicott, 2018).   
 
When activated, CDK1 can phosphorylate, Ser, Thr and Tyr residues through the addition of a 
phosphate group (PO3- ), as shown in FIGURE 6.6.  CDK1 phosphorylates proteins that contain the 
optimal phosphorylation consensus sequence, Ser/Thr-Pro-x-x-Lys/Arg (S/T-P-x-x-K/R) (Rhind and 
Russell, 2012) although it can also phosphorylate numerous proteins with the minimal consensus 
sequence: Ser/Thr-Pro (S/T-P) (Suzuki et al., 2015).  And more recently it has been shown that CDK1 
can also phosphorylate non-S/T-P sites (Enserink and Kolodner, 2010).  
Phosphorylation is a reversible post-translational modification (PTM) and plays a critical role in the 
regulation of many cellular processes including cell growth, cell cycle and apoptosis.  It is estimated 
that one third of proteins in the human proteome are substrates for phosphorylation (Ardito et al., 
2017).   The addition of a phosphate group changes the amino acid environment through the 
addition of a negative charge, which can have a large effect on protein function and phenotype 
within the cell.  The addition of a phosphate can cause conformational changes in the protein’s 
structure, which may then regulate catalytic activity or allow the phosphorylated region to recruit 
neighbouring proteins that can recognise and bind phospho-motifs, such as Src homology domains 




FIGURE 6.6: MECHANISM OF PHOSPHORYLATION 
(A) Diagram illustrating that the phosphorylation PTM is a reversible reaction, phosphorylation is mediated 
through a kinase adding a phosphate group from ATP and phosphatases remove phosphate group.  (B) 
Diagram illustrating the phosphorylation of the amino acid serine.  The protein transfer from (-OH) group on 
the Ser stimulates the nucleophilic attack of the γ-phosphate group on ATP resulting in the transfer of a 
phosphate group (from ATP) to serine to form phosphoserine and ADP.  (-B:) indicates the phosphatase 




6.1.5 Cell adhesions regulated by CDK1  
The CDK family plays a vital role in regulating the cell cycle, but until recently they were not 
regarded as being involved with the regulation of cellular adhesions (Robertson et al., 2015).  
Through the publication of the phospho-adhesome, a report of the proteomic and 
phosphoproteomic sites on adhesion complexes, it was revealed that many proteins involved in 
integrin-matrix adhesions are phosphorylated by CDK1, proposing the idea that the CDK family 
could play a role in adhesion regulation (Robertson et al., 2015). 
Since then, work from M.C. Jones et al. have shown that cell adhesions are regulated by CDK1 
during the cell cycle.  They found that cells transitioning from G1 to S phase had a CDK1 dependent 
increase in focal adhesion formation, which was partially mediated by phosphorylation of adhesion 
proteins such as the formin-like protein 2 (FMNL2) (Jones et al., 2018) (see FIGURE 6.7).   
Study of CDK1 in adhesions revealed that CDK1 inhibition triggers disassembly of focal adhesions 
and leads to a decrease in the area of cells covered by adhesions with only smaller nascent 
adhesion left (Robertson et al., 2015).  This provides the first clear evidence that CDK1 may be 






FIGURE 6.7: ADHESION AREA IS DEPENDENT ON THE CELL CYCLE PHASE 
Schematic diagram of the cell cycle indicating the size of cell-matrix adhesions (red) at different phases of 
the cell cycle.  Figure based form: (Jones et al., 2018) 
 
This role of CDK1 is distinct from its more well-described role with cyclinB-CDK1 (driving the G2 
phase into mitosis), because a knock-down of cyclin B did not cause changes in adhesion formation 
throughout the cell cycle.  This finding makes sense as cyclinB-CDK1 is only seen in G2 phase of the 
cell cycle (cell adhesion growth found in S phase) and so, instead of cyclinB it appears that cyclinA 
is required for the CDK1-dependent adhesion regulation.   
Furthermore, cell adhesion area increases between G1 to S phase and decreases as cells enter G2 
phase, following the pattern of cyclin A concentration in the cell (see FIGURE 6.3) (Jones et al., 
2018).  Jones et al. concluded, that additional CDK1-cyclinA substrates might be involved in the 
regulation of adhesion formation.  Could the CDK1:talin interaction play a role in the cell adhesion 
regulation and could talin binding to CDK1 be a recruiting factor of CDK1 to adhesions?   
In the previous chapter, it was described how a designed LD talin-binding motif, was used to screen 
through talin proteomic datasets in order to identify talin-binding partners.  Sequence 
conservation and structural characteristics of these potential talin-binding proteins were further 
169 
 
assessed and from these data, one protein stood out as an interesting talin binding protein.  This 
protein was cyclin dependent kinase1 (CDK1).  This chapter describes the characterisation of this 
protein-protein interaction through biochemical and biophysical methods, and addresses the 
effects of talin on the phosphorylation activity of CDK1, to attempt to determine the existence of 
a link between cell cycle and adhesion regulation. 
6.2 Results 
The designed LD talin-binding motif (described in chapter 5) identified two regions of CDK1 that 
could potentially interact with talin: CDK1 206-223 and CDK1 283-297.  These regions of CDK1 were 
designed as synthetic peptides and ordered with C-terminal Cys residues, as previously described 
in Chapter 5.  The affinity of both CDK1 peptides to talin was measured using FP assays, which 
showed that the CDK1 283-297 region did not interact with talin, whilst the 206-223 peptide bound 
to the talin1 fragment R4-R8.   
6.2.1 Determination of the CDK1 binding site(s) on talin 
Chapter 5, FIGURE 5.11 shows binding data between the CDK1 206-223 peptide and the large talin 
rod fragments (R1-R3, R4-R8, R9-R10, R11-R12 and R13-DD).  CDK1 binds to the talin1 fragment 
R4-R8 with a KD of 16 µM.  To further refine the CDK1 binding site on talin, the large R4-R8 fragment 
was broken down into smaller domains, no binding was observed for domains R4 (residues 913-
1044), R5 (residues 1046-1206), and R6 (residues 1206-1357), leading to the conclusion that the 
CDK1 binding site is in the R7-R8 region of talin.  However, the double domain R7R8 (residues 1357-
1653) was found to bind the CDK1 peptide with an affinity of 15 µM (shown in FIGURE 6.8A).  It 
was also determined that both talin isoforms (talin1 and talin2) could bind to the CDK1 peptide 
with similar affinity; talin2 R7R8 bound the CDK1 peptide with an affinity of 11 µM.   
Subsequently the individual talin domains: R7 (residues 1357-1365 ∆1454-1586) and R8 (residues 
1461-1580) binding affinity was measured to the CDK1 peptide.  FIGURE 6.8B shows the CDK1 
peptide bound very weakly to talin1 R7 with a binding KD of 56 µM.   Talin1 R8 on the other hand, 
had an affinity of 18 µM to the CDK1 peptide concluding that the CDK1 binds to the talin1 R8 




FIGURE 6.8: BIOCHEMICAL CHARACTERISATION OF CDK1 BINDING TO TALIN 
(A-B) Binding of BODIPY-labelled CDK1 206-223C peptide individual talin domains; talin1 R7-R8 (1357–1659), 
talin2 R7R8 (1360-1656), talin1 R7 (1357-1653Δ(1454-1586) and talin1 R8(1461-1580).  Binding affinities 
were measured using a Fluorescence Polarization assay.  Talin domain R10 (1815-1973) was used as a 
negative control.  Dissociation constants ± SE (μM) for the interactions are indicated in the legend.  All 
measurements were performed in triplicate.  ND, not determined.  (C) Helical prediction of CDK1 peptide 
based on the structure CDK1 (PDB ID:4YC6).  (D) structural prediction of CDK1 peptide from CDK1 structure 
(PDB ID:4YC6) (green) overlaid with DLC1 peptide structure (PDB ID:5FZT) with CDK1 residues threaded onto 




6.2.2 Chemical shift mapping of the CDK1 binding site on talin1 R7R8 
To further explore the talin:CDK1 interaction and determine the CDK1 binding surface on talin R7R8, 
NMR chemical shift mapping was used.  15N-labelled talin1 R7R8 (residues 1357-1653) were 
expressed and a 15N TROSY spectrum of talin1 R7R8 (140 µM) (black FIGURE 6.9) was carried out.  
The talin1 R7R8 spectrum had good peak dispersion indicating that the protein was folded; CDK1 
206-223 peptide was then added to talin1 R7R8 at a ratio of 6:1 (green in FIGURE 6.9) and a very 
similar peak dispersion remained indicating that the interaction between talin:CDK1 did not alter 
the folding of talin1 R7R8.  However, a subset of the talin1 R7R8 peaks shifted upon addition of 
CDK1 whilst some remained in the same position, indicating that the CDK1 peptide bound to a 
specific region on talin.  To determine which peaks had shifted, the CDK1:talin spectrum was 
overlaid with a talin1 R8 spectrum (data not shown), which highlighted it was talin1 R8 peaks that 
had shifted with no significant shift changes observed on the R7 peaks; corroborating the FP data 
(FIGURE 6.8) that talin1 R8 is the main CDK1 binding site on talin.  
 
FIGURE 6.9: 15N TROSY NMR TITRATION TALIN1 R7R8 AND CDK1 206-223C PEPTIDE 
1H,15N TROSY spectra of 140 μM 15N-labelled talin1 R7R8 (residues 1357–1659) in the absence (black) or 




6.2.3 Chemical shift mapping of the CDK1 binding site on talin R8 
The peaks in the R7R8 TROSY spectrum (FIGURE 6.9) are quite overlapped making the mapping of 
individual peaks challenging.  To overcome this a titration of the individual talin1 R8 (residues 1461-
1580) domain was carried out.  15N-labelled talin1 R8 was titrated against increasing concentrations 
of the CDK1 206-223 peptide, the most saturated point in the titration is shown in FIGURE 6.10A; 
talin R8 on its own (black) and CDK1 titrated in at a ratio 12:1 (blue).  There was less overlap of the 
individual peaks with the talin1 R8 domain, allowing a clearer tracking of each peak, shown in 
FIGURE 6.10B (talin1 R8 on its own (black), and in the presence of CDK1 at a ratio 3:1 (pink), 6:1 
(green) and 12:1 (blue)). The talin peaks move differently compared to when the KANK1 30-60C 
peptide was added to talin1 R7, instead of splitting (slow exchange) they move progressively in a 
linear line (with increasing concentrations of CDK1 peptide).  This movement is showing the peaks 
are in fast exchange on the NMR timescale, which allows for easy and accurate peak tracking.  
FIGURE 6.10C highlights one peak, corresponding to talin residue Asn1534 to show the linear shift 
changes as a higher concentration of CDK1 peptide is added.   
To map exactly which talin1 R8 residues shift upon addition of the CDK1 peptide, the talin1 R8 
chemical shift assignments were downloaded from the BioMagResBank (BMRB ID:19339) and 
analysed using CcpNMR Analysis software allowing each peak in the talin R8 spectrum to be 
assigned to the corresponding talin1 R8 residue.  For analysis, the talin1 R8 spectrum was 
overlapped with the talin1R8:CDK1 1:6 spectra to allow measurement of the distance shifted for 
each peak.   
These shift distances were determined using the weighted combination of 1H and 15N amide 
secondary shifts (∆(H,N)).  ∆(H,N) are determined using EQUATION 2: as described in chapter 4.  
The shift distances for each peak were plotted and can be seen in FIGURE 6.11A; residues where 
the peak shifted over 0.02 ppm (which represented a significant shift) are highlighted in red on the 
graph and on the talin1 R7R8 structure (FIGURE 6.11B).  The talin residues that shifted upon 
addition of the CDK1 peptide mapped onto talin helices 32 and 33 (FIGURE 6.11B).  This was 
interesting as these talin helices also form the binding surface for several other talin ligands 






FIGURE 6.10: 15N HSQC NMR TITRATION OF TALIN1 R8 AND CDK1 206-223C PEPTIDE 
(A-C) 1H,15N HSQC spectra of 70 μM 15N-labelled talin1 R8 (residues 1461-1580) in the absence (black) or 
presence of CDK1 206-223C peptide (pink/green/blue).  Spectra are talin:CDK1 at a ratios of 1:12 (blue), 1:6 
(green) and 1:3 (pink).  (B) Zoomed in view of the box shown in (A). (C) Zoomed in region highlighting the 
peak corresponding to residue Asn1534, showing progressive chemical shift changes, demonstrating the 





FIGURE 6.11: CHEMICAL SHIFT MAPPING OF TALIN1 R8 AND CDK1 206-223C 
(A) Chemical shift mapping of the CDK1 binding site on talin1 R8 as detected by NMR using weighted chemical 
shift distances. (B) Residues that moved more than 0.02 ppm (highlighted in red) mapped onto the talin1 




6.2.4 Biochemical comparison of DLC1 and CDK1 binding talin1 R8  
CDK1 binds to talin R8 via helices 32 and 33, which is the same binding surface as DLC1.   Our 
understanding of how LD ligands and their LDBD are regulated is limited so here I wanted to 
compare how the two ligands, DLC1 and CDK1 interact with talin1 R8.   
Both CDK1 and DLC1 bind to talin via a similar LD talin-binding motif; the DLC1 LD-motif is between 
residues 465-489 (IFPELDDILYHVKGMQRIVNQWSEK).  The motif is slightly different to CDK1 shown 
in FIGURE 6.12B as CDK1 contains an ‘ID’ rather than the canonical ‘LD” found in DLC1.  To 
determine if this makes a difference in binding to talin; the FP assay was used to measure affinity 
between talin1 R7R8 and the DLC1 and CDK1 peptides.   The data shown in FIGURE 6.12A shows 
DLC1 binds talin1 R7R8 with a higher affinity than CDK1; DLC1 binds talin R7R8 with a KD of 3.5 µM 
whereas CDK1 has a KD of 14 µM.   
 
FIGURE 6.12:  BINDING OF DLC1 AND CDK1 TO TALIN1 R7R8 
(A) Binding of BODIPY-TMR labelled CDK1 206-223C peptide and DLC1 465-489C peptide to talin1 R7-R8 
(1357–1653).  Binding affinities were measured using a Fluorescence Polarization assay dissociation 
constants ± SE (μM) for the interactions are indicated in the legend.  All measurements were performed in 
triplicate.  (B) The CDK1 (206-223) and DLC1 (465-489) peptide sequences shown with the LD talin-binding 




A 15N HSQC of talin1 R8 (black) is shown in FIGURE 6.13; both CDK1 (green) and DLC1 (blue) 
peptides were added to talin R8.  The spectra were compared to highlight the differences the two 
peptides had on the talin R8 environment.   The DLC1 spectrum shows more peaks have shifted, 
compared to the CDK1 spectrum, (red box on FIGURE 6.13 and FIGURE 6.13B).  This suggests that 
more residues may be involved in the binding of talin:DLC1 compared to talin:CDK1.   
FIGURE 6.13C shows a region of the spectrum where most talin shifts take place when CDK1 is 
added.  In this region the same talin peaks shift in the presence of both DLC1 and CDK1 indicating 
that the same core residues are mediating the binding of CDK1 and DLC1.  Additionally, some talin 
peaks in this region shift in opposite directions with the two ligands (FIGURE 6.13C highlighted by 
black dotted box).   This change highlights the differences in the ligands CDK1 and DLC1 sequences, 
these different residues cause different environmental changes to talin when binding.  This 
indicates that, even though there is residue variation in the talin binding sequence on CDK1 and 
DLC1, they still binding to the same talin residues.  Together this provides evidence that the same 





FIGURE 6.13: 15N TROSY SPECTRA SHOWING DLC1 AND CDK1 BINDING TO TALIN1 R7R8 
(A-B )1H,15N TROSY spectra of 140 μM 15N-labelled talin1 R7R8 (residues 1357–1659) in the absence (black) 
and presence of 400 μM CDK1 206-223C peptide (green) or 400 μM DLC1 465-489C peptide (blue). Black box 
highlights region of talin residues shifted upon addition of CDK1. Red box highlights area of the spectra where 
the peaks have shifted upon addition of DLC1 to talin R7R8 but not CDK1.  (C) Zoomed in region of the HSQC 
spectra, highlighting the different directions of the peaks when CDK1 or DLC1 peptides are added to talin1 




6.2.5 Designing a CDK1 mutant to disrupt the talin:CDK1 interaction 
CDK1 binds to talin through an LD talin-binding motif.  This LD-motif is similar to the KANK LD talin-
binding motif discussed in chapter 4.  Designing a CDK1 mutant to perturb talin:CDK1 binding was 
greatly assisted from the design of the KANK_4A mutant (see section 4.2.6), that successfully 
perturbed the binding between talin:KANK.   
The KANK_4A mutant was designed to perturb binding via mutating the Leu and Asp residues in 
the LD-motif for Ala.  This prevented KANK from forming the salt bridge between the charged Asp 
residue and talin and consequently perturbing binding.   
FIGURE 6.14A shows a model of CDK1 binding to talin R8 which demonstrates how the Asp211 
residue (in the LD-motif) likely forms a salt bridge with talin residue Lys1544.  This interaction 
orients the CDK1 peptide and allows the hydrophobic Ile210 residue to form a hydrophobic 
interaction with talin.  Using the same strategy we developed for KANK, we mutated the CDK1 I 
le210 and Asp211 residues to Ala.  A peptide CDK1_2A 206-223 (GDSEAAQLFRIFRALGTPC) 
containing the mutation was ordered (shown FIGURE 6.14C) allowing the FP assay to be used to 
determine the binding of the CDK1_2A mutant with talin1 and talin2 R7R8.  FIGURE 6.14D shows 
the CDK1_2A mutant is effective as it did not generate a determinable KD confirming it is an 




FIGURE 6.14: DESIGN OF ACDK1_2A MUTANT TO PERTURB TALIN:CDK1 INTERACTION 
(A-B) Structural model of CDK1 206-223C (green) binding to talin1 R8 domain (grey) - the talin:DLC1 structure 
used with CDK1 residues threaded onto DLC1 helix (PDB ID: 5FZT).  (A) Ile210 and Asp211 residues are 
highlighted (B) the mutations Ala210 and Ala211 are highlighted. (C) CDK1 and CDK1_2A peptide sequences: 
green highlights the Ile and Asp residues in the LD-motif and red highlights the Ala residues in the CDK1_2A 
mutation. (D) Binding of BODIPY-TMR labelled CDK1 206-223C and CDK1_2A 206-223C peptides to talin2 
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R7R8 (1360–1656).  Dissociation constants ± SE (μM) are indicated in the legend.  All measurements were 
performed in triplicate.  ND, not determined.   
 
To confirm the effectiveness of the CDK1_2A mutant for disrupting the interaction between CDK1 
and talin, NMR titrations were carried out with talin1 R7R8 (residues 1357–1659) and the CDK1_2A 
206-223 peptide.  The15N TROSY talin1 R7R8 spectra are shown in FIGURE 6.15.  For both FIGURE 
6.15A and B, the spectra in black correspond to talin1 R7R8; in green (FIGURE 6.15A) spectrum 
corresponds to the addition of the CDK1 206-223 peptide (ratio 6:1) and, in red, FIGURE 6.15B the 
spectrum of mutant CDK1_2A 206-223 added at a ratio of 6:1.  No shifts can be observed when the 
CDK1_2A peptide is added, in contrast to the addition of CDK1 WT peptide.   
 
FIGURE 6.15: NMR TROSY OF THE CDK1_2A MUTANT ON BINDING TO TALIN R7R8 
(A) 1H,15N TROSY spectra of 140 μM 15N-labelled talin1 R7R8 (residues 1357–1653) in the absence (black) or 
presence of CDK1 206-223C peptide (green) at a ratio of 1:6.  (B) 1H,15N TROSY spectra of 140 μM 15N-labelled 
talin1 R7R8 in the absence (black) or presence of CDK1_2A mutant peptide (red)at a ratio of 1:6 
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Furthermore, a 15N HSQC titration with the individual talin R8 domain was carried out.  FIGURE 
6.16 shows the most saturated point of the titration with 420 µM CDK1 added to 70 µM talin R8.  
The HSQC showed no shifts occurred in presence of the mutant enabling us to conclude that the 
CDK1_2A mutant is effective in abrogating the talin:CDK1 interaction and would be a good mutant 
to use in cellular studies of the CDK1:talin interaction.   
 
FIGURE 6.16: NMR HSQC OF THE CDK1_2A MUTANT AFFECT ON BINDING TO TALIN R8 
(A) 1H,15N HSQC spectra of 70 μM 15N-labelled talin1 R8 (residues 1461-1580) in the absence (black) or 
presence of CDK1 206-223C peptide (green) at a ratio of 1:6.  (B) 1H,15N HSQC spectra of 70 μM 15N-labelled 
talin1 R8 in the absence (black) or presence of CDK1_2A mutant peptide (red) at a ratio of 1:6.   
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6.2.6 Structural characterization of the talin:CDK1 complex 
Following the design of a CDK1 mutant to perturb talin:CDK1 binding we wanted to design a talin 
mutant to perturb the interaction also.   In order to achieve this, it was important to understand 
the talin residues involved in the interaction with CDK1 and so we wanted to obtain an atomic 
structure of talin1 R7R8 and CDK1 206-223.    
6.2.6.1 Crystallography 
Crystallography screens of the CDK1:talin complex were set up including Hampton crystal screen 2 
(Hampton), JCSG (Molecular Dimensions), Wizard (Molecular Dimensions) and Pact (Molecular 
Dimensions).  Initially talin1 R7R8 (residues 1357–1653) was purified and mixed with CDK1 peptide 
at a ratio of 1:4. All screens were plated at a 1:1 ratio of protein: well solution and left at both 4 °C 
and 20 °C.  A number of crystals grew in the screening trays, some are shown in FIGURE 6.17, these 
crystals were placed into a CryoLoop and frozen in liquid nitrogen.  Diffraction datasets was 
collected at 100 K on beamline I03 at Diamond Light Source (Didcot, UK).   However, when solved 
it was found that the crystals were Apo structures and no CDK1 peptide was present.   Different 
ratios of talin:CDK1 were tried and also talin2 R7R8 but no structure could be obtained.   
 
 
FIGURE 6.17: CRYSTALLIZATION TRIALS OF TALIN1 R7R8 AND CDK1 206-223C PEPTIDE 
Crystals of talin1 R7R8 grown form a protein complex talin1 R7R8:CDK1 (ratio of 1:8) and laid at a 1:1 protein 




6.2.6.2 Predicted docking 
In the absence of a talin:CDK1 structure a docking prediction between the talin R7R8 domains and 
the CDK1 206-223 peptide was created.  This was achieved using the known talin1 R7R8:DLC1 
structure (PDB ID: 5FTZ), where the DLC1 peptide forms a short alpha helix that packs against the 
talin helices 32 and 33.  The DLC1 helix was used as a base and the CDK1 peptide 206-223 was 
threaded onto the DLC1 helix using PyMOL.  FIGURE 6.18 shows the structural model of a CDK1 
peptide threaded onto talin1 R8. In the model, Asp211 of CDK1 is positioned to form a salt bridge 
with talin Lys1544 residue; a key interaction found in all LD peptides bound to the talin R8 domain.   
 
 
FIGURE 6.18: STRUCTURAL MODEL OF TALIN1 R7R8:CDK1 206-223  
The binding of talin1 R7R8 and CDK1 peptide 206-223.  CDK1 peptide 206-223 was modelled onto the known 




6.2.7 Designing a talin mutant to perturb CDK1:talin binding  
A major aim of the biochemical characterisation of the interaction between talin and CDK1 was to 
design and validate mutations that were capable of modulating it, with the ultimate purpose of 
introducing these mutants into cells to explore the physiological role of the interaction (with and 
without the mutations).   
The CDK1_2A mutant disrupts talin:CDK1 binding and is useful in helping understand what the 
CDK1:talin interaction is doing in a cell.  However, because CDK1 is a promiscuous Ser/Thr  kinase 
and is known to phosphorylate hundreds of other proteins in different compartments of the cell 
(M.  C.  Jones, Askari, Humphries, & Humphries, 2018), having a CDK1 mutant may not give a clear 
picture of its talin-dependent functions.  The mutation in CDK1 may affect phosphorylation of other 
proteins in the cell, and this would have off target effects other than just disrupting the talin:CDK1 
interaction.  To resolve this, we proposed that a mutation on the talin R8 domain inhibiting the 
talin:CDK1 interaction would give a clearer insight in to the role CDK1:talin is playing in the cell.   
We wanted to design and test a talin mutant that would perturb the talin:CDK1 interaction and not 
prevent binding of other known talin R8 binding proteins such as DLC1 or RIAM (Goult, 
Zacharchenko, et al., 2013; Zacharchenko et al., 2016).  To determine if R8 ligand-specific 
mutations were feasible, the structures of DLC1:talin (PDB ID: 5FZT) and RIAM:talin (PDB ID: 4W8P) 




FIGURE 6.19: LD SPECIFICITY BETWEEN TALIN R8 LIGANDS: DLC1, RIAM AND CDK1 
(A) Structural model of talin: CDK1:talin highlighting the binding of LD talin-binding motif on the CDK1 
peptide (green)  initial talin LD binding site shown by a red box and the LD specificity region is also highlighted 
by a red box.  (B Structure of talin: RIAM (PDB ID: 4W8P) RIAM   LD talin-binding motif highlighted in orange.  
(C)The structure of talin:DLC1 (PDB ID: 5FZT) DLC1 (pink). 
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The salt bridge interaction that forms between the Asp on the LD-motif and talin1 R8 Lys1544 
residue might be the initial contact that defines the interaction.  Structural analysis confirms that 
the LD talin-binding motifs of: CDK1, RIAM and DLC1 dock to the talin R8 domain all form this 
interaction via the ‘initial LD binding site’ (see FIGURE 6.19).   
This interaction orients the LD talin-binding peptide and allows binding of other residues further 
downstream of the LD  to bind to talin in what is known as the ‘specificity region’ (Zacharchenko 
et al., 2016).  Talin1 Lys1544 was targeted when trying to perturb the DLC1:talin interaction 
(Zacharchenko et al., 2016), where the basic Lys residue was mutated to an acidic Glu.  This 
mutation however, only had a partial effect on perturbing the interaction between talin and DLC1 
suggesting that other interactions downstream of this in the ‘LD specificity region’ are integral for 
the interaction (Zacharchenko et al., 2016). 
The ‘LD specificity region’ potentially makes it plausible that a ligand specific mutation could be 
made to prevent only the perturbation of one LD ligand from talin R8.  The talin residue Lys1544 
could be mutated to abrogate the ‘LD initial binding site’ and then a residue making a contact 
unique to that LD talin-binding ligand could be mutated in the ‘specificity region’.   
FIGURE 6.19 shows the ‘LD specificity region’ in both DLC1 and RIAM;  DLC1 Glu488 forms a salt 
bridge with talin Lys1530 whereas RIAM Glu18 forms a salt bridge with talin Lys1510.  A double 
talin mutant that targeted both the ‘initial LD binding site’ (Lys1544) and the DLC1 ‘specificity site’ 
(Lys1530) was designed and tested using NMR (Zacharchenko et al., 2016).  This data indicated that 
the double mutation perturbed the binding of talin and DLC1 (Zacharchenko et al., 2016). 
Using a similar strategy we sought to design a talin mutant to perturb talin:CDK1 binding and to 
achieve this the CDK1 ‘specificity site’ needed to be identified.  The CDK1: talin docking structure 
(FIGURE 6.19A) was used as a reference and a potential salt bridge between CDK1 Glu232 and talin 
Lys1523 was identified.  A further contact between CDK1 and talin in the ‘specificity region’ could 
come from hydrophobic interactions between CDK1 Trp228 and talin.   FIGURE 6.19A shows the 
Trp228 residue to be facing away from the talin helices however, if helical propensity of this region 
was modelled we would predict that the hydrophobic Trp residue would point in-between the two 




FIGURE 6.20: IDENTIFYING IF CDK1 TRP228 AND GLU230 RESIDUES ARE IMPORTANT FOR TALIN BINDING 
 (A) The CDK1 206-223 and CDK1 206-232 peptide sequences used.  (B-C) Helical prediction of CDK1 peptides 
based on the structure CDK1 (PDB ID:4YC6).  (D) Binding of BODIPY-TMR labelled CDK1 206-223C and CDK1 
206-232C peptides to individual talin1 R7-R8 (1357–1659).  Binding affinities were measured using a 
Fluorescence Polarization assay.  Dissociation constants ± SE (μM) for the interactions are indicated in the 
legend.  All measurements were performed in triplicate.   
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Neither CDK1 residues Trp228 and E230 are found in DLC1 or RIAM nor do DLC1 or RIAM appear 
to contact talin Lys1523.   We hypothesised that if these regions could be targeted in conjunction 
with the talin Lys1544 residue a CDK1 specific talin mutation could be made.   
Before designing the talin mutants we wanted to determine if the CDK1 residues encompassing 
the predicted LD specificity region would increase the affinity for CDK1 as they were not included 
in the original CDK1 206-223 peptide.  To explore whether Trp228 and Glu230 were involved; we 
designed a longer CDK1 peptide- CDK1 206-232 (shown in FIGURE 6.20A).  Fluorescence 
polarisation was used to measure the binding affinities for the two CDK1 peptides with talin1 R7R8. 
FIGURE 6.20D shows there was no significant difference between the longer and shorter CDK1 
peptides: the short CDK1 206-223 peptide bound with a KD of16 µM and the longer peptide bound 
with a KD of 21 µM.  Therefore, we concluded that Trp228 and Glu230 are not important for the 
interaction with talin and thus we have determined that the CDK1 residues 206-223 comprise the 
talin binding site.  Determining that only CDK1 residues 206-223 are important for talin binding 
meant that a new strategy for designing a CDK1 specific mutant had to be implemented as talin 
residues around Trp228 and Glu230 could no longer be targeted as they were not part of the talin 
binding site, meaning the ‘LD specificity region’ was not where originally anticipated.  The next 
strategy we implemented was to disrupt hydrophobic interactions between talin and CDK1 206-
223.  FIGURE 6.21 highlights the hydrophobic residues on CDK1 that could interact with talin helices 
32 and 33, these include CDK1 residues: Ile210, Phe214 and Phe217.   
To target these CDK1 residues, talin1 R7R8 mutants were designed, the CDK1 Phe217 (from the 
CDK1:talin binding model) looked to be situated near two alanine residues on the talin surface 
Ala1495 and Ala1499 (shown in FIGURE 6.21).  Ala1495 and Ala1499 potentially create a pocket 
for the aromatic ring of Phe217 and Phe214.   
This observation of conserved small residues in the interface had some similarity to the docking of 
KANK to talin R7; KANK had a bulky hydrophobic residue Tyr48, which formed hydrophobic 
interactions with talin helices 29 and 36.  The design of the talin mutant G1404L utilised a bulky 
leucine residue and prevented KANK1 Tyr48 from interacting with talin.  Learning from the success 
of the G1404L talin mutant we employed a similar strategy of trying to prevent the CDK1 residues; 
Phe217 and Phe214, from fitting in-between the talin helices.  Talin1 Ala1495 and Ala1499 were 
mutated to leucine residues with the hypothesis that the two Leu residues would fill the gap 
between talin helices 32 and 33 preventing CDK1 Phe214/ Phe217 from fitting in to the pocket and 







FIGURE 6.21: DESIGNING A TALIN R8 MUTANT TO PERTURB CDK1 BINDING 
Structural model of Talin1:CDK1 206-223 predicted based on talin:DLC1 structure(PDB ID: 5FZT).  Residues 
on talin R8 that look to be interacting or in close proximity to CDK1 residues are highlighted in yellow.  The 




A second mutagenesis approach was to target the CDK1 ‘initial LD binding site’ by designing a talin 
mutant that could prevent the salt bridge between talin Lys1544 and CDK1 Asp211 as showing in 
FIGURE 6.19A.  These included:  
i. A charge reversal mutant K1544D aimed to repel the Asp211 residue on CDK1 and 
prevent binding.   
ii. A charged mutant V1540D targeting the Ile210 hydrophobic residue on CDK1 to 
prevent hydrophobic interaction with talin.  The addition of a charged aspartate 
residue in the hydrophobic pocket on talin aimed to repel the CDK1 Ile210 residue.   
Our studies with the longer CDK1 206-232 peptide indicated that the region 223-232 was not 
essential for binding to talin (FIGURE 6.20); however, we postulated that by introducing a mutation 
in talin that would prevent this region of CDK1 being able to bind talin, the entire CDK1 peptide 
binding to talin R8 could still be disrupted.  The talin mutant S1513L was, therefore, designed with 
a Leu residue filling the gap between the talin helices and thus preventing the CDK1 Trp228 residue 
(or surrounding residues) from forming hydrophobic interactions with talin.   
In summary, we designed a total of four talin1 R7R8 mutants:  
i. A1495L: Targeting the interaction sustained by Phe214 on CDK1 
ii. S1513L+A1495L: Targeting binding of CDK1 through Phe214 and Trp228 
iii. A1499L+A1495L: Targeting binding of CDK1 through Phe214 and Phe217 




6.2.8 Testing of designed talin mutants to perturb CDK1 binding  
The designed talin mutants were put into the pET151 talin1 R7R8 vector allowing for recombinant 
expression and purification.  Mutants were not put into the single talin domain R8 due to the 
domain not being as stable as R7R8.  The talin1 R7R8 mutants were all concentrated to an equal 
concentration of 300 µM along with talin1 R7R8 WT and used in the FP assay to measure affinity 
with BODIPY-TMR labelled CDK1 206-232 peptide, results are shown in FIGURE 6.22. 
The talin Leu mutations (A1495L, A1499L) did not have a big effect on the binding affinity between 
CDK1 and talin compared to talin1 R7R8 WT.  These mutations were designed to prevent the 
hydrophobic Phe residues on CDK1 forming hydrophobic interactions with talin, the fact it had no 
effect on CDK1 binding suggests either a Leu substitution may not have been enough to disrupt the 
hydrophobic interaction or instead a charged residue could have been used.  It could also have 
been that the talin residues Ala1495 and Ala1499 were not close enough to the Phe residues on 
CDK1 or that the Ala residues provided a hydrophobic environment that the Phe could still interact 
with.  On the other hand, it could imply that the CDK1 Phe residues are not involved in the 
interaction.  The double mutant S1513L and A1495L had a slightly bigger effect on CDK1’s binding 
affinity to talin, it doubled the KD however, and this would not probably not be enough to perturb 
binding within a cell.  The most effective mutation was the V1540D and K1544D (VDKD) mutation, 





FIGURE 6.22: DETERMINING IF THE DESIGNED TALIN R7R8 MUTANTS PERTURB CDK1 BINDING 
(A) Table of KD values determined from FP assay with CDK1 peptide 206-223 and talin1 R7R8 mutants: 
V1540D+K1544D, A1499L+A1495L, S1513L+A1495L and A1495L.  Dissociation constants ± SE (μM) for the 
interactions are indicated and all measurements were performed in triplicate.  (B) talin1 R8 structure (PDB 




6.2.9 Is the talin mutant ‘VDKD’ specific to perturbing the talin:CDK1 
Interaction? 
After determining the talin VDKD mutant to be successful in perturbing the talin:CDK1 interaction 
it was important to conclude if the mutation only perturbed  CDK1 binding or if it affected the 
binding of other R8 ligands; RIAM and DLC1.  To determine this the binding affinities of talin1 R7R8 
WT and talin1 R7R8 VDKD were tested against DLC1 465-489 and RIAM 4-30 peptides, using in vitro 
FP assays (FIGURE 6.23).  The VDKD mutation appears to affect both RIAM and DLC1 binding to 
talin; the KD of DLC1 changed from 3.5 μM (talin1 WT) to 15 μM with the talin1 VDKD mutation.  
Likewise, the KD for the interaction with RIAM changed from 3.9 μM to 22 μM with WT and VDKD 
mutant, respectively.   
The VDKD talin mutation was designed to target the ‘LD initial binding site’ of CDK1 however, due 
to this being a common mechanism of binding for all LD talin-binding motifs the mutant also 
affected RIAM and DLC1 binding to talin.  This is a difficult problem to navigate around as the other 
talin mutants designed to target CDK1 in the ‘specificity region’ downstream of the LD-motif did 
not seem to have an effect on talin:CDK1 binding.  This is a useful talin mutant for cellular studies 
as it does perturb the talin:CDK1 interaction.  It will just be important to consider that when looking 
for a talin:CDK1 phenotype within a cell, other ligands (RIAM and DLC1) would also be prevented 




FIGURE 6.23: DETERMINING THE BINDING AFFINITY FOR DLC1, RIAM AND CDK1 AGAINST THE TALIN1 
R7R8 VDKD MUTATION. 
(A-C) Binding of BODIPY-TMR labelled; CDK1 206-223C, DLC1 465-489C and RIAM 4-30C peptides to talin1 
R7-R8 (1357–1659).  Binding affinities were measured using a Fluorescence Polarization assay.  Dissociation 
constants ± SE (μM) for the interactions are indicated in the legend.  All measurements were performed in 
triplicate.   
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6.2.10 Can CDK1:Cyclin:talin form a complex? 
In our biochemical studies we have used the CDK1 peptide 206-223 as a representation of the CDK1 
protein.  We know that this region provides the talin binding epitope.   In order to visualize the 
interaction between talin R7R8 and full-length CDK1, the known CDK1 (PDB ID: 4YC6) and talin1 
R7R8 (PDB ID: 5FZT) structures were docked together combining both modelling approaches and 
the knowledge gained from our biochemical studies.  FIGURE 6.24A shows CDK1 and R7R8 docked, 
highlighting that the interaction is sterically feasible and there is space for both proteins to bind.  
There is a slight clash between talin R8 and the flexible loop near the CDK1 LD talin-binding motif.  
This region on CDK1 is flexible and would be able to take a different confirmation so would not be 
anticipated to cause problems.   
 
I was also intrigued to model the tripartite complex of cyclin:CDK1:talin.  Cyclin is needed to 
activate CDK1 and so it would be possible talin-cyclin-CDK1 could form a complex.  To determine if 
the interaction was sterically possible the known structures; CDK1-cyclinB1 (PDB ID:4YC3) and 
talin1 R7R8 (PDB ID:5FZT), were used to model the interaction (FIGURE 6.24B).  Again, it looks 
sterically feasible for talin to bind cyclin-CDK1; there is a small clash between talin R7 and cyclin B1.  
However, the talin R7R8 domains are connected via a flexible linker which would allow for 
sufficient movement to prevent a clash with cyclinB1 implying that a tripartite interaction is 





FIGURE 6.24: STRUCTURAL MODEL OF TALIN1 R7R8:CDK2:CYCLINA2 
(A) Structural model of CDK1:talin1R7R8 using X-Ray crystallography structures of CDK1 (PDB ID:4YC6) and 
talin R7R8 (PDB ID:5FZT). (B) Structural Model of CyclinB1:CDK1:talin1R7R8 using the CDK1/cyclinB1 
structure (PDB:4YC3) and the talin structure (PDB ID:5FZT).  CyclinB1 is coloured in yellow, CDK1 (blue) and 
talin R7R8 (green).  Residues from CDK1 206-223 peptide are highlighted in red.   
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6.2.11 How does talin affect CDK1 kinase activity? 
We wanted to determine if talin binding to CDK1 would affect the kinase function of CDK1.  To 
explore this further, we collaborated with Martin Humphries from the University of Manchester.  
The Humphries group had been studying the CDK1-dependent phosphorylation of Formin Like 
Protein-2 (FMNL2), an adhesion protein required for actin assembly and turnover (Grikscheit et al., 
2015).  They identified the phosphorylation of FMNL2 using an in vitro kinase assay, where GST-
tagged FMNL2 was incubated with purified cyclinA2-CDK1/ cyclinB1-CDK1 and ATP.  Using pull-
down assays and western blots with S/T-P antibody (MPM2); MPM2 is an anti-phospho Ser/Thr-
Pro antibody and can be used to detect phosphorylated Ser/Thr residues in the CDK1 
phosphorylation sequence Ser/Thr-Pro.  The Humphries group found that FMNL2 was 
phosphorylated by CDK1 in the presence of both cyclinA2 and cyclinB1 (Jones et al., 2018).   
This in vitro kinase assay with FMNL2 provided an ideal platform to determine if talin was affecting 
CDK1s kinase activity, by adding talin to the assay we predicted one of three outcomes: 
 
i. Talin prevents phosphorylation of FMNL2; talin binding to CDK1 inactivates the kinase.   
ii. FMNL2 can be phosphorylated by CDK1 in the absence of cyclin as talin activates the 
kinase. 
iii. FMNL2 is phosphorylated with cyclin-CDK1 and ATP; talin binding to CDK1 is not 
affecting the kinase activity. 
 
I carried out the following experiments in the Humphries lab at the University of Manchester.  
Purified talin1 R7R8 (residues 1357-1653) (in 3-fold excess 3 µg) was added to purified FMNL2 1 
µg/µL, cyclinA2-CDK1 1 ng/µL (Invitrogen), and ATP 1 mM.  Following this we performed 
immunoblotting against MPM2, CDK1 and cyclinA2.   The blot shown in FIGURE 6.15, shows FMNL2 
was phosphorylated at similar levels in both the presence and absence of talin (when ATP was 
present), confirming talin was not inhibiting the kinase activity of CDK1.  Unexpectedly, the assay 
revealed that the talin1 R7R8 was also being phosphorylated by CDK1 (highlighted by a red box in 
FIGURE 6.15).  Talin phosphorylation by CDK1 had not been anticipated due to no known 
phosphorylation sites on the talin R7R8 domain (despite phosphoproteomic analysis of talin in the 
phospho-adhesome (Robertson et al., 2015)) and no obvious CDK1 phosphorylation sequence in 
the talin R7R8 sequence.    
198 
 
A high intensity talin R7R8 band was visualized in the western blot at approximately 32 kDa, in the 
presence of CDK1-cyclinA2 and ATP when probed with MPM2.  In the absence of either cyclinA2 
or ATP, no band is observed, indicating that talin could not activate CDK1 and that the activity was 
still cyclin dependent.   
 
FIGURE 6.25: CDK1 KINASE ACTIVITY IS NOT AFFECTED BY TALIN BINDING 
(A)Immunoblot analysis of in vitro kinase assay with purified talin1 R7R8, FMNL2 and CDK1-cyclinA2 
(Invitrogen) with and without ATP.  Immunoblot is blotted using anti- CDK1, GST-cyclin and anti-MPM2.  Red 
box indicates talin1 R7R8 phosphorylation by CDK1 and FMNL2 phosphorylation by CDK1.  (B) The reaction 
occurring in the in vitro kinase assay.   
  
6.2.12 Talin phosphorylation by CDK1 is cyclin specific 
To further investigate the phosphorylation of talin R7R8 by CDK1, the in vitro kinase assay was 
repeated in the absence of FMNL2 and at lower concentrations of talin (1 µg/µL).  Both talin1 R7R8 
(residues 1357-1653) and talin2 R7R8 (residues 1360–1656) were used in the in vitro kinase assay 
and cyclinA2 and cyclinB1 were used to determine if the interaction was cyclin specific. FIGURE 
6.26 shows a representative western blot of the assays and here the in vitro kinase assay was used 
as a qualitative assessment, rather than a quantitative measurement to determine CDK1 
phosphorylation.    
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The immunoblots shown in FIGURE 6.26 again confirm talin R7R8 is phosphorylated by CDK1-
cyclinA2; a large increase in talin phosphorylation is shown FIGURE 6.26A when ATP is added to 
the assay with both talin1 R7R8.  This same increase in talin phosphorylation when ATP is added 
can be seen in the talin2 R7R8 confirming that both talin isoforms are being phosphorylated by 
CDK1.   
Interestingly the CDK1 phosphorylation on talin 1 and talin2 R7R8 looks to be cyclin specific as less 
phosphorylation is seen when CDK1-cyclinB1 is added to talin than with the CDK1-cyclinA2.  This 
cyclin isoform specific phosphorylation can also be seen in FIGURE 6.26B; talin1 R7R8 and talin2 
R7R8 phosphorylation is highlighted by a red box and it is clear that an increase in signal of talin 
phosphorylation when ATP is added can be identified when cyclinA2 is present but not when 
cyclinB1 is present.   
Further immunoblots were carried out with CDK1-CyclinA2, talin1 R7R8 and talin2 R7R8 that can 
be seen in FIGURE 6.27.  The blots provide further evidence that talin R7R8 is phosphorylated by 





FIGURE 6.26: TALIN R7R8 IS PHOSPHORYLATED BY CDK1-CYCLINA2 
 (A-B) Immunoblot analysis of in vitro kinase assay with purified talin1 R7R8/talin2 R7R8, CDK1-cyclinA2 
(Invitrogen) or cyclinB2 (Invitrogen) with and without ATP.  (A) Immunoblot is blotted using anti-MPM2.  Red 
box indicates talin1 R7R8 phosphorylation by CDK1 cyclinA2.  (B) Immunoblot is blotted against anti-MPM2, 





FIGURE 6.27: IMMUNOBLOTS CONFIRMING TALIN R7R8 IS PHOSPHORYLATED BY CDK1-CYCLINA2 
(A-B) Immunoblot analysis of in vitro kinase assay with purified talin1 R7R8/talin2 R7R8, CDK1-cyclinA2 
(Invitrogen) with and without ATP.  (A) Immunoblot is blotted using anti-MPM2 and anti-GST, red box 
indicates talin1 R7R8 phosphorylation by CDK1 cyclinA2.  (B) Immunoblot is blotted against anti-MPM2, anti-




6.2.13 Mass spectrometry-based phosphosite mapping of talin 
phosphorylation 
The in vitro kinase assays showed that both talin1 R7R8 and talin2 R7R8 could be phosphorylated 
by CDK1-cyclinA2.  From the assay it is not possible to quantify the number of phosphorylation 
sites or identify the phosphorylation site(s).  In order to map the phosphorylation sites on talin1 
and 2 R7R8 Mass Spectrometry (MS)-based phosphosite mapping was used.   
6.2.13.1 Identifying phosphorylation site(s) on talin1 R7R8 
The in vitro kinase assay was carried out in triplicate and products were run on an SDS-PAGE gel 
shown in FIGURE 6.28A.  Talin1 R7R8 bands were cut from the gel and processed by in-gel tryptic 
digest as described previously (Horton et al., 2016).  The peptides produced from the digest were 
analysed using liquid chromatography Mass Spectrometry (LC-MS) and the data from LC-MS was 
analysed using the proteome software Mascot (Perkins et al., 1999).   
A screen shot of the Mascot output is shown in FIGURE 6.28B.  The software lists the proteins 
identified in MS from the excised SDS-PAGE band (talin1 R7R8).  The top panel shows the list of 
proteins found and the abundance of peptides found in each gel band (1-6); as expected the most 
abundant protein identified was mouse talin1 (UniProt: P26039).  The Mascot software then 
searches for phosphorylated Ser or Thr residues on the peptides identified through LC-MS.  Mascot 
can identify phosphorylated residues because of the addition of a PO42- group; which adds 80 Da 
weight to the peptide.  Talin1 R7R8 was found to have a single phosphorylated residue, Ser1589, 
found in all repeats (where ATP was present).  FIGURE 6.28B shows the Ser1589 residue 




FIGURE 6.28: PHOSPHOSITE MAPPING OF TALIN1 R7R8 
(A) SDS PAGE loaded with samples of incubated talin1 R7R8, CyclinA2:CDK1; bands 2,4 and 6 had ATP added.  
The talin1 protein bands at ~32 kDa, were excised for proteomics analysis.  (B)  Scaffold viewer highlighting 
the sequence in talin1 R7 that was found to be phosphorylated by CDK1-cyclinA2.  The residue Ser1589 was 




6.2.13.2 Identifying phosphorylation site(s) on talin2 R7R8 
Similarly, to determine the phosphorylation site on talin2 R7R8 the products from in vitro kinase 
assay were separated by SDS-PAGE and the talin2 R7R8 bands at approximately 32 kDa were 
excised.  The talin2 R7R8 bands were processed by in-gel tryptic digest as with talin1 R7R8 and the 
peptides produced from the digest were analysed using LC-MS and then the proteome software 
Mascot (Perkins et al., 1999).   Mascot identified talin2 R7R8 to be the most abundant protein in 
the sample and identified a phosphorylated residue between 1488-1491 (Ser, Ser, Pro, Ser).  The 
programme was unable to determine which serine in this sequence was being phosphorylated as 
the trypsin digestion did not produce overlapping peptides in this region and, therefore, the exact 
phosphorylated Ser residue could not be determined.   
To overcome this problem and determine the exact residue on talin2 undergoing phosphorylation, 
an Asp-N/trypsin digestion was used.  The in vitro kinase assay was re-run and separated using SDS-
PAGE as seen in FIGURE 6.29A and processed by in-gel Asp-N/trypsin digestion.   
Asp-N is a highly specific endoproteinase that cleaves at the N-terminal side of Asp and  Cys 
residues (Lahm and Langen, 2000).  This approach was used alongside the trypsin digest to obtain 
additional overlapping peptides and improve sample characterisation.  The data from LC-MS was 
imputed into Mascot; the Asp-N/trypsin digestion appeared to be successful in creating 
overlapping peptides in the 1489-1491 regions and allowed the software to identify a single 





FIGURE 6.29: PHOSPHOSITE MAPPING OF TALIN2 R7R8 PHOSPHORYLATION SITE 
(A) SDS PAGE gel showing talin2 R7R8 protein bands ~32 kDa that were separated from in vitro kinase assay. 
(B) Scaffold viewer highlighting the sequence in talin2 R8 found to be phosphorylated by CDK1cyclinA2.  The 
residue Ser1489 was shown to have 99% confidence of being phosphorylated.   
 
6.2.14 Isoform differences in CDK1 talin phosphorylation 
The phosphosite mapping identified that both talin1 and talin2 R7R8 have a single CDK1 
phosphorylation site.  However interestingly, each talin isoform was phosphorylated at a different 
site by CDK1 raising the possibility that this is a mechanism to regulate CDK1 binding in the cell.  To 
further explore why there are these differences in the talin isoforms, a sequence alignment of 




6.2.14.1 Talin1 R7R8 Ser1589 phosphorylation site 
FIGURE 6.30 shows a conservation alignment, using Clustal Omega (Larkin et al., 2007), of twenty-
one talin1 species (green) and talin2 (red).  The species aligned were chosen to cover a wide range 
of vertebrates across different animal classes.  FIGURE 6.30 shows the talin alignment between 
residues 1534-1604, encompassing the talin1-phosphorylated residue Ser1589.  The blue box 
highlights the phosphorylated talin1 Ser1589 residue and the surrounding residues.  Ser1589 is 
completely conserved in both talin1 and talin2 species, but the following Pro1590 residue is fully 
conserved in talin1 and not in talin2.  Instead, talin2 has a semi-conserved Ser residue in this 
position; the removal of the Pro residue in talin2 means that it no longer is a consensus CDK1 
phosphorylation site as it does not contain the minimal Ser/Thr-Pro motif, possibly explaining why 
we did not see this site as a hit in the phosphosite mapping analysis of talin2 R7R8.   
The talin1 sequence ‘SPEGR’ around the Ser1589 is highly conserved across all the species which 
implies the sequence may have an important function. This sequence makes up the optimal 






FIGURE 6.30: ALIGNMENT HIGHLIGHTING THE TALIN1 PHOSPHORYLATION SITE BY CDK1:CYLINA2 
Human talin1 and talin 2 sequences aligned using Clustal Omega (Thompson, Gibson and Higgins, 2002), 
residues that are conserved in both talin 1 and talin2 are highlighted by a ‘*’ closely conserved residues with 
similar properties highlighted with a ‘:’ .  Talin1 species are in green and talin2 species are in red; the Ser1589 




6.2.14.2 Talin2 R7R8 Ser1489 phosphorylation site 
To further investigate the talin2 CDK1 phosphorylation site the same talin1 and talin2 sequences 
as above were aligned using Clustal Omega (Larkin et al., 2007) and FIGURE 6.31 shows the 
conservation alignment around the phosphorylated talin2 Ser1489.  Ser1489, as well as the 
surrounding residues Ser-Ser(p)-Pro-Ser-Gln, are completely conserved in talin2 across all species 
used in the alignment.   These conserved residues do not fit the optimal CDK1 consensus sequence 
(Ser/Thr-Pro-X-X-Arg/Lys) found in the talin1 Ser1589 phosphorylation site.  However, the residues 
do fit the Ser/Thr-Pro site sequence also known to be phosphorylated by CDK1.   
Interestingly though, the talin1 sequence in this region is also conserved across species but is 
conserved differently from talin2.  The talin1 sequence Pro-Cys-Thr-Gln is a reported O-
glycosylation site with residue Thr1487 being glycosylated (Hagmann, Grob and Burger, 1992).  
This concludes the finding of two unique CDK1 phosphorylation sites in talin R7R8.  Each CDK1 
phosphorylation site is isoform specific and the high conservation across species suggests that they 
are of functional importance.  Determining the role of the different isoform-specific 






FIGURE 6.31: ALIGNMENT HIGHLIGHTING THE TALIN2 PHOSPHORYLATION SITE BY CDK1:CYLINA2 
Human talin1 and talin 2 sequences aligned using Clustal Omega (Thompson, Gibson and Higgins, 2002), 
residues that are conserved in both talin 1 and talin2 are highlighted by a ‘*’ closely conserved residues with 
similar properties highlighted with a ‘:’ .  Talin1 species are in green and talin 2 species are in red; the Ser1489 




6.2.15 Biochemically characterising the CDK1 phosphorylation site on 
talin1 R7R8 
To determine the functional role of the talin1 CDK1 phosphorylation we looked at its positioning 
on the talin1 structure; FIGURE 6.32A shows the Ser1589 residue is positioned on talin R7 domain.  
The residue is positioned near the flexible linker region that joins R7 and R8 (FIGURE 6.32B).  The 
flexible linker is a beta sheets that is held together by hydrogen bonds.   
FIGURE 6.32B shows Ser1589 is positioned near two charged residues, Asp1451 and Glu1591.  
When Ser1589 is phosphorylated a PO42- group will be added to the residue making the residue 
have a negative overall charge. This could repel the surrounding negatively charged Asp1451 and 
Glu1591 residues, which in turn could cause the hydrogen bonds in the beta sheet to break open.  
The instability generated in the linker could then lead to instability across both R7 and R8 domains 
potentially weakening the binding of any ligands to R7R8.   
To determine if phosphorylation of Ser1589 would cause an effect on the stability of talin R7R8 a 
phosphomimetic mutant was designed.  Ser1589 was substituted for an Asp residue; which is a 
negatively charged residue that provides a good mimic of phosphorylation.  An Asp in position 1589 
(S1589D) was introduced into talin1 R7R8 and using the FP assay, the affinity between BODIPY-
TMR labelled CDK1 206-223 peptide and the talin S1589D mutant was measured.   FIGURE 6.32 
shows the binding between CDK1 and talin1 R7R8 does not change when the S1589D mutant is 
introduced.  The KD for talin WT and CDK1 interaction was 20 µM and the talin S1589D had a KD of 




FIGURE 6.32: TALIN1 CDK1 PHOSPHORYLATION SITE S1589 
(A) Talin1 R7R8 structure (PDB ID:5FZT) with CDK1 phosphorylation site (Ser1589) highlighted with a red 
sphere on the R7 domain.  (B) talin1 R7 domain and R7R8 linker (yellow).  Black dotted line showing hydrogen 
bonds across beta sheet.  
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To determine if the phosphomimetic effected the binding of other talin R7R8 ligands, FP was used 
to measure the affinity between talin S1589D and KANK30-60C and DLC1 465-489C.  FIGURE 6.33 
shows that the phosphomimetic, S1589D, had no change on binding affinity to DLC1; DLC1 bound 
to the talin1 R7R8 S1589D with a KD 6 µM and talin1 R7R8 WT 4 µM.  The R7 ligand KANK however, 
did bind more weakly to the S1589D mutant than talin R7R8 WT there was approximately a four-
fold difference in KD 4 µM and 1 µM, respectively.    
 
FIGURE 6.33: TALIN1 SER1589 BINDING AFFINITY TO DLC1, KANK1 AND CDK1 
Binding of BODIPY-TMR labelled CDK1 206-223C, DLC1 465-489C and KANK1 30-60C peptides to  talin1 R7R8 
(1357–1653) and Talin1 R7R8 S1589D.  Binding affinities were measured using a fluorescence polarization 
assay.  Dissociation constants ± SE (μM) for the interactions are indicated in the legend.  All measurements 





6.2.16 Biochemically characterising CDK1 phosphorylation site on talin2 
R7R8 
To determine the functional role of the talin2 CDK1 phosphorylation site Ser1489 we looked at its 
positioning on the talin2 structure.  The talin2 R7R8 (Phyre2 (Kelley and Sternberg, 2009)) structure 
in FIGURE 6.34 shows the Ser1489 residue is positioned on the talin R8 domain.  The residue is 
positioned on helix 32 at the very top near the linker between helices 31 and 32.  This talin helix 
makes up the binding surface for CDK1 and is also important for actin binding.   
The R8 domain is one of five domains that make up the Actin Binding Site 2 (ABS2) region on talin.  
As previously mentioned ABS2 is important in focal adhesion maturation and generating traction 
force in the cell (Atherton et al., 2015; Klapholz and Brown, 2017).  The main actin binding surfaces 
on ABS2 are on the R4 and R8 domains.  Both R4 and R8 talin domains have a higher isoelectric 
point (pI) values, compared to the other domains in the talin rod, causing the surface of R4 and R8 
to be positively charged at physiological pH.  The positive charge on the domains surface enables 
interactions with actin, which is negatively charged.  A series of charge reversal mutants 
(Arg1500Glu, Arg1510Glu and Lys1522Glu) on the R8 domain, helices 31 and 32, have been shown 
to perturb the interaction between talin ABS2 and actin (Atherton et al., 2015; Kumar et al., 2016).  
When Ser1489 is phosphorylated by CDK1 a phosphate group addition will cause the residue to 
become negatively charged.  Could phosphorylation of this residue reduce actin binding to the talin 




FIGURE 6.34: TALIN2 CDK1 PHOSPHORYLATION SITE S1489 
 
Talin2 R7R8 structure prediction (Phyre2 (Kelley and Sternberg, 2009)) with CDK1 phosphorylation site 




6.2.17 Does CDK1 localise to adhesions  
Having designed and biochemically characterised a successful CDK1 mutant (CDK1_2A) capable of 
perturbing the talin:CDK1 interaction,  the next step was to understand the significance this 
interaction in conjunction within the cellular context and determine its role in adhesion phenotype.  
In order to achieve this, our collaborator Martin Humphries, from the University of the Manchester, 
carried out cell biology experiments using our designed CDK1 mutant – CDK1_2A.   
Initially, we wanted to confirm the presence of CDK1 in cell adhesions. The Humphries’ group 
transfected U2OS cells with GFP-CDK1 and stained the cells for the adhesion marker paxillin. 
FIGURE 6.35A and B show that CDK1 is distributed ubiquitously across the cell rather than uniquely 
localised to adhesions. However, it also shows that CDK1 is found at adhesions as it clusters around 





FIGURE 6.35: LOCALISATION OF GFP-CDK1 IN THE CELL 
(A-B) Immunofluorescence images of U2OS cells plated on glass coverslips for 24 hours. (A)  Cells co-
expressed GFP-CDK1 and stained for paxillin.  (B) Cells co-expressed GFP-CDK1 and stained for Beta5 integrin. 
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6.2.18 Characterisation of CDK1_2A mutant in mammalian cells 
Following this, to explore the importance of the talin:CDK1 interaction within the cell the 
Humphries’ lab used a series of CDK1 and talin constructs: full-length HA-tagged CDK1; HA-tagged 
CDK1_2A (our biochemically validated CDK1 mutant); GFP-talin1 and GFP-talin1∆R8 (a talin mutant 
that would perturb interaction).   
To determine if the CDK1 and talin mutants perturbed the talin:CDK1 interaction, different 
combinations of CDK1 and talin constructs  were transfected into U2OS cells.  GFP-trap pulldown 
assays were preformed, as shown in FIGURE 6.36A.  These data show that the CDK1_2A mutant 
reduced the interaction between talin and CDK1, corroborating my biochemical findings.  
Furthermore, the talin mutant GFP-talin∆R8 also disrupted binding between talin and CDK1 
indicating that the talin R8 domain is the main CDK1 binding site.   
After confirming the existence of an in vivo interaction between CDK1 and talin, we set out to 
determine if the CDK1_2A mutant affected adhesion size.  FIGURE 6.36B shows CDK1 knock-down 
cells rescued with HA-CDK1 and the HA-CDK1_2A.  In cells with the HA-CDK1_2A mutant the 
adhesion area was significantly reduced (FIGURE 6.36C) compared to the HA-CDK1 WT.  This 




FIGURE 6.36: CDK1_2A MUTANT PREVENTS TALIN BINDING 
(A) Protein extracts of U2OS cells co-expressing GFP-talin1, GFP talin1∆R8 (or GFP control) and HA-tagged 
CDK1 or CDK1_2A were subjected to GFP-pulldowns and analysed using western blots with an anti-HA 
antibody and an anti-GFP antibody.  Due to the large amount of GFP-control, the signal was expanded to 
nearby lane.  (B) Immunofluorescence images of U2OS cells transfected with LifeAct showing control with 
scrambled siRNA, CDK1-knock-down cells, and CDK1-knock-down cells expressing either HA-CDK1 or HA-
CDK1_2A. Cells were then stained against HA, as well as paxillin. (C) Quantification of adhesion area per cell 
after CDK1-knock-down and rescue with HA-tagged CDK1 and CDK1_2A. (D) Western blot showing knock-




6.3.1 What is targeting CDK1 to adhesions? 
Through the use of biochemical and biophysical techniques we have discovered an interaction 
between CDK1 and the talin R8 domain, and a CDK1 mutant (CDK1_2A) capable of disrupting 
binding between the two proteins.  Furthermore, the talin:CDK1 interaction has been confirmed in 
vivo and we show that the disruption of this interaction leads to a decrease in adhesion area in 
cells. Additionally, in U2OS cells, CDK1 localises to adhesions suggesting that the talin:CDK1 
interaction is adhesion-specific.  A question that still remains unanswered is: what is the 
mechanism that drives CDK1 to the adhesion at certain points in the cell cycle? 
One hypothesis could be that talin actively recruits CDK1 from cytosol to the adhesion site. This 
scenario is, however, unlikely and, as discussed in section 5.3.3.1, talin can form homodimer 
complexes which are able to adopt a compact auto inhibited conformation in the cytosol (Goult, 
Xu, et al., 2013).   This auto-inhibited form would prevent talin from binding to CDK1 as the R8 
domain is hidden.  Additionally, the binding affinity between talin:CDK1 is in the micro molar range, 
meaning that a high concentration of either talin or CDK1 is needed to facilitate an interaction.  It 
is unlikely that such high concentration is present in the cytosol, leading to the conclusion that such 
interaction is only occurs at adhesion sites.  
In cells (section 6.2.17),  CDK1 is well dispersed across the cytosol. It is also possible that CDK1 
could be found in the vicinity of adhesions through non-directed signalling. 
Alternatively, cyclins could play a large role in the regulation of CDK1 localisation to adhesions.  The 
in vitro kinase assay demonstrated that the phosphorylation of talin was potentially cyclin specific 
(phosphorylation mainly occurred by the CDK1-cyclinA2 complex).  This has also been described in 
the literature, with adhesion area growth occurring in the G1 and predominantly S phase of the cell 
cycle through the association of CDK1 to cyclinA2.  Adhesion area then dramatically decreases in 
G2, just before the cell enters mitosis.  Adhesion size reduction correlates with  elevated levels of 
CDK1 in complex with cyclinB1 (Jones et al., 2018).   The binding of cyclinA2 to CDK1 could increase 
the selectivity for CDK1 to adhesion substrates, drawing it to the adhesion area.  When cyclinA2 
activity is reduced the selectivity for adhesion targeting could be diminished and CDK1 is no longer 
recruited to adhesions.   
Another potential way that CDK1 could be targeted to adhesions is via MTs.  MT networks are 
constantly changing during the course of the cell cycle and, as discussed in Chapter 4, MTs are 
linked to FAs through the binding of KANK to talin.  There is no evidence of the phosphorylation of 
220 
 
tubulin phosphorylated by CDK1 (Fourest-Lieuvin, 2005); however, a number of MT-binding 
proteins are phosphorylated by CDK1.  This could be a possible mechanism to further explore in 
the future.   
6.3.2 Why is talin phosphorylated by CDK1?  
The in vitro kinase assays in section 6.2.12, revealed that talin R7R8 is phosphorylated by CDK1-
cyclinA2.  Further analysis using phosphoproteomics also identified two talin isoform-specific sites: 
talin1 Ser1589 and talin2 Ser1489.  Phosphorylation of adhesion proteins by CDK1 has been found 
to be important in regulating cell-matrix adhesion complexes (Jones et al., 2018) and, for this 
reason, understanding the functional role of the talin phosphorylation sites would contribute to 
the general knowledge on adhesion regulation by CDK1  through the cell cycle.   
6.3.2.1 Talin1 
The talin 1 phosphorylation site is located in the R7 domain near to the flexible linker that joins the 
R7 and R8 talin domains. The talin1 Ser1589 is in an ‘optimal consensus CDK1 phosphorylation 
sequence’ (Ser/Thr-Pro-X-X-Arg/Lys) (Suzuki et al., 2015).  As described in the results, the sequence 
‘SPEGR’ around Ser1589 is highly conserved across species suggesting that the sequence is of 
functional importance.  In the results a phosphomimetic S1589D was used to determine if 
phosphorylation had any effect on the biding of CDK1 to talin.  We hypothesised that the added 
phosphate group would destroy the hydrogen bonds in the linker region between R7 and R8 
domains, affecting the binding of LD ligands on R8.   However, we observed no difference in binding 
affinity of the CDK1 peptide to the phosphomimetic talin R7R8 compared to talin1 R7R8 WT, there 
was no difference in binding affinity with DLC1 either.   
Interestingly, a four-fold difference in binding affinity was noted with the KANK1 30-60 peptide and 
Talin1 R7R8 S1589D compared to KANK1 30-60 and talin1 R7R8 WT.  The KANK peptide still bound 
to talin S1589D but at a reduced affinity, which could affect the linkage between FA and the CMSC 
(see section 4.3.4).  Future experiments could add the phosphomimetic mutant and a non-
phosphorylatable mutant into cells to determine if there is a phenotype of talin phosphorylation.  
However, from our current data we think it would be unlikely that phosphorylation of this site is 




The talin2 phosphorylation site is located on the R8 domain of talin at position Ser1489, the 
position is well conserved across talin 2 isoforms, which suggests a functional importance for the 
region.  Unlike with the talin 1 phosphorylation site (Ser1589), the talin2 phosphorylation site 
Ser1489, does not fit the canonical CDK1 sequence.  Instead, it fits the Ser/Thr-Pro sequence also 
known to be phosphorylated by CDK1.   
This region on talin R8 is also conserved in talin1, not as a phosphorylation site but instead as a O-
glycosylation site.  O-glycosylation has been reported on talin1 Thr1487 (Hagmann, Grob and 
Burger, 1992).  O-Glycosylation is a common PTM that attaches a sugar molecule to a Thr or Ser 
residue resulting in structural and functional changes of the protein.  Talin1 has two reported O-
glycosylation sites, one in R8 and one in R10, neither of which are conserved in talin2 (reviewed: 
Gough & Goult, 2018).  Thus understanding the function of the Ser1489 phosphorylation site in 
talin2 could uncover a potential functional difference between the talin isoforms.  
Unlike with the talin1 phosphorylation site, the talin2 site, Ser1489, is located on the same domain 
as the CDK1 binding site, at the top of helix 32 (see FIGURE 6.34).  This is situated near the binding 
sites of all the R8 LD-motifs (RIAM, DLC1 and CDK1) and talin actin binding site 2 (ABS2).  Could the 
addition of a phosphate group have an effect on the binding of CDK1 and of actin?  FIGURE 6.37 
models talin2 R7R8 with an electrostatic surface.  The surface of talin that binds to actin is 
negatively charged (shown in blue on FIGURE 6.37), mutations of this area (K1500E, K1522E and 
R1510E) have been found to disrupt binding of talin and actin by addition of a negatively charged 
residue (P Atherton et al., 2015). The phosphate group addition to Ser1489 through 
phosphorylation would cause a negatively charged surface to be present on talin R8 and this could 
be enough to cause disruption between talin and actin.  This dissociation between actin and talin 
would result in loss of force across the adhesion, it is unclear why this would be needed in talin2 
and not in talin1.  Further investigation to understand if this mutation does affect actin binding 
would need to be carried out.  Future analysis and characterisation of this site could be an 
important step to gain a better understanding of role of talin2 at adhesions.  A phosphomimetic 
and a non-phosphorylatable mutant of Ser1489 to search for a phenotype in cells could prove 
useful.  Furthermore, it would be important to assess at which stages of the cell cycle 
phosphorylation occurs, and determine if it occurs in S-phase, thus aiding adhesion growth as it 
has been described for other adhesion proteins  phosphorylated by CDK1 (Jones et al., 2018).   
Biochemical characterisation of a phsophomimetic mutation would also answer binding to actin 






FIGURE 6.37: TALIN2 PHOSHO MUTATION MAY PERTURB ACTIN BINDING 
(A-C) Structural prediction of talin2 R7R8  Phyre2 (Kelley and Sternberg, 2009)) modelled in PyMOL with 
electrostatic surfaces indicating the surface charge on the protein.  Blue indicates positively charged and red 
indicated negatively charged. B modelled phosphomimetic S1489D, C known actin bidning mutants K1500E, 
K1522E and R1510E.  
6.4 Does CKS1 binding talin regulate the talin:CDK1 interaction? 
A CDK1 structure (PDB ID: 4YC6) shows CDK1 bound to a cyclin kinase substrate 1 (CKS1).  CKS 
proteins are small cyclin-dependent kinase proteins frequently found overexpressed in cancers, 
especially breast cancer (Liberal et al., 2011).  However, a mechanistic link between overexpression 
of CKS proteins and oncogenesis is still not known.  An increase in CKS proteins (CKS1 and CKS2) 
leads to an ‘override’ of the S-phase checkpoint.  The S-phase checkpoint occurs between the S-
phase and G2-phase and it controls DNA replication, preventing replication if the cell is under stress 
(Liberal et al., 2011).   Binding of CKS proteins to CDK2 overrides this checkpoint and allows the 
cells to continue to replicate DNA even under conditions of replicative stress.   
Interestingly, CKS1 and CKS2 bind to CDK1 in the same place as talin R8 (shown in FIGURE 6.38).   
This overlap in binding area could provide a mechanism that determines when CDK1 binds to talin 
and when it is targeted to adhesions.  CDK1 binds to talin via an LD motif through a predicted salt 
bridge between the CDK1’s Asp211 and talin Lys1544 (as shown in FIGURE 6.38B).  From structural 
analysis of the CKS1 and CDK1 structure it is apparent that the CDK1 Asp211 residue is involved in 
the interaction with CKS1 through the same mechanism, whereby there is the formation of a salt 
bridge with the CKS1 His21 residue (as shown in FIGURE 6.38A).  This similar binding mechanism 
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means that the designed CDK1_2A mutant could also perturb the CDK1:CSK1 interaction. To verify 
this, further experiments would have to be carried.     
The binding of cyclins to CDKs regulates the latter’s ability to phosphorylate substrates; in addition 
to cyclins, CKS can also influence the selection of substrates.  Biochemical studies in Xenopus 
suggest that CKS proteins enhance the phosphorylation of selected CDK1 substrates in mitosis 
(Patra et al., 1999).  From this knowledge, we could suggest that talin might also have a similar 
effect when bound to CDK1 and help to enhance phosphorylation of selected substrates 
(potentially at adhesions).   Furthermore, it would be interesting to explore if there is a connection 
between CKSs and talin binding to CDK1, to determine if CKS1/CKS2 acts as a regulatory mechanism 
that prevents talin binding to CDK1, until the correct time.  
 
 
FIGURE 6.38: TALIN AND CKS1 BIDNING SITES ON CDK1 
(A) structure of CDK1 (blue) and CKS1 (orange) (PDB ID: 4YC6).  (B) Predicted structure of CDK1 (blue) and talin R7R8 
(green).  Both A and B highlight the Ile Asp residues (black) on CDK1 required for talin binding, (A) shows a His residue 
on CKS1 that could form electrostatic interaction with CDK1 and (B) shows Lys residue on talin that forms electrostatic 




6.4.1 Could other members of the CDK family bind to talin? 
As previously mentioned, humans have 20 different CDK genes that all encode for a different 
member of the CDK family (Egelhofer et al., 2008).  Intriguingly, our talin proteomics data only 
detected CDK1 as a binding partner for talin.  What makes CDK1 different to the other CDKs, and 
does talin have the potential to bind to any of the other members? 
To investigate this, the 20 human CDK isoforms were aligned using Clustal Omega, which 
immediately highlighted that some members of the CDK family are more similar in sequence than 
others. For example, CDK1 and CDK2 have very similar sequences sharing 65% sequence identity 
FIGURE 6.39 shows the alignment of the LD-TBM across all the CDK family members.  It appears 
that the sequence is well conserved in CDK1, CDK2 and CDK3 and that a similar sequence is also 
found in CDK11a and CDK11b.  Although CDK4 and CDK6 (highlighted in red) are not deemed 
essential for cell cycle progression (Bockstaele et al., 2006), both have become significant targets 
for breast cancer drug therapies (Lamb et al., 2013).   




FIGURE 6.39 SEQUENCE ALIGNMENT OF HUMAN CDK ISOFORMS 
 
The region of sequence containing the CDK1 206-223 peptide is shown and the CDK isoforms that contain an 
LD-motif are highlighted in green.  (B) CDK family proteins with correct nomenclature the sequences have 
been aligned and analysed using Clusstal2 using the nearest neighbour method (Malumbres et al., 2009).  
Human CDK1(P06493), CDK2(P24941), CDK3(Q00526), CDK4(P11802), CDK5(Q00535), CDK6(Q00534), 
CDK7(P50613), CDK8(P49336), CDK9(P50750), CDK10(Q15131), CDK11A (P21127), CDK11B(Q9UQ88), 
CDK12(Q9NYV4), CDK13(Q14004), CDK14(O94921), CDK15(Q96Q40), CDK16(Q00536), CDK17(Q00537), 
CDK18(Q07002), CDK19 (Q9BWU1), CDK20 (Q8IZL9) sequences aligned in Cluster Omega. 
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The conserved LD talin binding motif sequence found in CDK1 is absent in both CDK4 and CDK6, 
instead of an Ile residue at the start of the motif, they contain an Ala or Val residue, respectively.   
Ala and Val residues have shorter side chains than Ile that has not been identified in any LD-motif 
to date.   
Closer inspection of the sequence alignment of CDK1, CDK2, CDK3, CDK11a and CDK11b revealed 
that the 206-223 region is well conserved (shown in FIGURE 6.40) and the ‘Glu, Ile, Asp, Gln’ 
residues can be found in all isoforms.   
 
FIGURE 6.40: SEQUENCE ALIGNMENT OF LD-TBM ACROSS THE CDK ISOFORMS 
Human CDK1 (P06493), CDK2 (P24941), CDK3 (Q00526), CDK11a (Q9UQ88) and CDK11b (P21127) sequences 
were aligned using Cluster Omega.  (*) indicates fully conserved residue, (:) indicates similar property residue.  
Green highlights the CDK1 peptide 206-223. 
 
CDK11 is different to the other CDK proteins as the CDK11 gene is duplicated in humans giving rise 
to different but highly conserved isoforms: CDC2L1 (CDK11a) and CDC2L2 (CDK11b) (Zhou et al., 
2016).  CDK11a and CDK11b have 98% sequence identity and while their role within the cell is not 
fully understood, it is thought that CDK11 kinases are essential for cell viability and early embryonic 
development (Li et al., 2004).  Section 6.1.2 discussed that the CDK family was split into 
transcriptional CDKs and cell cycle CDKs unlike CDK2,3,4 and 6, CDK11 is a transcriptional CDK.  
CDK11 null mice result in early embryonic lethality due to apoptosis of blastocyst cells between 
days 3-4; cells from these embryos displayed proliferative defects, mitotic arrest and apoptosis (T.  
Li et al., 2004).  The CDK11 sequence between 641-655 is similar to that of CDK1 206-223, the only 
major difference being that instead of CDK1’s Phe214, CDK11 has Asn648, which is not hydrophobic 
and, therefore,  unlikely to bury itself into the groove of talin helices 32 and 33 in the same way as 
the Phe residue could.    This could translate into a lower affinity to talin, compared to CDK1 or 
CDK2.  Furthermore, when looking at the CDK11a structure (Phyre2 (Kelley et al., 2015))shown in 
FIGURE 6.41, the putative talin binding region (highlighted in red) does not have a predicted 
secondary structure like CDK1, CDK2 and CDK3.  This, again suggests that there is a low possibility 




FIGURE 6.41 STRUCTURAL OF HUMAN CDK11A 
 
Structure CDK11a (Phyre2 prediction) modelled in PyMOL with the CDK1:talin binding region highlighted on 
the structure in red. 
 
It is, however likely that CDK2 and CDK3 could bind to talin based on the sequence of their LD-TBM.  
FIGURE 6.42 shows the alignment for the predicted structures of the motifs for CDK1, CDK2 and 
CDK3 (PDB ID: 4YC6, 4EK3, Phyre2 prediction (Kelley et al., 2015) , respectively) using PyMOL.  The 
LD-TBM region is highlighted by a black box and is predicted to be helical on all the structures.   It 
would be interesting to identify if there is an interaction between talin and CDK2/CDK3 and 
determine if this interaction only occurs at specific points in the cell cycle.  Furthermore, if there 
was an interaction between talin and the CDK2/CDK3 it would be interesting to determine if they 





FIGURE 6.42 STRUCTURAL ALIGNMENT OF  HUMAN CDK1 AND CDK2 AND CDK3 
Structures CDK1 (PDB ID:4YC6), CDK2 (PDB ID: 4EK3), CDK3 (Phyre2 prediction) modelled in PyMOL and 
aligned.  CDK1 (grey), CDK2 (green) and CDK3 (red) aligned closely together.  With the CDK1:talin binding 
region highlighted on the structure with a black dashed box. 
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7.1 Summary  
This thesis has focussed on the adapter protein talin, a crucial player in integrin-matrix adhesions.  
The investigation set out to identify novel binding partners for talin rod domains and explore the 
mechanism of LD-motifs binding to talin; with the view that identifying new talin interactors would 
lead to a deeper understanding of integrin-matrix adhesions.  
The first novel binding partner we identified to bind talin, was the adapter protein KANK.  Through 
biochemical characterisation it was determined that talin R7 could bind to the KANK KN domain 
via an LD-motif.  Structural analysis of the interaction allowed a series of talin and KANK mutants 
to be designed that could perturb the interaction.  Having designed and biochemically 
characterised both a successful KANK mutant (KANK_4A) and a talin mutant (G1404L and W1630A) 
to perturb the talin:KANK interaction it allowed us to understand the significance the talin:KANK 
interaction in conjunction with the rest of the cell.  These studies revealed that the talin:KANK 
interaction was the key link to associating focal adhesions (FAs) and the cortical microtubule 
stabilising complex (CMSC) and that abrogation of the interaction resulted in uncontrolled MT 
growth and loss of association of the MT complex with FAs.   
Identifying this interaction has provided an answer to the long standing questions surrounding the 
mechanism that targeted microtubules to grow towards focal adhesions and regulate adhesion 
turnover.   
 
FIGURE 7.1: THE TALIN KANK INTERACTION LINKS FA WITH CMSC 
Model of how talin1 directs the assembly of the cortical microtubule stabilizing complex in three stages. 1) 
KANK1 KN domain binds to talin R7, 2) KANK1 coiled-coil domain binds to liprin β1, 3) this allows LL5β to bind 





Furthermore, the talin:KANK interaction revealed KANK to be a novel LD-motif that could bind to 
talin and gave new insight into the binding of LD-motifs to five-helix bundles.   The structure of talin 
rod domains are highly conserved across evolution, providing compelling evidence that every 
domain within talin has an important functional role.  Coupling this to the knowledge that LD-
motifs can bind to both four and five-helix bundles it was hypothesised that every talin rod domain 
has the potential to bind an LD motif(s). 
Literature described previous attempts at sequence searching for LD motifs to be unsuccessful due 
to the canonical LD motif sequence (LDxLLxxL) identifying many false positives results.  To combat 
this problem, I compiled all the knowledge of known talin binding LD-motifs and designed a novel 
LD talin binding motif (LD-TBM) that could be used as a query search to interrogate a vast talin1 
proteomics dataset.  This sequence search was coupled with a structural evaluation of potential 
binding partners to reduce the chance of false positive hits being identified.  The LD-TBM was 
successful at identifying potential talin binding partners and through the design of a novel pipeline 
the potential binding proteins were rapidly screened against talin to determine if binding occurred.  
From this initial screening the protein CDK1 was taken forward for biochemical characterisation.   
Using a similar biochemical approach that was implemented to characterise the talin:KANK 
interaction, CDK1 was identified to bind to talin R8.  NMR revealed the binding surface on which 
CDK1 binds to the talin R8, was the same site as other LD-motifs, DLC1 and RIAM.   Structural 
analysis of the talin:CDK1 interaction allowed for the design and characterisation of a successful 
CDK1 (CDK1_2A) mutant to perturb the talin:CDK1 interaction.  This mutation was used to 
understand the significance of the interaction in conjunction with the rest of the cell and it revealed 
that disruption of the interaction reduced adhesion area in the cell.    
Furthermore, biochemical data combined with phosphoproteomics shows that the CDK1-cyclinA 
complex phosphorylates talin1 and talin2 isoforms at two unique sites (Ser1589 in talin1 and 
Ser1489 in talin2).  Interestingly, in talin2 this novel phosphorylation site is in the talin actin-binding 
site (ABS2).  We postulate that this could be a mechanism to regulate the coupling/uncoupling of 
actin to talin.   This interaction between talin and CDK1 gives an insight into how adhesions and 
the cell cycle are entwined and poses many questions regarding how adhesion formation and 






7.2 Potential Limitations  
The cellular work presented in this thesis, studying both the talin:KANK and talin:CDK1 interactions 
has been carried out in a two dimensional (2D) environment, which allows for unrestricted 
movement of cells on a flat surface such as glass or plastic.   The study of these mechanisms in 2D 
has provided us with the understanding of the mechanisms involved in linking FAs to the CMSC and 
linking adhesion regulation to the cell cycle.  However, it is still not yet fully understood how 
migration in 2D relates to cellular migration in 3D.  In 2D substrates the surface is typically 
homogenous so cells only have to adhere and generate force for a single environment however, in 
3D the environment has a different topography, rigidity and uniformity.  This requires the cell to 
recognize and respond to the different surrounding environments in order to migrate and 
proliferate.  It is therefore unsurprising that the cell has adopted a number of different ways to 
migrate through a 3D environment.  It would be intriguing to study the talin:KANK interaction in a 
3D environment and to determine if perturbing the interaction between talin and KANK affects 
cells in the same way as a 2D environment.   To study cells in a 3D environment a 3D matrix hydrogel 
or tissue environment could be used, this provides a different topography, rigidity and uniformity 
to the surface mimicking that of a 3D environment (Tibbitt and Anseth, 2009).   
Large strides are being made in developing techniques to visualise and image complex 3D 
environments such as the development of high resolution light sheet microscopes (Gao et al., 2012).  
However, there are many complexities that surround both visualising and quantifying cells in 3D 
environments and so there is still a necessity to study adhesion complexes in 2D.  
 
7.3 Future Directions  
The work presented here is some of the first evidence in the field that defines the link between FAs 
and MT assemblies.  Furthermore, this is the first confirmation of an interaction between talin and 
CDK1 and it gives further evidence of adhesions being regulated by CDK1 in the cell cycle.  These 
findings give great basis for future work and exploration for both the KANK and CDK1 interactions 
with talin.    
An exciting avenue of exploration for future research will be to understand further the relationship 
between the cell cycle and regulation of adhesion assembly.  Furthermore, it will be interesting to 
explore if the mechanism involving the cell cycle and integrin-matrix adhesions transposes across 
to cell-cell adhesions.  The link between cell-matrix adhesions and cell-cell adhesions is often 
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thought of as spatially and functionally separate.  However, both cell-cell and cell-matrix adhesions 
are intrinsically linked to each other through the actin cytoskeleton and they share many common 
signalling proteins as well as downstream effectors (Weber, Bjerke and DeSimone, 2011).  It is 
thought that these two adhesion systems can form an integrated network that allows 
communication through biochemical signalling pathways and changes in the actin cytoskeleton 
(Weber, Bjerke and DeSimone, 2011).  The CDK1-cyclinA complex has been identified to 
phosphorylate actin associated proteins such as FMNL2 within cell-matrix FAs (Jones et al., 2018).  
It would be interesting to identify if any actin binding proteins involved in cell-cell junctions were 
too phosphorylated by CDK1.  Then to explore if phosphorylation of these proteins lead to adhesion 
growth in S phase of the cell cycle.  If this were the case, then this would reveal further evidence 
into cross-talk between cell matrix adhesions and cell-cell junctions and provide a bigger picture 
on how the cell cycle regulates adhesions.     
Additionally, it would be interesting to look for cross-talk between MTs and CDK1 at adhesions and 
further explore the idea that CDK1 may be transported to adhesions via MTs which could suggest 
that CMSC regulation is also linked to the cell cycle.  It would also be intriguing to examine at which 
points in the cell cycle FAs and CMSC complexes are most abundant, and to identify if this links to 
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